[
  {
    "id": "41412441",
    "title_en": "Sulforaphane ameliorates DSS-induced colitis and secondary liver injury in mice: Proposed mechanism in the SCFAs-FFAR2/3-macrophage polarization axis.",
    "pub_date": "2026 Apr",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from cruciferous vegetables, has shown therapeutic potential in inflammatory diseases. Our previous studies demonstrated that SFN ameliorates ulcerative colitis (UC) and restores gut microbiota composition in dextran sulfate sodium (DSS)-induced mice. In the present study, we further investigate the protective effects and underlying mechanisms of SFN against secondary liver injury associated with UC. The results revealed that SFN significantly alleviated pathological damage in both the colon and liver, improved liver function parameters, upregulated intestinal tight junction proteins and Muc2 expression, and inhibited inflammation in DSS-induced colitis mice. Additionally, SFN significantly elevated short-chain fatty acid (SCFA) concentrations, enhanced the expression of SCFA receptors (free fatty acid receptors 2 and 3, FFAR2/3), and modulated macrophage polarization by inhibiting M1 and promoting M2 phenotypes in the colon and liver. Collectively, these findings suggest that SFN may alleviate colitis and secondary liver injury by enhancing intestinal barrier function and reducing inflammatory responses, potentially via the SCFAs-FFAR2/3-macrophage polarization signaling cascade. Thus, SFN may serve as a promising adjunctive therapeutic agent for the prevention and treatment of UC.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç‚ç—‡æ€§ç–¾ç—…çš„ç®¡ç†ä¸Šã€‚ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼æ¸›è¼•ç”±æ½°ç˜æ€§çµè…¸ç‚å¼•èµ·çš„è‚è‡Ÿæå‚·æœ‰å¹«åŠ©ã€‚é€™æ„å‘³è‘—é€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ï¼Œé€²è€Œå½±éŸ¿æ•´é«”çš„å¥åº·ç‹€æ³ã€‚é€™å°æ–¼é‚£äº›é¢è‡¨è…¸é“ç–¾ç—…é¢¨éšªçš„äººä¾†èªªï¼Œæˆ–è¨±æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„é£²é£Ÿé¸æ“‡ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ç›¸é—œçš„è‚è‡ŸäºŒæ¬¡æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼Œä¸¦æ¢è¨å…¶æ½›åœ¨çš„æ©Ÿåˆ¶ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å¸¸è¦‹çš„è…¸é“ç–¾ç—…ï¼Œå¯èƒ½å°è‡´å¤šç¨®ä½µç™¼ç—‡ï¼Œå› æ­¤äº†è§£å…¶æ²»ç™‚æ–¹æ³•å°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªè‡³é—œé‡è¦ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬çµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿå…¶å°è…¸é“å’Œè‚è‡Ÿçš„å½±éŸ¿ã€‚ç ”ç©¶è€…è©•ä¼°äº†å°é¼ çš„ç—…ç†æå‚·ã€è‚åŠŸèƒ½æŒ‡æ¨™ã€è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ä»¥åŠç‚ç—‡åæ‡‰ç­‰å¤šå€‹æ–¹é¢ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœåŠå…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å°é¼ çš„è…¸é“å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½æŒ‡æ¨™ï¼Œä¸¦ä¸Šèª¿è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’ŒMuc2çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·çŸ­éˆè„‚è‚ªé…¸å—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç‚ç—‡åæ‡‰ä¾†ç·©è§£æ½°ç˜æ€§çµè…¸ç‚åŠå…¶å¼•èµ·çš„è‚è‡Ÿæå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºè¼”åŠ©æ²»ç™‚åŠ‘çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç‚ç—‡æ€§ç–¾ç—…çš„ç®¡ç†ä¸Šã€‚ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼æ¸›è¼•ç”±æ½°ç˜æ€§çµè…¸ç‚å¼•èµ·çš„è‚è‡Ÿæå‚·æœ‰å¹«åŠ©ã€‚é€™æ„å‘³è‘—é€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ï¼Œé€²è€Œå½±éŸ¿æ•´é«”çš„å¥åº·ç‹€æ³ã€‚é€™å°æ–¼é‚£äº›é¢è‡¨è…¸é“ç–¾ç—…é¢¨éšªçš„äººä¾†èªªï¼Œæˆ–è¨±æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„é£²é£Ÿé¸æ“‡ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ç›¸é—œçš„è‚è‡ŸäºŒæ¬¡æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å’Œè‚è‡Ÿçš„å¥åº·ï¼Œä¸¦æ¢è¨å…¶æ½›åœ¨çš„æ©Ÿåˆ¶ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å¸¸è¦‹çš„è…¸é“ç–¾ç—…ï¼Œå¯èƒ½å°è‡´å¤šç¨®ä½µç™¼ç—‡ï¼Œå› æ­¤äº†è§£å…¶æ²»ç™‚æ–¹æ³•å°æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªè‡³é—œé‡è¦ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„æ½°ç˜æ€§çµè…¸ç‚å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬çµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿå…¶å°è…¸é“å’Œè‚è‡Ÿçš„å½±éŸ¿ã€‚ç ”ç©¶è€…è©•ä¼°äº†å°é¼ çš„ç—…ç†æå‚·ã€è‚åŠŸèƒ½æŒ‡æ¨™ã€è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ä»¥åŠç‚ç—‡åæ‡‰ç­‰å¤šå€‹æ–¹é¢ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœåŠå…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•å°é¼ çš„è…¸é“å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œæ”¹å–„è‚åŠŸèƒ½æŒ‡æ¨™ï¼Œä¸¦ä¸Šèª¿è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½å’ŒMuc2çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æé«˜çŸ­éˆè„‚è‚ªé…¸çš„æ¿ƒåº¦ï¼Œå¢å¼·çŸ­éˆè„‚è‚ªé…¸å—é«”çš„è¡¨é”ï¼Œä¸¦èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éå¢å¼·è…¸é“å±éšœåŠŸèƒ½å’Œæ¸›å°‘ç‚ç—‡åæ‡‰ä¾†ç·©è§£æ½°ç˜æ€§çµè…¸ç‚åŠå…¶å¼•èµ·çš„è‚è‡Ÿæå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºè¼”åŠ©æ²»ç™‚åŠ‘çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2026 å¹´ 4 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœä¸åƒ…å¥½åƒï¼Œé‚„å¯èƒ½å°ä½ çš„è…¸é“å¥åº·å¤§æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœçš„æˆåˆ†ï¼Œå¯èƒ½å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆé€™æ˜¯ä¸€ç¨®å¸¸è¦‹çš„è…¸é“ç–¾ç—…ï¼‰å¼•èµ·çš„è‚è‡Ÿæå‚·æœ‰ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…å€‘ç”¨å°é¼ ä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„å½±éŸ¿ï¼Œä¸¦è§€å¯Ÿäº†å®ƒå°è…¸é“å’Œè‚è‡Ÿçš„å¥åº·å¦‚ä½•ç™¼æ®ä½œç”¨ã€‚ \n\nä»–å€‘ç™¼ç¾ï¼Œçµ¦å°é¼ æ”å–è˜¿è””ç¡«ç´ å¾Œï¼Œè…¸é“å’Œè‚è‡Ÿçš„ç—…ç†æå‚·æ˜é¡¯æ¸›è¼•ï¼Œè‚åŠŸèƒ½æŒ‡æ¨™ä¹Ÿæœ‰æ‰€æ”¹å–„ã€‚æ­¤å¤–ï¼Œè…¸é“çš„ç·Šå¯†é€£æ¥è›‹ç™½å’Œä¸€ç¨®å«åšMuc2çš„ç‰©è³ªçš„è¡¨é”ä¹Ÿå¢åŠ äº†ï¼Œé¡¯ç¤ºå‡ºè…¸é“å±éšœåŠŸèƒ½å¾—åˆ°äº†å¢å¼·ã€‚é€™äº›çµæœè®“äººçœ‹åˆ°è˜¿è””ç¡«ç´ åœ¨æ¸›å°‘ç‚ç—‡å’Œä¿è­·è…¸é“æ–¹é¢çš„æ½›åŠ›ã€‚ \n\nç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æ¸›è¼•æ½°ç˜æ€§çµè…¸ç‚å¼•èµ·çš„è‚è‡Ÿæå‚·ã€‚\n2. å¢åŠ åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œæˆ–è¨±æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ã€‚\n3. é€™é …ç ”ç©¶ç‚ºè…¸é“ç–¾ç—…çš„ç®¡ç†æä¾›äº†æ–°çš„é£²é£Ÿé¸æ“‡ï¼",
    "image_prompt": "Create a simple and informative illustration that explains the experimental method and main findings of a study on sulforaphane. The image should have a light-colored background and a flat design style. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines to indicate the steps of the experiment, and a section that highlights the main results, such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41412441/"
  },
  {
    "id": "41620896",
    "title_en": "Sulforaphane attenuates high-fat diet-induced myocardial injury via AMPK/SIRT1/P65 signaling in mice.",
    "pub_date": "2026 Mar",
    "journal": "Pakistan journal of pharmaceutical sciences",
    "abstract_en": "Obesity-induced metabolic disorders are closely associated with myocardial injury, in which lipid accumulation and chronic inflammation play critical roles. Activation of the AMPK/SIRT1 pathway has been reported to suppress NF-ÎºB-mediated inflammatory responses and protect cardiac function. Sulforaphane (SFN), a bioactive isothiocyanate derived from cruciferous vegetables, exhibits potent metabolic and anti-inflammatory properties; however, its protective effects and underlying mechanisms in obesity-related myocardial injury remain incompletely understood. This study aimed to investigate whether SFN alleviates high-fat diet (HFD)-induced myocardial injury and to elucidate the involvement of the AMPK/SIRT1/NF-ÎºB signaling pathway. Male C57BL/6 mice were fed a normal diet or HFD, with or without SFN treatment, for 16 weeks. Metabolic parameters, serum lipid profiles, myocardial injury markers, inflammatory cytokines and histopathological changes were evaluated. In vitro, palmitic acid-treated H9c2 cardiomyocytes were used to assess the mechanistic role of AMPK/SIRT1 signaling, with pharmacological inhibition of AMPK. SFN significantly reduced body weight, fasting glucose, serum triglycerides, total cholesterol, free fatty acids, and LDL levels in HFD-fed mice. SFN markedly attenuated myocardial structural damage and decreased serum CK, CK-MB, and cTnI levels. Inflammatory cytokines (TNF-Î±, IL-1Î², IL-6) were suppressed at both serum and myocardial mRNA levels. Mechanistically, SFN enhanced AMPK phosphorylation and SIRT1 expression while inhibiting p65 phosphorylation. In vitro, AMPK inhibition reversed the anti-inflammatory effects of SFN. SFN effectively alleviates HFD-induced myocardial injury by activating the AMPK/SIRT1 pathway and suppressing NF-ÎºB-mediated inflammation, highlighting its potential as a therapeutic agent for obesity-related cardiac injury.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¦‚ä½•é é˜²èˆ‡è‚¥èƒ–ç›¸é—œçš„å¿ƒè‡Ÿæå‚·çš„å•Ÿç¤ºã€‚è‚¥èƒ–æœƒå¼•ç™¼ä»£è¬å¤±èª¿ï¼Œé€²è€Œå½±éŸ¿å¿ƒè‡Ÿå¥åº·ï¼Œé€™æ˜¯å› ç‚ºè„‚è‚ªå †ç©å’Œæ…¢æ€§ç™¼ç‚çš„å½±éŸ¿ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éæ´»åŒ–ç‰¹å®šçš„ç”Ÿç‰©é€”å¾‘ï¼Œåƒæ˜¯AMPK/SIRT1ï¼Œå¯ä»¥æ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œå¾è€Œä¿è­·å¿ƒè‡ŸåŠŸèƒ½ã€‚é€™æ„å‘³è‘—ï¼ŒæŸäº›å¤©ç„¶æˆåˆ†ï¼Œå¦‚è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½åœ¨æ”¹å–„å¿ƒè‡Ÿå¥åº·æ–¹é¢æ‰®æ¼”é‡è¦è§’è‰²ï¼Œå°¤å…¶æ˜¯åœ¨è‚¥èƒ–æ‚£è€…ä¸­ã€‚é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼é«˜è„‚é£²é£Ÿå¼•èµ·çš„å¿ƒè‡Ÿæå‚·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•ç”±è‚¥èƒ–å¼•èµ·çš„å¿ƒè‡Ÿæå‚·ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„ç”Ÿç‰©æ©Ÿåˆ¶ã€‚ç”±æ–¼è‚¥èƒ–èˆ‡å¿ƒè‡Ÿç–¾ç—…ä¹‹é–“çš„å¯†åˆ‡é—œè¯ï¼Œäº†è§£é€™äº›æ©Ÿåˆ¶å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•è‡³é—œé‡è¦ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ ä¾†æ”¹å–„å¿ƒè‡Ÿå¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚¥èƒ–æ‚£è€…ä¸­ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†é›„æ€§C57BL/6å°é¼ ï¼Œé€™äº›å°é¼ è¢«åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œæ¥å—æ­£å¸¸é£²é£Ÿæˆ–é«˜è„‚é£²é£Ÿï¼Œä¸¦ä¸”æœ‰äº›çµ„åˆ¥æœƒæ¥å—è˜¿è””ç¡«ç´ çš„æ²»ç™‚ï¼ŒæŒçºŒ16é€±ã€‚ç ”ç©¶è€…è©•ä¼°äº†å°é¼ çš„ä»£è¬åƒæ•¸ã€è¡€æ¸…è„‚è³ªæŒ‡æ¨™ã€å¿ƒè‡Ÿæå‚·æ¨™è¨˜ç‰©ã€ç™¼ç‚ç´°èƒå› å­ä»¥åŠçµ„ç¹”ç—…ç†è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨é«”å¤–ä½¿ç”¨äº†ç¶“æ£•æ«šé…¸è™•ç†çš„H9c2å¿ƒè‚Œç´°èƒï¼Œä»¥é€²ä¸€æ­¥æ¢è¨AMPK/SIRT1ä¿¡è™Ÿé€šè·¯çš„æ©Ÿåˆ¶ï¼Œä¸¦é€²è¡Œäº†AMPKçš„è—¥ç†æŠ‘åˆ¶å¯¦é©—ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›å°‘é«˜è„‚é£²é£Ÿå°é¼ çš„é«”é‡ã€ç©ºè…¹è¡€ç³–ã€è¡€æ¸…ä¸‰é…¸ç”˜æ²¹è„‚ã€ç¸½è†½å›ºé†‡ã€è‡ªç”±è„‚è‚ªé…¸å’Œä½å¯†åº¦è„‚è›‹ç™½æ°´å¹³ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„é¡¯è‘—æ¸›è¼•äº†å¿ƒè‡Ÿçš„çµæ§‹æå‚·ï¼Œä¸¦é™ä½äº†è¡€æ¸…ä¸­çš„CKã€CK-MBå’ŒcTnIæ°´å¹³ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œç™¼ç‚ç´°èƒå› å­ï¼ˆå¦‚TNF-Î±ã€IL-1Î²ã€IL-6ï¼‰åœ¨è¡€æ¸…å’Œå¿ƒè‡Ÿçš„mRNAæ°´å¹³ä¸Šå‡æœ‰æ‰€æŠ‘åˆ¶ã€‚æ©Ÿåˆ¶ä¸Šï¼Œè˜¿è””ç¡«ç´ ä¿ƒé€²äº†AMPKçš„ç£·é…¸åŒ–å’ŒSIRT1çš„è¡¨é”ï¼ŒåŒæ™‚æŠ‘åˆ¶äº†p65çš„ç£·é…¸åŒ–ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ´»åŒ–AMPK/SIRT1é€šè·¯å’ŒæŠ‘åˆ¶NF-ÎºBä»‹å°çš„ç™¼ç‚ä¾†æ¸›è¼•é«˜è„‚é£²é£Ÿå¼•èµ·çš„å¿ƒè‡Ÿæå‚·ï¼Œé¡¯ç¤ºå…¶åœ¨è‚¥èƒ–ç›¸é—œå¿ƒè‡Ÿæå‚·ä¸­çš„æ½›åœ¨æ²»ç™‚åƒ¹å€¼ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¦‚ä½•é é˜²èˆ‡è‚¥èƒ–ç›¸é—œçš„å¿ƒè‡Ÿæå‚·çš„å•Ÿç¤ºã€‚è‚¥èƒ–æœƒå¼•ç™¼ä»£è¬å¤±èª¿ï¼Œé€²è€Œå½±éŸ¿å¿ƒè‡Ÿå¥åº·ï¼Œé€™æ˜¯å› ç‚ºè„‚è‚ªå †ç©å’Œæ…¢æ€§ç™¼ç‚çš„å½±éŸ¿ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éæ´»åŒ–ç‰¹å®šçš„ç”Ÿç‰©é€”å¾‘ï¼Œåƒæ˜¯AMPK/SIRT1ï¼Œå¯ä»¥æ¸›å°‘ç™¼ç‚åæ‡‰ï¼Œå¾è€Œä¿è­·å¿ƒè‡ŸåŠŸèƒ½ã€‚é€™æ„å‘³è‘—ï¼ŒæŸäº›å¤©ç„¶æˆåˆ†ï¼Œå¦‚è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½åœ¨æ”¹å–„å¿ƒè‡Ÿå¥åº·æ–¹é¢æ‰®æ¼”é‡è¦è§’è‰²ï¼Œå°¤å…¶æ˜¯åœ¨è‚¥èƒ–æ‚£è€…ä¸­ã€‚é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼é«˜è„‚é£²é£Ÿå¼•èµ·çš„å¿ƒè‡Ÿæå‚·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ¸›è¼•ç”±è‚¥èƒ–å¼•èµ·çš„å¿ƒè‡Ÿæå‚·ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„ç”Ÿç‰©æ©Ÿåˆ¶ã€‚ç”±æ–¼è‚¥èƒ–èˆ‡å¿ƒè‡Ÿç–¾ç—…ä¹‹é–“çš„å¯†åˆ‡é—œè¯ï¼Œäº†è§£é€™äº›æ©Ÿåˆ¶å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•è‡³é—œé‡è¦ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ ä¾†æ”¹å–„å¿ƒè‡Ÿå¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚¥èƒ–æ‚£è€…ä¸­ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†é›„æ€§C57BL/6å°é¼ ï¼Œé€™äº›å°é¼ è¢«åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œæ¥å—æ­£å¸¸é£²é£Ÿæˆ–é«˜è„‚é£²é£Ÿï¼Œä¸¦ä¸”æœ‰äº›çµ„åˆ¥æœƒæ¥å—è˜¿è””ç¡«ç´ çš„æ²»ç™‚ï¼ŒæŒçºŒ16é€±ã€‚ç ”ç©¶è€…è©•ä¼°äº†å°é¼ çš„ä»£è¬åƒæ•¸ã€è¡€æ¸…è„‚è³ªæŒ‡æ¨™ã€å¿ƒè‡Ÿæå‚·æ¨™è¨˜ç‰©ã€ç™¼ç‚ç´°èƒå› å­ä»¥åŠçµ„ç¹”ç—…ç†è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨é«”å¤–ä½¿ç”¨äº†ç¶“æ£•æ«šé…¸è™•ç†çš„H9c2å¿ƒè‚Œç´°èƒï¼Œä»¥é€²ä¸€æ­¥æ¢è¨AMPK/SIRT1ä¿¡è™Ÿé€šè·¯çš„æ©Ÿåˆ¶ï¼Œä¸¦é€²è¡Œäº†AMPKçš„è—¥ç†æŠ‘åˆ¶å¯¦é©—ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›å°‘é«˜è„‚é£²é£Ÿå°é¼ çš„é«”é‡ã€ç©ºè…¹è¡€ç³–ã€è¡€æ¸…ä¸‰é…¸ç”˜æ²¹è„‚ã€ç¸½è†½å›ºé†‡ã€è‡ªç”±è„‚è‚ªé…¸å’Œä½å¯†åº¦è„‚è›‹ç™½æ°´å¹³ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„é¡¯è‘—æ¸›è¼•äº†å¿ƒè‡Ÿçš„çµæ§‹æå‚·ï¼Œä¸¦é™ä½äº†è¡€æ¸…ä¸­çš„CKã€CK-MBå’ŒcTnIæ°´å¹³ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œç™¼ç‚ç´°èƒå› å­ï¼ˆå¦‚TNF-Î±ã€IL-1Î²ã€IL-6ï¼‰åœ¨è¡€æ¸…å’Œå¿ƒè‡Ÿçš„mRNAæ°´å¹³ä¸Šå‡æœ‰æ‰€æŠ‘åˆ¶ã€‚æ©Ÿåˆ¶ä¸Šï¼Œè˜¿è””ç¡«ç´ ä¿ƒé€²äº†AMPKçš„ç£·é…¸åŒ–å’ŒSIRT1çš„è¡¨é”ï¼ŒåŒæ™‚æŠ‘åˆ¶äº†p65çš„ç£·é…¸åŒ–ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ´»åŒ–AMPK/SIRT1é€šè·¯å’ŒæŠ‘åˆ¶NF-ÎºBä»‹å°çš„ç™¼ç‚ä¾†æ¸›è¼•é«˜è„‚é£²é£Ÿå¼•èµ·çš„å¿ƒè‡Ÿæå‚·ï¼Œé¡¯ç¤ºå…¶åœ¨è‚¥èƒ–ç›¸é—œå¿ƒè‡Ÿæå‚·ä¸­çš„æ½›åœ¨æ²»ç™‚åƒ¹å€¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPakistan journal of pharmaceutical sciencesã€‹æ–¼ 2026 å¹´ 3 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å¿ƒè‡Ÿä¹Ÿæœƒå› ç‚ºè‚¥èƒ–è€Œå—å‚·ï¼é€™ç¯‡ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼Œè˜¿è””ç¡«ç´ é€™å€‹å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½å°æ”¹å–„å¿ƒè‡Ÿå¥åº·æœ‰å¹«åŠ©å“¦ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°é«˜è„‚é£²é£Ÿå¼•èµ·çš„å¿ƒè‡Ÿæå‚·çš„å½±éŸ¿ã€‚ç ”ç©¶è€…æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ¸›è¼•å› è‚¥èƒ–é€ æˆçš„å¿ƒè‡Ÿå•é¡Œï¼Œä¸¦æ¢ç´¢å®ƒçš„é‹ä½œæ©Ÿåˆ¶ã€‚ä»–å€‘ä½¿ç”¨äº†å°é¼ é€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿå®ƒå€‘åœ¨ä¸åŒé£²é£Ÿä¸‹çš„è®ŠåŒ–ï¼Œä¸¦ç ”ç©¶è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¸›å°‘å°é¼ çš„é«”é‡ï¼Œé‚„èƒ½æ”¹å–„è¡€ç³–å’Œè†½å›ºé†‡æ°´å¹³ï¼Œæ›´é‡è¦çš„æ˜¯ï¼Œå®ƒèƒ½æ¸›è¼•å¿ƒè‡Ÿçš„æå‚·å’Œç™¼ç‚åæ‡‰ï¼é€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†å¿ƒè‡Ÿå¥åº·çš„å¥½å¹«æ‰‹ï¼\n\nâœ¨é‡é»ç¸½çµï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ”¹å–„è‚¥èƒ–å¼•èµ·çš„å¿ƒè‡Ÿå¥åº·ã€‚\n2. å®ƒèƒ½æ¸›å°‘é«”é‡ã€è¡€ç³–å’Œè†½å›ºé†‡æ°´å¹³ã€‚\n3. é€éæŠ‘åˆ¶ç™¼ç‚åæ‡‰ï¼Œä¿è­·å¿ƒè‡ŸåŠŸèƒ½ï¼",
    "image_prompt": "Create an informative infographic that explains the experimental methods and main results of a study on the effects of sulforaphane on heart damage caused by a high-fat diet. The image should have a flat design style with a white or light-colored background and soft color palette. Include simplified icons representing broccoli or sulforaphane, experimental subjects like mice or cells, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "å¿ƒè‡Ÿæå‚· Myocardial Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41620896/"
  },
  {
    "id": "41565088",
    "title_en": "Sulforaphane attenuates HFD-induced enteritis in yellow river carp by restoring immune homeostasis, repairing intestinal barrier, and modulating gut microbiota.",
    "pub_date": "2026 Mar",
    "journal": "Fish & shellfish immunology",
    "abstract_en": "High-fat diets (HFD) exacerbate intestinal health risks in aquaculture. This study evaluated effects of dietary sulforaphane (SFN) supplementation on intestinal morphology, biochemistry, microbiota, and metabolism in Yellow River carp (Cyprinus carpio haematopterus) fed HFD. Five isoprotein diets diets were formulated: control (CN, 6Â % lipid), HFD (12.29Â % lipid), and HFD with 10 (HS10), 15 (HS15), or 20 (HS20) mg/kg SFN. Results demonstrated that HFD induced marked intestinal inflammation featuring villi deformation, oxidative stress, epithelial exfoliation, mitochondrial swelling, significantly elevated pro-inflammatory cytokines (TNF-Î±/IL-1Î²/IL-6; pÂ <Â 0.05), and downregulated tight junction protein genes (Occludin/ZO-1/Claudin-3; pÂ <Â 0.05), concomitant with microbial dysbiosis (Proteobacteria dominance>70Â %, reduced Cetobacterium) and disrupted metabolic pathways (amino acid imbalance). SFN supplementation significantly enhanced antioxidant enzyme activities (SOD/CAT/GSH-Px, pÂ <Â 0.05), peaking in HS15, which also exhibited minimized pro-inflammatory cytokines and maximized tight junction expression (pÂ <Â 0.05). Furthermore, 16S rRNA gene sequencing of the gut microbiota indicated that SFN restored microbial homeostasis, notably by increasing the abundance of Cetobacterium. Metabolomic analysis based on KEGG enrichment revealed that these beneficial effects were associated with the activation of FoxO signaling, enhanced lysosomal function, and upregulation of coenzyme A biosynthesis. Critically, HS15 demonstrated optimal efficacy across all parameters. Therefore, 15Â mg/kg SFN is identified as the optimal dose to ameliorate intestinal health in Yellow River carp, providing a theoretical basis for functional aquafeed development.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†å¯èƒ½å°è…¸é“å¥åº·æœ‰æ­£é¢å½±éŸ¿ã€‚ç‰¹åˆ¥æ˜¯é«˜è„‚é£²é£Ÿå¯èƒ½æœƒå°è…¸é“é€ æˆæå®³ï¼Œè€Œæ·»åŠ è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„é€™äº›å•é¡Œã€‚é€™ä¸åƒ…å°æ°´ç”¢é¤Šæ®–æ¥­æœ‰é‡è¦æ„ç¾©ï¼Œä¹Ÿå¯èƒ½å°äººé¡çš„é£²é£Ÿé¸æ“‡æä¾›ä¸€äº›å•Ÿç¤ºï¼Œè®“æˆ‘å€‘æ€è€ƒå¦‚ä½•é€éé£²é£Ÿä¾†ç¶­è­·è…¸é“å¥åº·ï¼Œæ¸›å°‘ç‚ç—‡å’Œå…¶ä»–å¥åº·é¢¨éšªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°é»ƒæ²³é¯‰é­šåœ¨é«˜è„‚é£²é£Ÿä¸‹çš„è…¸é“å¥åº·å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é«˜è„‚é£²é£Ÿå¦‚ä½•å½±éŸ¿é­šé¡çš„è…¸é“å½¢æ…‹ã€ç”ŸåŒ–æŒ‡æ¨™ã€å¾®ç”Ÿç‰©ç¾¤è½åŠå…¶ä»£è¬æƒ…æ³ï¼Œä¸¦å¸Œæœ›æ‰¾å‡ºè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„é€™äº›å› é«˜è„‚é£²é£Ÿè€Œå¼•èµ·çš„è² é¢å½±éŸ¿ã€‚é€™å°æ–¼æå‡æ°´ç”¢é¤Šæ®–çš„æ•ˆç›ŠåŠé­šé¡çš„å¥åº·è‡³é—œé‡è¦ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äº”ç¨®ä¸åŒçš„é£²é£Ÿé…æ–¹ï¼Œåˆ†åˆ¥æ˜¯æ§åˆ¶çµ„ï¼ˆè„‚è‚ªå«é‡6%ï¼‰ã€é«˜è„‚é£²é£Ÿçµ„ï¼ˆè„‚è‚ªå«é‡12.29%ï¼‰ï¼Œä»¥åŠä¸‰å€‹æ·»åŠ ä¸åŒåŠ‘é‡è˜¿è””ç¡«ç´ çš„é«˜è„‚é£²é£Ÿçµ„ï¼ˆåˆ†åˆ¥ç‚º10ã€15å’Œ20æ¯«å…‹/å…¬æ–¤ï¼‰ã€‚ç ”ç©¶å°è±¡æ˜¯é»ƒæ²³é¯‰é­šï¼Œé€éè§€å¯Ÿå…¶è…¸é“çš„å½¢æ…‹è®ŠåŒ–ã€ç‚ç—‡æŒ‡æ¨™ã€å¾®ç”Ÿç‰©çµ„æˆåŠä»£è¬é€”å¾‘ï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œé«˜è„‚é£²é£Ÿæœƒå¼•èµ·è…¸é“çš„æ˜é¡¯ç‚ç—‡ï¼Œä¸¦å°è‡´å¾®ç”Ÿç‰©å¤±è¡¡å’Œä»£è¬é€”å¾‘çš„ç ´å£ã€‚è€Œæ·»åŠ è˜¿è””ç¡«ç´ å¾Œï¼Œç‰¹åˆ¥æ˜¯åœ¨15æ¯«å…‹/å…¬æ–¤çš„åŠ‘é‡ä¸‹ï¼Œèƒ½é¡¯è‘—æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œæ¸›å°‘ç‚ç—‡æŒ‡æ¨™ï¼Œä¸¦ä¿ƒé€²è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œå¾®ç”Ÿç‰©çµ„çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ¢å¾©å¾®ç”Ÿç‰©çš„å¹³è¡¡ï¼Œé€™äº›çµæœç‚ºæœªä¾†é–‹ç™¼åŠŸèƒ½æ€§æ°´ç”¢é£¼æ–™æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé£²é£Ÿä¸­çš„æŸäº›æˆåˆ†å¯èƒ½å°è…¸é“å¥åº·æœ‰æ­£é¢å½±éŸ¿ã€‚ç‰¹åˆ¥æ˜¯é«˜è„‚é£²é£Ÿå¯èƒ½æœƒå°è…¸é“é€ æˆæå®³ï¼Œè€Œæ·»åŠ è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„é€™äº›å•é¡Œã€‚é€™ä¸åƒ…å°æ°´ç”¢é¤Šæ®–æ¥­æœ‰é‡è¦æ„ç¾©ï¼Œä¹Ÿå¯èƒ½å°äººé¡çš„é£²é£Ÿé¸æ“‡æä¾›ä¸€äº›å•Ÿç¤ºï¼Œè®“æˆ‘å€‘æ€è€ƒå¦‚ä½•é€éé£²é£Ÿä¾†ç¶­è­·è…¸é“å¥åº·ï¼Œæ¸›å°‘ç‚ç—‡å’Œå…¶ä»–å¥åº·é¢¨éšªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°é»ƒæ²³é¯‰é­šåœ¨é«˜è„‚é£²é£Ÿä¸‹çš„è…¸é“å¥åº·å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é«˜è„‚é£²é£Ÿå¦‚ä½•å½±éŸ¿é­šé¡çš„è…¸é“å½¢æ…‹ã€ç”ŸåŒ–æŒ‡æ¨™ã€å¾®ç”Ÿç‰©ç¾¤è½åŠå…¶ä»£è¬æƒ…æ³ï¼Œä¸¦å¸Œæœ›æ‰¾å‡ºè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„é€™äº›å› é«˜è„‚é£²é£Ÿè€Œå¼•èµ·çš„è² é¢å½±éŸ¿ã€‚é€™å°æ–¼æå‡æ°´ç”¢é¤Šæ®–çš„æ•ˆç›ŠåŠé­šé¡çš„å¥åº·è‡³é—œé‡è¦ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äº”ç¨®ä¸åŒçš„é£²é£Ÿé…æ–¹ï¼Œåˆ†åˆ¥æ˜¯æ§åˆ¶çµ„ï¼ˆè„‚è‚ªå«é‡6%ï¼‰ã€é«˜è„‚é£²é£Ÿçµ„ï¼ˆè„‚è‚ªå«é‡12.29%ï¼‰ï¼Œä»¥åŠä¸‰å€‹æ·»åŠ ä¸åŒåŠ‘é‡è˜¿è””ç¡«ç´ çš„é«˜è„‚é£²é£Ÿçµ„ï¼ˆåˆ†åˆ¥ç‚º10ã€15å’Œ20æ¯«å…‹/å…¬æ–¤ï¼‰ã€‚ç ”ç©¶å°è±¡æ˜¯é»ƒæ²³é¯‰é­šï¼Œé€éè§€å¯Ÿå…¶è…¸é“çš„å½¢æ…‹è®ŠåŒ–ã€ç‚ç—‡æŒ‡æ¨™ã€å¾®ç”Ÿç‰©çµ„æˆåŠä»£è¬é€”å¾‘ï¼Œä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œé«˜è„‚é£²é£Ÿæœƒå¼•èµ·è…¸é“çš„æ˜é¡¯ç‚ç—‡ï¼Œä¸¦å°è‡´å¾®ç”Ÿç‰©å¤±è¡¡å’Œä»£è¬é€”å¾‘çš„ç ´å£ã€‚è€Œæ·»åŠ è˜¿è””ç¡«ç´ å¾Œï¼Œç‰¹åˆ¥æ˜¯åœ¨15æ¯«å…‹/å…¬æ–¤çš„åŠ‘é‡ä¸‹ï¼Œèƒ½é¡¯è‘—æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œæ¸›å°‘ç‚ç—‡æŒ‡æ¨™ï¼Œä¸¦ä¿ƒé€²è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ã€‚æ­¤å¤–ï¼Œå¾®ç”Ÿç‰©çµ„çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ¢å¾©å¾®ç”Ÿç‰©çš„å¹³è¡¡ï¼Œé€™äº›çµæœç‚ºæœªä¾†é–‹ç™¼åŠŸèƒ½æ€§æ°´ç”¢é£¼æ–™æä¾›äº†ç†è«–åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFish & shellfish immunologyã€‹æ–¼ 2026 å¹´ 3 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿé¸æ“‡ä¸åƒ…å½±éŸ¿èº«é«”ï¼Œé‚„å¯èƒ½å½±éŸ¿è…¸é“å¥åº·ï¼æœ€è¿‘ä¸€é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°é»ƒæ²³é¯‰é­šåœ¨é«˜è„‚é£²é£Ÿä¸‹çš„å½±éŸ¿ï¼Œè®“æˆ‘å€‘ä¸€èµ·ä¾†çœ‹çœ‹é€™äº›ç™¼ç¾å§ï¼\n\nç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œé«˜è„‚é£²é£Ÿæœƒè®“é­šçš„è…¸é“å‡ºç¾æ˜é¡¯çš„ç‚ç—‡ï¼Œç”šè‡³å½±éŸ¿è…¸é“å…§çš„å¾®ç”Ÿç‰©å¹³è¡¡ã€‚é€™å¯ä¸åªæ˜¯é­šçš„å•é¡Œï¼Œå°æˆ‘å€‘äººé¡çš„é£²é£Ÿé¸æ“‡ä¹Ÿæœ‰å•Ÿç¤ºï¼ç‚ºäº†äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼Œä»–å€‘è¨­è¨ˆäº†äº”ç¨®ä¸åŒçš„é£²é£Ÿé…æ–¹ï¼Œä¸¦è§€å¯Ÿé­šçš„è…¸é“è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œç•¶é­šæ”å–äº†æ·»åŠ è˜¿è””ç¡«ç´ çš„é«˜è„‚é£²é£Ÿå¾Œï¼Œç‰¹åˆ¥æ˜¯åœ¨15æ¯«å…‹/å…¬æ–¤çš„åŠ‘é‡ä¸‹ï¼Œè…¸é“çš„ç‚ç—‡æŒ‡æ¨™æ˜é¡¯æ¸›å°‘ï¼ŒæŠ—æ°§åŒ–èƒ½åŠ›æå‡ï¼Œç”šè‡³é‚„ä¿ƒé€²äº†è…¸é“çš„å¥åº·é€£æ¥ï¼é€™äº›ç™¼ç¾ä¸åƒ…æœ‰åŠ©æ–¼æå‡æ°´ç”¢é¤Šæ®–çš„æ•ˆç›Šï¼Œä¹Ÿç‚ºæˆ‘å€‘çš„é£²é£Ÿé¸æ“‡æä¾›äº†æ–°æ€è·¯ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š  \n1. é«˜è„‚é£²é£Ÿæœƒå¼•èµ·è…¸é“ç‚ç—‡å’Œå¾®ç”Ÿç‰©å¤±è¡¡ã€‚  \n2. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡å’Œæå‡è…¸é“å¥åº·ã€‚  \n3. é€™äº›çµæœç‚ºé–‹ç™¼åŠŸèƒ½æ€§æ°´ç”¢é£¼æ–™æä¾›äº†æ”¯æŒï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental process and main results of a study on the effects of sulforaphane on the gut health of fish under a high-fat diet. Use a light background with soft colors. Include simple illustrations of broccoli or sulforaphane, simplified representations of fish, and arrows or flow lines to indicate the experimental steps. Add a section labeled 'Main Results' highlighting key protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41565088/"
  },
  {
    "id": "41678915",
    "title_en": "Sulforaphane-rich aqueous broccoli seed extract suppresses diet-induced obesity via 5-HT2A/AMPK signaling in mice.",
    "pub_date": "2026 Feb",
    "journal": "Phytomedicine : international journal of phytotherapy and phytopharmacology",
    "abstract_en": "Obesity remains a major global health challenge, and current pharmacotherapies have limitations in long-term efficacy, safety, and cost. Broccoli (Brassica oleracea L. var. italica) seeds are a rich source of sulforaphane (SFN), which has demonstrated anti-obesity effects. However, the bioavailability of SFN from broccoli seeds is limited by suboptimal conversion conditions and competing nitrile-formation pathways. This study aims to standardize a high-yield, SFN-rich broccoli seed hydrolysate (BSH), to evaluate its anti-obesity efficacy in mice fed a high-fat diet (HFD), and to elucidate its mechanism via molecular docking and molecular dynamics (MD). SFN hydrolysis was optimized by Liquid chromatography-high-resolution mass spectrometry (LC-HRMS) and High-performance liquid chromatography (HPLC) across pH, temperature, time, and L-ascorbic acid; 5-hydroxytryptamine receptor 2A (5-HT2A) binding was probed by network pharmacology, molecular docking, and 100 ns MD. HFD-fed male C57BL/6 mice (n = 6 per group) received oral broccoli seed water extract (BWE), BSH, or SFN for 8 weeks. Anti-obesity efficacy was assessed by body/tissue weights, micro-computed tomography (Micro-CT), histology, and serum lipid profiling, while 5-HT2A, adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and other markers in epididymal white adipose tissue (eWAT) and liver were assessed by quantitative real-time PCR (qRT-PCR) and Western blot. SFN production from broccoli seeds was maximized under two hydrolysis regimes: short-term (pH 4 at 35Â°C for 2 h) and long-term (pH 5 at 25Â°C for 24 h). In silico analyses predicted stable binding of the sulforaphane-glutathione conjugate (SFN-GSH) to 5-HT2A. In HFD-fed mice, BSH (40-800 mg/kg, p.o.) dose-dependently attenuated HFD-induced body weight gain (800 mg/kg vs HFD, p < 0.001). BWE 400 mg/kg and BSH 40 mg/kg showed broadly comparable effects on body weight. Furthermore, gene and protein analyses in eWAT and liver showed 5-HT2A (Htr2a) suppression, restored AMPK phosphorylation, and downregulation of lipogenic regulators. However, co-administration of the AMPK inhibitor Compound C (5 mg/kg, i.p.) with BSH abolished these BSH-induced effects. Oral administration of a sulforaphane standard (1-10 mg/kg) produced similar effects to BSH (10 mg/kg vs HFD, p < 0.01), suggesting that the anti-obesity effect of BSH is mediated primarily by SFN. In this study, SFN-rich BSH ameliorated obesity in HFD-fed mice via a peripheral 5-HT2A suppression-AMPK activation axis. However, further mechanistic clarification will require studies to more precisely define the role of 5-HT2A in adipocytes.",
    "para1": "è‚¥èƒ–å•é¡Œåœ¨å…¨çƒå¥åº·ä¸­ä»ç„¶æ˜¯ä¸€å€‹é‡å¤§æŒ‘æˆ°ï¼Œç›®å‰çš„è—¥ç‰©æ²»ç™‚åœ¨é•·æœŸæ•ˆæœã€å®‰å…¨æ€§å’Œæˆæœ¬ä¸Šéƒ½æœ‰å…¶é™åˆ¶ã€‚é€™é …ç ”ç©¶æ¢è¨äº†é’èŠ±æ¤°èœç¨®å­ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œé€™æ˜¯ä¸€ç¨®å·²çŸ¥å…·æœ‰æŠ—è‚¥èƒ–æ•ˆæœçš„åŒ–åˆç‰©ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯èƒ½èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†å°æŠ—è‚¥èƒ–ï¼Œä¸¦æ”¹å–„ç›¸é—œçš„å¥åº·å•é¡Œï¼Œé€™å°æ–¼å¸Œæœ›æ¸›é‡æˆ–ç¶­æŒå¥åº·é«”é‡çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯å€‹å¥½æ¶ˆæ¯ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°é’èŠ±æ¤°èœç¨®å­ä¸­çš„è˜¿è””ç¡«ç´ é€²è¡Œæ·±å…¥æ¢è¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨æŠ—è‚¥èƒ–æ–¹é¢çš„æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œä¸¦è©•ä¼°å…¶åœ¨é«˜è„‚é£²é£Ÿä¸‹å°è‚¥èƒ–çš„å½±éŸ¿ã€‚é€™ä¸åƒ…æ¶‰åŠåˆ°è˜¿è””ç¡«ç´ çš„æå–å’Œæ¨™æº–åŒ–ï¼Œé‚„åŒ…æ‹¬å…¶ä½œç”¨æ©Ÿåˆ¶çš„ç ”ç©¶ï¼Œé€™å°æ–¼æœªä¾†çš„è‚¥èƒ–æ²»ç™‚æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é«˜è„‚é£²é£Ÿçš„é›„æ€§å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ï¼Œä¸¦å°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥æ¥å—é’èŠ±æ¤°èœç¨®å­æ°´æå–ç‰©ã€é’èŠ±æ¤°èœç¨®å­æ°´è§£ç‰©å’Œè˜¿è””ç¡«ç´ çš„å£æœçµ¦äºˆï¼ŒæŒçºŒ8é€±ã€‚ç ”ç©¶è€…é€éæ¶²ç›¸è‰²è­œå’Œè³ªè­œæŠ€è¡“å„ªåŒ–è˜¿è””ç¡«ç´ çš„æ°´è§£æ¢ä»¶ï¼Œä¸¦åˆ©ç”¨åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸åˆ†æå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚å¯¦é©—ä¸­é‚„è©•ä¼°äº†å°é¼ çš„é«”é‡è®ŠåŒ–ã€çµ„ç¹”é‡é‡ã€ä»¥åŠè¡€æ¸…è„‚è³ªçš„è®ŠåŒ–ç­‰å¤šé …æŒ‡æ¨™ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œé’èŠ±æ¤°èœç¨®å­æ°´è§£ç‰©åœ¨é«˜è„‚é£²é£Ÿçš„å°é¼ ä¸­èƒ½å¤ æœ‰æ•ˆæ¸›å°‘é«”é‡å¢åŠ ï¼Œä¸”å…¶æ•ˆæœèˆ‡è˜¿è””ç¡«ç´ çš„åŠ‘é‡æœ‰é—œã€‚æ­¤å¤–ï¼ŒåŸºå› å’Œè›‹ç™½è³ªåˆ†æé¡¯ç¤ºï¼Œé’èŠ±æ¤°èœç¨®å­æ°´è§£ç‰©èƒ½å¤ æŠ‘åˆ¶5-HT2Açš„è¡¨é”ï¼Œæ¢å¾©AMPKçš„ç£·é…¸åŒ–ï¼Œä¸¦ä¸‹èª¿è„‚è‚ªç”Ÿæˆçš„èª¿æ§å› å­ã€‚ç„¶è€Œï¼Œç•¶èˆ‡AMPKæŠ‘åˆ¶åŠ‘å…±åŒä½¿ç”¨æ™‚ï¼Œé€™äº›æ•ˆæœæœƒè¢«æŠ‘åˆ¶ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨æŠ—è‚¥èƒ–ä¸­çš„é‡è¦æ€§ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„è‚¥èƒ–æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä»¥æ˜ç¢º5-HT2Aåœ¨è„‚è‚ªç´°èƒä¸­çš„è§’è‰²ã€‚",
    "explanation_zh": "è‚¥èƒ–å•é¡Œåœ¨å…¨çƒå¥åº·ä¸­ä»ç„¶æ˜¯ä¸€å€‹é‡å¤§æŒ‘æˆ°ï¼Œç›®å‰çš„è—¥ç‰©æ²»ç™‚åœ¨é•·æœŸæ•ˆæœã€å®‰å…¨æ€§å’Œæˆæœ¬ä¸Šéƒ½æœ‰å…¶é™åˆ¶ã€‚é€™é …ç ”ç©¶æ¢è¨äº†é’èŠ±æ¤°èœç¨®å­ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œé€™æ˜¯ä¸€ç¨®å·²çŸ¥å…·æœ‰æŠ—è‚¥èƒ–æ•ˆæœçš„åŒ–åˆç‰©ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯èƒ½èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†å°æŠ—è‚¥èƒ–ï¼Œä¸¦æ”¹å–„ç›¸é—œçš„å¥åº·å•é¡Œï¼Œé€™å°æ–¼å¸Œæœ›æ¸›é‡æˆ–ç¶­æŒå¥åº·é«”é‡çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯å€‹å¥½æ¶ˆæ¯ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°é’èŠ±æ¤°èœç¨®å­ä¸­çš„è˜¿è””ç¡«ç´ é€²è¡Œæ·±å…¥æ¢è¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨æŠ—è‚¥èƒ–æ–¹é¢çš„æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œä¸¦è©•ä¼°å…¶åœ¨é«˜è„‚é£²é£Ÿä¸‹å°è‚¥èƒ–çš„å½±éŸ¿ã€‚é€™ä¸åƒ…æ¶‰åŠåˆ°è˜¿è””ç¡«ç´ çš„æå–å’Œæ¨™æº–åŒ–ï¼Œé‚„åŒ…æ‹¬å…¶ä½œç”¨æ©Ÿåˆ¶çš„ç ”ç©¶ï¼Œé€™å°æ–¼æœªä¾†çš„è‚¥èƒ–æ²»ç™‚æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é«˜è„‚é£²é£Ÿçš„é›„æ€§å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ï¼Œä¸¦å°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥æ¥å—é’èŠ±æ¤°èœç¨®å­æ°´æå–ç‰©ã€é’èŠ±æ¤°èœç¨®å­æ°´è§£ç‰©å’Œè˜¿è””ç¡«ç´ çš„å£æœçµ¦äºˆï¼ŒæŒçºŒ8é€±ã€‚ç ”ç©¶è€…é€éæ¶²ç›¸è‰²è­œå’Œè³ªè­œæŠ€è¡“å„ªåŒ–è˜¿è””ç¡«ç´ çš„æ°´è§£æ¢ä»¶ï¼Œä¸¦åˆ©ç”¨åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸åˆ†æå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚å¯¦é©—ä¸­é‚„è©•ä¼°äº†å°é¼ çš„é«”é‡è®ŠåŒ–ã€çµ„ç¹”é‡é‡ã€ä»¥åŠè¡€æ¸…è„‚è³ªçš„è®ŠåŒ–ç­‰å¤šé …æŒ‡æ¨™ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œé’èŠ±æ¤°èœç¨®å­æ°´è§£ç‰©åœ¨é«˜è„‚é£²é£Ÿçš„å°é¼ ä¸­èƒ½å¤ æœ‰æ•ˆæ¸›å°‘é«”é‡å¢åŠ ï¼Œä¸”å…¶æ•ˆæœèˆ‡è˜¿è””ç¡«ç´ çš„åŠ‘é‡æœ‰é—œã€‚æ­¤å¤–ï¼ŒåŸºå› å’Œè›‹ç™½è³ªåˆ†æé¡¯ç¤ºï¼Œé’èŠ±æ¤°èœç¨®å­æ°´è§£ç‰©èƒ½å¤ æŠ‘åˆ¶5-HT2Açš„è¡¨é”ï¼Œæ¢å¾©AMPKçš„ç£·é…¸åŒ–ï¼Œä¸¦ä¸‹èª¿è„‚è‚ªç”Ÿæˆçš„èª¿æ§å› å­ã€‚ç„¶è€Œï¼Œç•¶èˆ‡AMPKæŠ‘åˆ¶åŠ‘å…±åŒä½¿ç”¨æ™‚ï¼Œé€™äº›æ•ˆæœæœƒè¢«æŠ‘åˆ¶ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨æŠ—è‚¥èƒ–ä¸­çš„é‡è¦æ€§ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„è‚¥èƒ–æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä»¥æ˜ç¢º5-HT2Aåœ¨è„‚è‚ªç´°èƒä¸­çš„è§’è‰²ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPhytomedicine : international journal of phytotherapy and phytopharmacologyã€‹æ–¼ 2026 å¹´ 2 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“é’èŠ±æ¤°èœä¹Ÿèƒ½å¹«åŠ©å°æŠ—è‚¥èƒ–å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œé’èŠ±æ¤°èœç¨®å­ä¸­çš„ä¸€ç¨®æˆåˆ†â”€â”€è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½æ˜¯æ¸›é‡çš„å¥½å¹«æ‰‹ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨æŠ—è‚¥èƒ–æ–¹é¢çš„æ•ˆæœï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½æé«˜å®ƒçš„å¸æ”¶ç‡ï¼Œä¸¦çœ‹çœ‹å®ƒåœ¨é«˜è„‚é£²é£Ÿä¸‹çš„å½±éŸ¿ã€‚ç ”ç©¶åœ˜éšŠä½¿ç”¨äº†é«˜è„‚é£²é£Ÿçš„é›„æ€§å°é¼ ï¼Œçµ¦å®ƒå€‘ä¸åŒçš„é’èŠ±æ¤°èœç¨®å­æå–ç‰©ï¼ŒæŒçºŒè§€å¯Ÿäº†8é€±ã€‚\n\nçµæœé¡¯ç¤ºï¼Œé’èŠ±æ¤°èœç¨®å­æ°´è§£ç‰©èƒ½æœ‰æ•ˆæ¸›å°‘å°é¼ çš„é«”é‡å¢åŠ ï¼Œä¸¦ä¸”é€™å€‹æ•ˆæœèˆ‡è˜¿è””ç¡«ç´ çš„åŠ‘é‡æœ‰é—œï¼è€Œä¸”ï¼Œé€™å€‹æˆåˆ†é‚„èƒ½èª¿ç¯€ä¸€äº›å½±éŸ¿è„‚è‚ªç”Ÿæˆçš„å› å­ï¼Œé¡¯ç¤ºå‡ºå®ƒåœ¨æŠ—è‚¥èƒ–ä¸­çš„æ½›åŠ›ã€‚\n\nğŸ”‘é‡é»æ•´ç†ï¼š\n1. é’èŠ±æ¤°èœç¨®å­ä¸­çš„è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›é‡ã€‚\n2. ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½æœ‰æ•ˆæ¸›å°‘é«”é‡å¢åŠ ã€‚\n3. é€™ç‚ºæœªä¾†çš„è‚¥èƒ–æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ï¼",
    "image_prompt": "Create an informative and simple illustration explaining the experiment and main results of a study on sulforaphane from broccoli seeds and its effects on obesity. The image should have a light background and use soft colors. Include symbols for broccoli and sulforaphane, simplified representations of experimental subjects like mice, arrows or flow lines to show the experimental steps, and a section highlighting the main results such as weight reduction and protective effects.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚¥èƒ– Obesity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41678915/"
  },
  {
    "id": "41649614",
    "title_en": "Sulforaphane-Mediated Multitarget Therapeutic Effects in Methylmercury-Induced ALS-Like Pathology: Comparative Analysis and Multifaceted Approach to Neuroprotection and Systemic Recovery.",
    "pub_date": "2026 Feb",
    "journal": "Molecular neurobiology",
    "abstract_en": "Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder marked by motor neuron loss driven by oxidative stress, neuroinflammation, and dysregulated survival signaling. The objective of this study was to evaluate the neuroprotective efficacy and safety of sulforaphane (SUFP) in a methylmercury (MMHgâº)-induced preclinical rat model of ALS, with comparison to omaveloxolone (OVX) and dimethyl fumarate (DIMT). SUFP treatment, particularly at 4Â mg/kg, significantly restored antioxidant defense mechanisms through upregulation of Nrf2, HO-1, and SIRT1 while suppressing pro-inflammatory cytokines (IL-1Î², TNF-Î±), apoptotic markers (Bax, caspase-3), and stress-related signaling pathways including p75NTR, PI3K/Akt, and MAPKs. These molecular effects translated into meaningful functional recovery, as evidenced by improvements in grip strength, locomotor performance, spatial memory, and depressive-like behavior. Histopathological evaluation demonstrated attenuation of demyelination and preservation of neuronal architecture in cortical, hippocampal, and cerebellar regions. Beyond central neuroprotection, SUFP exerted systemic benefits by normalizing hepatic enzymes, improving skeletal muscle integrity, restoring redox balance, stabilizing neurofilament and myelin-associated proteins, and correcting hematological alterations. Comparative analysis revealed that SUFP conferred superior neuroprotection with a favorable safety profile relative to OVX and, although slightly less efficacious than DIMT, exhibited reduced systemic toxicity. Molecular docking further supported SUFP's interaction with Nrf2-Keap1 targets, reinforcing its antioxidant and anti-inflammatory mechanisms. Collectively, these findings identify SUFP as a multifaceted and well-tolerated therapeutic candidate for ALS, supporting its further translational and clinical evaluation.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°ç¥ç¶“é€€åŒ–æ€§ç–¾ç—…å¦‚è‚Œèç¸®å´ç´¢ç¡¬åŒ–ç—‡ï¼ˆALSï¼‰æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚ALSæ˜¯ä¸€ç¨®é€²è¡Œæ€§ç–¾ç—…ï¼Œæœƒå°è‡´é‹å‹•ç¥ç¶“å…ƒçš„å–ªå¤±ï¼Œä¸¦ä¸”èˆ‡æ°§åŒ–å£“åŠ›å’Œç¥ç¶“ç™¼ç‚æœ‰é—œã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥çœ‹åˆ°ï¼ŒæŸäº›å¤©ç„¶åŒ–åˆç‰©å¦‚è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„ç¥ç¶“å¥åº·ï¼Œä¸¦æ¸›å°‘èˆ‡é€™é¡ç–¾ç—…ç›¸é—œçš„æå‚·ï¼Œé€™å°æ–¼æœªä¾†çš„é é˜²å’Œæ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ åœ¨ä¸€ç¨®ç”±ç”²åŸºæ±èª˜å°çš„å‰è‡¨åºŠå¤§é¼ æ¨¡å‹ä¸­å°è‚Œèç¸®å´ç´¢ç¡¬åŒ–ç—‡çš„ç¥ç¶“ä¿è­·æ•ˆæœåŠå®‰å…¨æ€§ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„ç¥ç¶“åŠŸèƒ½ï¼Œä¸¦èˆ‡å…¶ä»–å·²çŸ¥çš„æ²»ç™‚è—¥ç‰©å¦‚å¥§é¦¬ç¶­æ´›å…‹éš†å’ŒäºŒç”²åŸºå¯Œé¦¬é…¸é€²è¡Œæ¯”è¼ƒã€‚é€™æ¨£çš„æ¯”è¼ƒå¯ä»¥å¹«åŠ©æˆ‘å€‘äº†è§£è˜¿è””ç¡«ç´ åœ¨æ²»ç™‚ALSæ–¹é¢çš„æ½›åŠ›åŠå…¶ç›¸å°å„ªå‹¢ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç”²åŸºæ±èª˜å°çš„ALSå¤§é¼ æ¨¡å‹ï¼Œä¸¦å°é€™äº›å¤§é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„æ²»ç™‚ï¼Œç‰¹åˆ¥æ˜¯ä»¥æ¯å…¬æ–¤4æ¯«å…‹çš„åŠ‘é‡é€²è¡Œçµ¦è—¥ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°æŠ—æ°§åŒ–é˜²ç¦¦æ©Ÿåˆ¶çš„å½±éŸ¿ï¼Œä¸¦æ¸¬é‡äº†èˆ‡ç‚ç—‡ã€ç´°èƒå‡‹äº¡åŠå£“åŠ›ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†å¤§é¼ çš„æ¡åŠ›ã€é‹å‹•è¡¨ç¾ã€ç©ºé–“è¨˜æ†¶å’ŒæŠ‘é¬±è¡Œç‚ºç­‰åŠŸèƒ½æ€§æ¢å¾©æƒ…æ³ï¼Œä¸¦é€²è¡Œäº†çµ„ç¹”å­¸è©•ä¼°ä»¥è§€å¯Ÿç¥ç¶“çµæ§‹çš„è®ŠåŒ–ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¢å¾©æŠ—æ°§åŒ–é˜²ç¦¦æ©Ÿåˆ¶ï¼Œä¸¦æ¸›å°‘ç‚ç—‡å’Œç´°èƒå‡‹äº¡çš„æ¨™è¨˜ï¼Œé€™äº›åˆ†å­æ•ˆæ‡‰è½‰åŒ–ç‚ºåŠŸèƒ½ä¸Šçš„æ”¹å–„ï¼Œå¦‚æ¡åŠ›å’Œé‹å‹•èƒ½åŠ›çš„æå‡ã€‚çµ„ç¹”å­¸è©•ä¼°ä¹Ÿé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æ¸›å°‘ç¥ç¶“è„«é«“é˜ç¾è±¡ï¼Œä¸¦ä¿è­·ç¥ç¶“çµæ§‹ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ åœ¨å®‰å…¨æ€§æ–¹é¢è¡¨ç¾è‰¯å¥½ï¼Œèˆ‡å…¶ä»–è—¥ç‰©ç›¸æ¯”ï¼Œé¡¯ç¤ºå‡ºè¼ƒä½çš„ç³»çµ±æ€§æ¯’æ€§ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ æ˜¯ä¸€å€‹å¤šé¢å‘ä¸”è€å—æ€§è‰¯å¥½çš„æ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠè©•ä¼°ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°ç¥ç¶“é€€åŒ–æ€§ç–¾ç—…å¦‚è‚Œèç¸®å´ç´¢ç¡¬åŒ–ç—‡ï¼ˆALSï¼‰æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚ALSæ˜¯ä¸€ç¨®é€²è¡Œæ€§ç–¾ç—…ï¼Œæœƒå°è‡´é‹å‹•ç¥ç¶“å…ƒçš„å–ªå¤±ï¼Œä¸¦ä¸”èˆ‡æ°§åŒ–å£“åŠ›å’Œç¥ç¶“ç™¼ç‚æœ‰é—œã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥çœ‹åˆ°ï¼ŒæŸäº›å¤©ç„¶åŒ–åˆç‰©å¦‚è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„ç¥ç¶“å¥åº·ï¼Œä¸¦æ¸›å°‘èˆ‡é€™é¡ç–¾ç—…ç›¸é—œçš„æå‚·ï¼Œé€™å°æ–¼æœªä¾†çš„é é˜²å’Œæ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ åœ¨ä¸€ç¨®ç”±ç”²åŸºæ±èª˜å°çš„å‰è‡¨åºŠå¤§é¼ æ¨¡å‹ä¸­å°è‚Œèç¸®å´ç´¢ç¡¬åŒ–ç—‡çš„ç¥ç¶“ä¿è­·æ•ˆæœåŠå®‰å…¨æ€§ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„ç¥ç¶“åŠŸèƒ½ï¼Œä¸¦èˆ‡å…¶ä»–å·²çŸ¥çš„æ²»ç™‚è—¥ç‰©å¦‚å¥§é¦¬ç¶­æ´›å…‹éš†å’ŒäºŒç”²åŸºå¯Œé¦¬é…¸é€²è¡Œæ¯”è¼ƒã€‚é€™æ¨£çš„æ¯”è¼ƒå¯ä»¥å¹«åŠ©æˆ‘å€‘äº†è§£è˜¿è””ç¡«ç´ åœ¨æ²»ç™‚ALSæ–¹é¢çš„æ½›åŠ›åŠå…¶ç›¸å°å„ªå‹¢ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç”²åŸºæ±èª˜å°çš„ALSå¤§é¼ æ¨¡å‹ï¼Œä¸¦å°é€™äº›å¤§é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„æ²»ç™‚ï¼Œç‰¹åˆ¥æ˜¯ä»¥æ¯å…¬æ–¤4æ¯«å…‹çš„åŠ‘é‡é€²è¡Œçµ¦è—¥ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†è˜¿è””ç¡«ç´ å°æŠ—æ°§åŒ–é˜²ç¦¦æ©Ÿåˆ¶çš„å½±éŸ¿ï¼Œä¸¦æ¸¬é‡äº†èˆ‡ç‚ç—‡ã€ç´°èƒå‡‹äº¡åŠå£“åŠ›ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†å¤§é¼ çš„æ¡åŠ›ã€é‹å‹•è¡¨ç¾ã€ç©ºé–“è¨˜æ†¶å’ŒæŠ‘é¬±è¡Œç‚ºç­‰åŠŸèƒ½æ€§æ¢å¾©æƒ…æ³ï¼Œä¸¦é€²è¡Œäº†çµ„ç¹”å­¸è©•ä¼°ä»¥è§€å¯Ÿç¥ç¶“çµæ§‹çš„è®ŠåŒ–ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¢å¾©æŠ—æ°§åŒ–é˜²ç¦¦æ©Ÿåˆ¶ï¼Œä¸¦æ¸›å°‘ç‚ç—‡å’Œç´°èƒå‡‹äº¡çš„æ¨™è¨˜ï¼Œé€™äº›åˆ†å­æ•ˆæ‡‰è½‰åŒ–ç‚ºåŠŸèƒ½ä¸Šçš„æ”¹å–„ï¼Œå¦‚æ¡åŠ›å’Œé‹å‹•èƒ½åŠ›çš„æå‡ã€‚çµ„ç¹”å­¸è©•ä¼°ä¹Ÿé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æ¸›å°‘ç¥ç¶“è„«é«“é˜ç¾è±¡ï¼Œä¸¦ä¿è­·ç¥ç¶“çµæ§‹ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ åœ¨å®‰å…¨æ€§æ–¹é¢è¡¨ç¾è‰¯å¥½ï¼Œèˆ‡å…¶ä»–è—¥ç‰©ç›¸æ¯”ï¼Œé¡¯ç¤ºå‡ºè¼ƒä½çš„ç³»çµ±æ€§æ¯’æ€§ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ æ˜¯ä¸€å€‹å¤šé¢å‘ä¸”è€å—æ€§è‰¯å¥½çš„æ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠè©•ä¼°ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular neurobiologyã€‹æ–¼ 2026 å¹´ 2 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢è—è‘—çš„ç¡«ç´ ï¼Œå¯èƒ½å°æˆ‘å€‘çš„ç¥ç¶“å¥åº·æœ‰é©šäººçš„å¥½è™•ï¼ğŸŒ±é€™é …ç ”ç©¶é‡å°ä¸€ç¨®å«è‚Œèç¸®å´ç´¢ç¡¬åŒ–ç—‡ï¼ˆALSï¼‰çš„ç–¾ç—…é€²è¡Œäº†æ¢è¨ï¼Œé€™æ˜¯ä¸€ç¨®æœƒå½±éŸ¿é‹å‹•ç¥ç¶“å…ƒçš„é€²è¡Œæ€§ç–¾ç—…ï¼Œè®“äººè¶Šä¾†è¶Šç„¡æ³•æ§åˆ¶è‡ªå·±çš„é‹å‹•ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†ç”²åŸºæ±èª˜å°çš„è€é¼ æ¨¡å‹ï¼Œä¾†çœ‹çœ‹è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç¥ç¶“åŠŸèƒ½ï¼Œä¸¦èˆ‡å…¶ä»–æ²»ç™‚è—¥ç‰©é€²è¡Œæ¯”è¼ƒã€‚å¯¦é©—ä¸­ï¼Œä»–å€‘çµ¦è€é¼ æ–½æ‰“äº†è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå®ƒå°æŠ—æ°§åŒ–èƒ½åŠ›ã€ç‚ç—‡å’Œç¥ç¶“çµæ§‹çš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¸›å°‘ç‚ç—‡å’Œç´°èƒæ­»äº¡ï¼Œé‚„èƒ½æå‡æ¡åŠ›å’Œé‹å‹•èƒ½åŠ›ï¼Œç”šè‡³ä¿è­·ç¥ç¶“çµæ§‹ï¼é€™äº›ç™¼ç¾è®“äººæ„Ÿåˆ°æŒ¯å¥®ï¼Œå› ç‚ºè˜¿è””ç¡«ç´ çš„å®‰å…¨æ€§ä¹Ÿç›¸ç•¶ä¸éŒ¯ï¼Œé¡¯ç¤ºå‡ºæœªä¾†å¯èƒ½æˆç‚ºæ²»ç™‚çš„å€™é¸è€…ï¼âœ¨\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°ç¥ç¶“é€€åŒ–æ€§ç–¾ç—…æœ‰ä¿è­·ä½œç”¨ã€‚\n2. å¯¦é©—é¡¯ç¤ºå®ƒèƒ½æ”¹å–„æ¡åŠ›å’Œé‹å‹•èƒ½åŠ›ã€‚\n3. å®‰å…¨æ€§è‰¯å¥½ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental process and main results of a study on sulforaphane from radishes. The image should have a light background and soft colors. Include symbols representing sulforaphane, simplified illustrations of experimental subjects like rats, and arrows or flow lines indicating the steps of the experiment. There should also be a section highlighting the main results, such as protective effects and improvements in function.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚Œèç¸®å´ç´¢ç¡¬åŒ–ç—‡ Amyotrophic Lateral Sclerosis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41649614/"
  },
  {
    "id": "41651260",
    "title_en": "Mining of key genes involved in the sulforaphane biosynthetic pathway of moringa and cloning, expression, and functional verification of MoMYR1.",
    "pub_date": "2026 Feb",
    "journal": "International journal of biological macromolecules",
    "abstract_en": "Moringa oleifera, a plant of significant medicinal and edible value, is renowned for its bioactive compound isothiocyanates (ITCs) with multiple health benefits. This study investigates the biosynthetic mechanism of ITCs in M. oleifera. Local BLAST alignment and KEGG pathway analysis of the Moringa genome identified nine key genes encoding six enzymes-BCAT, CYP79F1, CYP83A1, UGT, SOT, and MYR-potentially involved in ITCs biosynthesis. Expression correlation analysis showed that only myrosinase genes MoMYR1 and MoMYR3 exhibited significant positive correlation with sulforaphane content across tissues (pÂ <Â 0.05). The MoMYR1 gene (GeneBank: PP738617) was successfully cloned for the first time. Heterologous expression in Escherichia coli BL21 produced recombinant MoMYR1 protein, while expression in Pichia pastoris GS115 yielded no detectable MoMYR3 protein. Molecular docking revealed a binding energy of -8.0Â kcal/mol between the protein and substrate, indicating strong affinity. In vitro enzymatic assays demonstrated that recombinant MoMYR1 catalyzed Sinigrin and GL with specific activities of 0.2565 and 0.2447Â Î¼molÂ·(minÂ·mg)<sup>-1</sup>, and catalytic efficiencies of 30.17 and 28.79Â UÂ·g<sup>-1</sup>, respectively. LC-MS analysis confirmed the conversion of GL to sulforaphane by heterologously expressed MoMYR1. This study identifies MoMYR1 as a key enzyme gene in ITCs biosynthesis in Moringa oleifera, providing a theoretical foundation and critical target for elucidating regulatory mechanisms and developing green production strategies.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œå¾ä¸€ç¨®åç‚ºè¾£æœ¨çš„æ¤ç‰©ä¸­æå–çš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰ç›Šã€‚è˜¿è””ç¡«ç´ è¢«èªç‚ºå…·æœ‰å¤šç¨®å¥åº·æ•ˆç›Šï¼Œé€™ä½¿å¾—äº†è§£å…¶åˆæˆæ©Ÿåˆ¶è®Šå¾—éå¸¸é‡è¦ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥é€²ä¸€æ­¥æ¢ç´¢å¦‚ä½•åˆ©ç”¨é€™äº›å¤©ç„¶åŒ–åˆç‰©ä¾†ä¿ƒé€²å¥åº·ï¼Œç”šè‡³å¯èƒ½åœ¨æŸäº›ç–¾ç—…çš„é é˜²æˆ–æ²»ç™‚ä¸­ç™¼æ®ä½œç”¨ï¼Œé›–ç„¶ç›®å‰å°šæœªæœ‰ç¢ºå®šçš„çµè«–ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è¾£æœ¨ä¸­ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ç•°ç¡«æ°°é…¸é…¯ï¼ˆITCsï¼‰çš„åˆæˆæ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯è¾£æœ¨åŸºå› çµ„ä¸­èˆ‡ç•°ç¡«æ°°é…¸é…¯åˆæˆç›¸é—œçš„åŸºå› ï¼Œç‰¹åˆ¥æ˜¯é‚£äº›ç·¨ç¢¼é…¶çš„åŸºå› ã€‚é€éåŸºå› æ¯”å°å’Œé€”å¾‘åˆ†æï¼Œç ”ç©¶è€…æ‰¾åˆ°äº†ä¹å€‹é—œéµåŸºå› ï¼Œé€™äº›åŸºå› å¯èƒ½åƒèˆ‡äº†ç•°ç¡«æ°°é…¸é…¯çš„åˆæˆéç¨‹ï¼Œé€™å°æ–¼ç†è§£è¾£æœ¨çš„å¥åº·æ•ˆç›Šè‡³é—œé‡è¦ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆé€²è¡Œäº†åŸºå› çµ„çš„æ¯”å°å’Œåˆ†æï¼Œä»¥ç¢ºå®šèˆ‡ç•°ç¡«æ°°é…¸é…¯åˆæˆç›¸é—œçš„åŸºå› ã€‚æ¥è‘—ï¼Œä»–å€‘å°é€™äº›åŸºå› çš„è¡¨é”é€²è¡Œäº†ç›¸é—œæ€§åˆ†æï¼Œç™¼ç¾æŸäº›åŸºå› èˆ‡è˜¿è””ç¡«ç´ çš„å«é‡æœ‰é¡¯è‘—çš„æ­£ç›¸é—œã€‚ç‰¹åˆ¥æ˜¯ï¼Œä»–å€‘æˆåŠŸå…‹éš†äº†MoMYR1åŸºå› ï¼Œä¸¦åœ¨å¤§è…¸æ¡¿èŒä¸­è¡¨é”äº†é‡çµ„è›‹ç™½ã€‚é€™äº›å¯¦é©—å¹«åŠ©ç ”ç©¶è€…äº†è§£äº†è¾£æœ¨ä¸­è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒMoMYR1åŸºå› è¢«ç¢ºå®šç‚ºè¾£æœ¨ä¸­ç•°ç¡«æ°°é…¸é…¯åˆæˆçš„é‡è¦é…¶åŸºå› ã€‚å¯¦é©—çµæœé¡¯ç¤ºï¼Œé‡çµ„çš„MoMYR1è›‹ç™½èƒ½æœ‰æ•ˆå‚¬åŒ–ç‰¹å®šåº•ç‰©çš„è½‰åŒ–ï¼Œä¸¦ä¸”åœ¨é«”å¤–é…¶æ´»æ€§æ¸¬è©¦ä¸­è¡¨ç¾å‡ºè‰¯å¥½çš„å‚¬åŒ–æ•ˆç‡ã€‚é€™äº›çµæœä¸åƒ…ç¢ºèªäº†MoMYR1åœ¨ç•°ç¡«æ°°é…¸é…¯åˆæˆä¸­çš„é—œéµè§’è‰²ï¼Œä¹Ÿç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†ç†è«–åŸºç¤ï¼Œä¸¦å¯èƒ½ä¿ƒé€²ç¶ è‰²ç”Ÿç”¢ç­–ç•¥çš„ç™¼å±•ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œå¾ä¸€ç¨®åç‚ºè¾£æœ¨çš„æ¤ç‰©ä¸­æå–çš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰ç›Šã€‚è˜¿è””ç¡«ç´ è¢«èªç‚ºå…·æœ‰å¤šç¨®å¥åº·æ•ˆç›Šï¼Œé€™ä½¿å¾—äº†è§£å…¶åˆæˆæ©Ÿåˆ¶è®Šå¾—éå¸¸é‡è¦ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘å¯ä»¥é€²ä¸€æ­¥æ¢ç´¢å¦‚ä½•åˆ©ç”¨é€™äº›å¤©ç„¶åŒ–åˆç‰©ä¾†ä¿ƒé€²å¥åº·ï¼Œç”šè‡³å¯èƒ½åœ¨æŸäº›ç–¾ç—…çš„é é˜²æˆ–æ²»ç™‚ä¸­ç™¼æ®ä½œç”¨ï¼Œé›–ç„¶ç›®å‰å°šæœªæœ‰ç¢ºå®šçš„çµè«–ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è¾£æœ¨ä¸­ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ç•°ç¡«æ°°é…¸é…¯ï¼ˆITCsï¼‰çš„åˆæˆæ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯è¾£æœ¨åŸºå› çµ„ä¸­èˆ‡ç•°ç¡«æ°°é…¸é…¯åˆæˆç›¸é—œçš„åŸºå› ï¼Œç‰¹åˆ¥æ˜¯é‚£äº›ç·¨ç¢¼é…¶çš„åŸºå› ã€‚é€éåŸºå› æ¯”å°å’Œé€”å¾‘åˆ†æï¼Œç ”ç©¶è€…æ‰¾åˆ°äº†ä¹å€‹é—œéµåŸºå› ï¼Œé€™äº›åŸºå› å¯èƒ½åƒèˆ‡äº†ç•°ç¡«æ°°é…¸é…¯çš„åˆæˆéç¨‹ï¼Œé€™å°æ–¼ç†è§£è¾£æœ¨çš„å¥åº·æ•ˆç›Šè‡³é—œé‡è¦ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆé€²è¡Œäº†åŸºå› çµ„çš„æ¯”å°å’Œåˆ†æï¼Œä»¥ç¢ºå®šèˆ‡ç•°ç¡«æ°°é…¸é…¯åˆæˆç›¸é—œçš„åŸºå› ã€‚æ¥è‘—ï¼Œä»–å€‘å°é€™äº›åŸºå› çš„è¡¨é”é€²è¡Œäº†ç›¸é—œæ€§åˆ†æï¼Œç™¼ç¾æŸäº›åŸºå› èˆ‡è˜¿è””ç¡«ç´ çš„å«é‡æœ‰é¡¯è‘—çš„æ­£ç›¸é—œã€‚ç‰¹åˆ¥æ˜¯ï¼Œä»–å€‘æˆåŠŸå…‹éš†äº†MoMYR1åŸºå› ï¼Œä¸¦åœ¨å¤§è…¸æ¡¿èŒä¸­è¡¨é”äº†é‡çµ„è›‹ç™½ã€‚é€™äº›å¯¦é©—å¹«åŠ©ç ”ç©¶è€…äº†è§£äº†è¾£æœ¨ä¸­è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒMoMYR1åŸºå› è¢«ç¢ºå®šç‚ºè¾£æœ¨ä¸­ç•°ç¡«æ°°é…¸é…¯åˆæˆçš„é‡è¦é…¶åŸºå› ã€‚å¯¦é©—çµæœé¡¯ç¤ºï¼Œé‡çµ„çš„MoMYR1è›‹ç™½èƒ½æœ‰æ•ˆå‚¬åŒ–ç‰¹å®šåº•ç‰©çš„è½‰åŒ–ï¼Œä¸¦ä¸”åœ¨é«”å¤–é…¶æ´»æ€§æ¸¬è©¦ä¸­è¡¨ç¾å‡ºè‰¯å¥½çš„å‚¬åŒ–æ•ˆç‡ã€‚é€™äº›çµæœä¸åƒ…ç¢ºèªäº†MoMYR1åœ¨ç•°ç¡«æ°°é…¸é…¯åˆæˆä¸­çš„é—œéµè§’è‰²ï¼Œä¹Ÿç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†ç†è«–åŸºç¤ï¼Œä¸¦å¯èƒ½ä¿ƒé€²ç¶ è‰²ç”Ÿç”¢ç­–ç•¥çš„ç™¼å±•ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational journal of biological macromoleculesã€‹æ–¼ 2026 å¹´ 2 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿæœ‰ä¸€ç¨®æ¤ç‰©å«è¾£æœ¨ï¼Œè£¡é¢æœ‰å€‹ç¥å¥‡çš„æˆåˆ†å«è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¾ˆå¤šå¥½è™•ï¼æœ€è¿‘æœ‰ç ”ç©¶å°ˆé–€æ¢è¨é€™å€‹æˆåˆ†çš„åˆæˆéç¨‹ï¼Œè®“æˆ‘å€‘ä¾†çœ‹çœ‹ä»–å€‘ç™¼ç¾äº†ä»€éº¼å§ï¼\n\né€™é …ç ”ç©¶çš„é‡é»æ˜¯äº†è§£è¾£æœ¨ä¸­ä¸€ç¨®å«ç•°ç¡«æ°°é…¸é…¯ï¼ˆITCsï¼‰çš„åŒ–åˆç‰©æ˜¯å¦‚ä½•åˆæˆçš„ã€‚ç ”ç©¶åœ˜éšŠåˆ†æäº†è¾£æœ¨çš„åŸºå› ï¼Œæ‰¾åˆ°äº†ä¹å€‹é—œéµåŸºå› ï¼Œé€™äº›åŸºå› å¯èƒ½åƒèˆ‡äº†é€™äº›æœ‰ç›ŠåŒ–åˆç‰©çš„è£½é€ ï¼Œé€™å°æ–¼æˆ‘å€‘ç†è§£è¾£æœ¨çš„å¥åº·æ•ˆç›Šéå¸¸é‡è¦ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡æ¯”å°äº†è¾£æœ¨çš„åŸºå› çµ„ï¼Œä¸¦ç™¼ç¾æŸäº›åŸºå› çš„è¡¨ç¾èˆ‡è˜¿è””ç¡«ç´ çš„å«é‡æœ‰æ­£ç›¸é—œã€‚ç‰¹åˆ¥æ˜¯ï¼Œä»–å€‘æˆåŠŸå…‹éš†äº†ä¸€å€‹å«MoMYR1çš„åŸºå› ï¼Œä¸¦åœ¨å¤§è…¸æ¡¿èŒä¸­è¡¨é”äº†å®ƒï¼Œé€™å¹«åŠ©ä»–å€‘æ›´å¥½åœ°ç†è§£è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ã€‚\n\næœ€é‡è¦çš„æ˜¯ï¼ŒMoMYR1åŸºå› è¢«ç¢ºå®šç‚ºåˆæˆç•°ç¡«æ°°é…¸é…¯çš„é‡è¦è§’è‰²ï¼Œå¯¦é©—é¡¯ç¤ºå®ƒèƒ½æœ‰æ•ˆå‚¬åŒ–åŒ–å­¸åæ‡‰ï¼Œé€™ç‚ºæœªä¾†çš„ç ”ç©¶å’Œç¶ è‰²ç”Ÿç”¢ç­–ç•¥æä¾›äº†é‡è¦åŸºç¤ã€‚\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. è¾£æœ¨ä¸­çš„è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å¥åº·ã€‚\n2. ç ”ç©¶æ‰¾åˆ°äº†ä¹å€‹é—œéµåŸºå› ï¼Œèˆ‡åŒ–åˆç‰©åˆæˆæœ‰é—œã€‚\n3. MoMYR1åŸºå› åœ¨ç•°ç¡«æ°°é…¸é…¯åˆæˆä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚",
    "image_prompt": "Create an informative illustration that explains the experimental process and main findings of a study on the synthesis of a health-beneficial compound called sulforaphane from the moringa plant. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, or cells, and arrows or flow lines showing the experimental steps. Include a section labeled 'Main Findings' that highlights key results, such as protective effects or directional changes.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41651260/"
  },
  {
    "id": "41659256",
    "title_en": "Efficacy and mechanisms of cisplatin and sulforaphane nanoparticles in alleviating cisplatin resistance in non-small cell lung cancer.",
    "pub_date": "2026 Jan",
    "journal": "Translational lung cancer research",
    "abstract_en": "Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and its morbidity and mortality rates continue to increase, placing tremendous pressure on global public health systems. Cisplatin (DDP), also known as diamminedichloroplatinum (II), is a traditional chemotherapy drug widely used in the treatment of NSCLC; however, it has serious side effects and can easily lead to drug resistance, which seriously limits its efficacy. The mechanism of DDP resistance is closely related to ferroptosis. Tumor cells evade the killing effect of drugs by regulating iron metabolism, anti-oxidant responses, and lipid metabolism. Sulforaphane (SFN) is a classic ferroptosis activator with potent anti-tumor effects. This study aims to develop a novel NSCLC-targeted nanoplatform loaded with cisplatin and sulforaphane, which is expected to reverse the drug resistance induced by cisplatin monotherapy. This study was conducted on three levels: materials science, cytology and zoology. First, nanostructured SFN and DDP particles (nSDDPs) with NSCLC-targeting functions were synthesized. The distribution characteristics and safety characteristics were evaluated through cell experiments and animal experiments using immunofluorescence imaging, in vivo imaging technology, and hematoxylin and eosin (H&E) staining. To explore the efficacy of the nSDDPs, we tested the cell activity, cell proliferation rate, cell scratch, and ferroptosis-related indicators. To further test the DDP resistance-improving effect and anti-tumor effect of the nSDDPs, we conducted subcutaneous tumor-bearing experiments to detect tumor size, assess histological status, investigate metastasis-related factors and ferroptosis-related indicators. The synthesized nSDDPs showed good targeting and biocompatibility in cell and animal models of NSCLC. In the cell experiments, the nSDDPs exerted a significant inhibitory effect on cell activity, reduced the cell proliferation rate, and exerted a strong growth inhibition effect in the cell scratch assays. In addition, the nSDDPs also exerted a significant activation effect on the ferroptosis-related indicators, further enhancing the anti-tumor effect. In the animal experiments, the nSDDPs significantly inhibited tumor growth. The tumor volume and weight were smaller, and the necrosis and apoptosis of the tumor tissue were more obvious in the nSDDP group than in the DDP group. The expression of metastasis-related factors was also significantly decreased, indicating that the nSDDPs had a strong effect in improving DDP resistance and inhibiting tumor metastasis. The nSDDPs exerted good anti-tumor effects and overcame DDP resistance to a certain extent, providing a new strategy for the treatment of NSCLC. The nSDDPs which were successfully synthesized in this study improved DDP resistance by activating the ferroptosis pathway and also exerted anti-tumor effects. Our findings provide new insights into the study of DDP drug resistance.",
    "para1": "éå°ç´°èƒè‚ºç™Œæ˜¯æœ€å¸¸è¦‹çš„è‚ºç™Œé¡å‹ï¼Œå…¶ç™¼ç—…ç‡å’Œæ­»äº¡ç‡æŒçºŒä¸Šå‡ï¼Œå°å…¨çƒå…¬å…±è¡›ç”Ÿç³»çµ±é€ æˆäº†å·¨å¤§çš„å£“åŠ›ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„æ€è·¯ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„å‚³çµ±åŒ–ç™‚è—¥ç‰©çš„æ•ˆæœå’Œæ¸›å°‘å…¶å‰¯ä½œç”¨æ–¹é¢ã€‚é€éé–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æé«˜æ‚£è€…çš„ç”Ÿå­˜ç‡å’Œç”Ÿæ´»å“è³ªï¼Œä¸¦æ¸›å°‘è‚ºç™Œå¸¶ä¾†çš„è² æ“”ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°éå°ç´°èƒè‚ºç™Œçš„æ²»ç™‚ï¼Œç‰¹åˆ¥æ˜¯æ¢è¨å¦‚ä½•å…‹æœå‚³çµ±åŒ–ç™‚è—¥ç‰©é †é‰‘ï¼ˆCisplatinï¼‰æ‰€å¼•èµ·çš„è—¥ç‰©æŠ—æ€§ã€‚ç ”ç©¶è€…å€‘é—œæ³¨çš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ç¨®ç‰©è³ªä¾†å¢å¼·é †é‰‘çš„ç™‚æ•ˆï¼Œä¸¦æ”¹å–„å…¶åœ¨æ²»ç™‚éç¨‹ä¸­çš„ä¸è¶³ä¹‹è™•ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è—¥ç‰©æŠ—æ€§çš„æ©Ÿåˆ¶ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para3": "å¯¦é©—çš„è¨­è¨ˆåŒ…æ‹¬ä¸‰å€‹å±¤é¢ï¼šææ–™ç§‘å­¸ã€ç´°èƒå­¸å’Œå‹•ç‰©å­¸ã€‚ç ”ç©¶è€…é¦–å…ˆåˆæˆäº†å…·æœ‰é‡å°éå°ç´°èƒè‚ºç™ŒåŠŸèƒ½çš„ç´ç±³çµæ§‹è˜¿è””ç¡«ç´ å’Œé †é‰‘é¡†ç²’ï¼Œä¸¦é€šéç´°èƒå¯¦é©—å’Œå‹•ç‰©å¯¦é©—ä¾†è©•ä¼°å…¶åˆ†ä½ˆç‰¹æ€§å’Œå®‰å…¨æ€§ã€‚ä½¿ç”¨å…ç–«ç†’å…‰æˆåƒã€é«”å…§æˆåƒæŠ€è¡“å’Œçµ„ç¹”æŸ“è‰²ç­‰æ–¹æ³•ä¾†é€²è¡Œè©•ä¼°ï¼Œä¸¦æ¸¬è©¦é€™äº›ç´ç±³é¡†ç²’å°ç´°èƒæ´»æ€§ã€å¢æ®–ç‡åŠç›¸é—œæŒ‡æ¨™çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œåˆæˆçš„ç´ç±³é¡†ç²’åœ¨ç´°èƒå’Œå‹•ç‰©æ¨¡å‹ä¸­é¡¯ç¤ºå‡ºè‰¯å¥½çš„é¶å‘æ€§å’Œç”Ÿç‰©ç›¸å®¹æ€§ã€‚åœ¨ç´°èƒå¯¦é©—ä¸­ï¼Œé€™äº›ç´ç±³é¡†ç²’é¡¯è‘—æŠ‘åˆ¶äº†ç´°èƒæ´»æ€§ï¼Œé™ä½äº†ç´°èƒå¢æ®–ç‡ï¼Œä¸¦åœ¨ç´°èƒåˆ®ç—•å¯¦é©—ä¸­é¡¯ç¤ºå‡ºå¼·å¤§çš„ç”Ÿé•·æŠ‘åˆ¶æ•ˆæœã€‚æ­¤å¤–ï¼Œé€™äº›ç´ç±³é¡†ç²’é‚„é¡¯è‘—æ¿€æ´»äº†èˆ‡éµæ­»äº¡ç›¸é—œçš„æŒ‡æ¨™ï¼Œé€²ä¸€æ­¥å¢å¼·äº†æŠ—è…«ç˜¤æ•ˆæœã€‚åœ¨å‹•ç‰©å¯¦é©—ä¸­ï¼Œç´ç±³é¡†ç²’é¡¯è‘—æŠ‘åˆ¶äº†è…«ç˜¤ç”Ÿé•·ï¼Œè…«ç˜¤é«”ç©å’Œé‡é‡è¼ƒå°ï¼Œè…«ç˜¤çµ„ç¹”çš„å£æ­»å’Œå‡‹äº¡ç¾è±¡ä¹Ÿæ›´åŠ æ˜é¡¯ï¼Œé¡¯ç¤ºå‡ºæ”¹å–„é †é‰‘æŠ—æ€§å’ŒæŠ‘åˆ¶è…«ç˜¤è½‰ç§»çš„æ½›åŠ›ã€‚",
    "explanation_zh": "éå°ç´°èƒè‚ºç™Œæ˜¯æœ€å¸¸è¦‹çš„è‚ºç™Œé¡å‹ï¼Œå…¶ç™¼ç—…ç‡å’Œæ­»äº¡ç‡æŒçºŒä¸Šå‡ï¼Œå°å…¨çƒå…¬å…±è¡›ç”Ÿç³»çµ±é€ æˆäº†å·¨å¤§çš„å£“åŠ›ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„æ€è·¯ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„å‚³çµ±åŒ–ç™‚è—¥ç‰©çš„æ•ˆæœå’Œæ¸›å°‘å…¶å‰¯ä½œç”¨æ–¹é¢ã€‚é€éé–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æé«˜æ‚£è€…çš„ç”Ÿå­˜ç‡å’Œç”Ÿæ´»å“è³ªï¼Œä¸¦æ¸›å°‘è‚ºç™Œå¸¶ä¾†çš„è² æ“”ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é‡å°éå°ç´°èƒè‚ºç™Œçš„æ²»ç™‚ï¼Œç‰¹åˆ¥æ˜¯æ¢è¨å¦‚ä½•å…‹æœå‚³çµ±åŒ–ç™‚è—¥ç‰©é †é‰‘ï¼ˆCisplatinï¼‰æ‰€å¼•èµ·çš„è—¥ç‰©æŠ—æ€§ã€‚ç ”ç©¶è€…å€‘é—œæ³¨çš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ç¨®ç‰©è³ªä¾†å¢å¼·é †é‰‘çš„ç™‚æ•ˆï¼Œä¸¦æ”¹å–„å…¶åœ¨æ²»ç™‚éç¨‹ä¸­çš„ä¸è¶³ä¹‹è™•ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è—¥ç‰©æŠ—æ€§çš„æ©Ÿåˆ¶ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ–¹å‘ã€‚\n\nå¯¦é©—çš„è¨­è¨ˆåŒ…æ‹¬ä¸‰å€‹å±¤é¢ï¼šææ–™ç§‘å­¸ã€ç´°èƒå­¸å’Œå‹•ç‰©å­¸ã€‚ç ”ç©¶è€…é¦–å…ˆåˆæˆäº†å…·æœ‰é‡å°éå°ç´°èƒè‚ºç™ŒåŠŸèƒ½çš„ç´ç±³çµæ§‹è˜¿è””ç¡«ç´ å’Œé †é‰‘é¡†ç²’ï¼Œä¸¦é€šéç´°èƒå¯¦é©—å’Œå‹•ç‰©å¯¦é©—ä¾†è©•ä¼°å…¶åˆ†ä½ˆç‰¹æ€§å’Œå®‰å…¨æ€§ã€‚ä½¿ç”¨å…ç–«ç†’å…‰æˆåƒã€é«”å…§æˆåƒæŠ€è¡“å’Œçµ„ç¹”æŸ“è‰²ç­‰æ–¹æ³•ä¾†é€²è¡Œè©•ä¼°ï¼Œä¸¦æ¸¬è©¦é€™äº›ç´ç±³é¡†ç²’å°ç´°èƒæ´»æ€§ã€å¢æ®–ç‡åŠç›¸é—œæŒ‡æ¨™çš„å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œåˆæˆçš„ç´ç±³é¡†ç²’åœ¨ç´°èƒå’Œå‹•ç‰©æ¨¡å‹ä¸­é¡¯ç¤ºå‡ºè‰¯å¥½çš„é¶å‘æ€§å’Œç”Ÿç‰©ç›¸å®¹æ€§ã€‚åœ¨ç´°èƒå¯¦é©—ä¸­ï¼Œé€™äº›ç´ç±³é¡†ç²’é¡¯è‘—æŠ‘åˆ¶äº†ç´°èƒæ´»æ€§ï¼Œé™ä½äº†ç´°èƒå¢æ®–ç‡ï¼Œä¸¦åœ¨ç´°èƒåˆ®ç—•å¯¦é©—ä¸­é¡¯ç¤ºå‡ºå¼·å¤§çš„ç”Ÿé•·æŠ‘åˆ¶æ•ˆæœã€‚æ­¤å¤–ï¼Œé€™äº›ç´ç±³é¡†ç²’é‚„é¡¯è‘—æ¿€æ´»äº†èˆ‡éµæ­»äº¡ç›¸é—œçš„æŒ‡æ¨™ï¼Œé€²ä¸€æ­¥å¢å¼·äº†æŠ—è…«ç˜¤æ•ˆæœã€‚åœ¨å‹•ç‰©å¯¦é©—ä¸­ï¼Œç´ç±³é¡†ç²’é¡¯è‘—æŠ‘åˆ¶äº†è…«ç˜¤ç”Ÿé•·ï¼Œè…«ç˜¤é«”ç©å’Œé‡é‡è¼ƒå°ï¼Œè…«ç˜¤çµ„ç¹”çš„å£æ­»å’Œå‡‹äº¡ç¾è±¡ä¹Ÿæ›´åŠ æ˜é¡¯ï¼Œé¡¯ç¤ºå‡ºæ”¹å–„é †é‰‘æŠ—æ€§å’ŒæŠ‘åˆ¶è…«ç˜¤è½‰ç§»çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠTranslational lung cancer researchã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± å¤§å®¶çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­æœ‰ä¸€äº›é£Ÿæä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½å¹«åŠ©å°æŠ—è‚ºç™Œï¼é€™ç¯‡æ–°ç ”ç©¶å°±èšç„¦åœ¨ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„ç‰©è³ªï¼Œæ¢ç´¢å®ƒå¦‚ä½•å¢å¼·è‚ºç™Œæ²»ç™‚çš„æ•ˆæœã€‚\n\néå°ç´°èƒè‚ºç™Œæ˜¯æœ€å¸¸è¦‹çš„è‚ºç™Œé¡å‹ï¼Œçµ¦è¨±å¤šå®¶åº­å¸¶ä¾†äº†å›°æ“¾ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æƒ³æ‰¾å‡ºå¦‚ä½•æ”¹å–„å‚³çµ±åŒ–ç™‚è—¥ç‰©çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯é‡å°ä¸€ç¨®å«é †é‰‘çš„è—¥ç‰©ï¼Œå› ç‚ºå®ƒå¸¸å¸¸æœƒé‡åˆ°æŠ—è—¥æ€§å•é¡Œã€‚ç ”ç©¶è€…å€‘è¨­è¨ˆäº†ä¸€ç³»åˆ—å¯¦é©—ï¼Œåˆ©ç”¨è˜¿è””ç¡«ç´ ä¾†çœ‹çœ‹èƒ½ä¸èƒ½æå‡é †é‰‘çš„ç™‚æ•ˆã€‚\n\nä»–å€‘é€²è¡Œäº†ææ–™ç§‘å­¸ã€ç´°èƒå­¸å’Œå‹•ç‰©å­¸çš„å¯¦é©—ï¼Œåˆæˆäº†æ–°çš„ç´ç±³é¡†ç²’ï¼Œä¸¦è§€å¯Ÿå®ƒå€‘åœ¨ç´°èƒå’Œå‹•ç‰©æ¨¡å‹ä¸­çš„è¡¨ç¾ã€‚çµæœé¡¯ç¤ºï¼Œé€™äº›ç´ç±³é¡†ç²’ä¸åƒ…èƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œé‚„èƒ½æ”¹å–„é †é‰‘çš„æŠ—æ€§ï¼Œé€™å°æœªä¾†çš„æ²»ç™‚æ–¹æ³•æœ‰å¾ˆå¤§çš„å•Ÿç™¼ï¼\n\nğŸ” ä¸»è¦ç™¼ç¾æœ‰ï¼š\n1. åˆæˆçš„ç´ç±³é¡†ç²’åœ¨ç´°èƒå¯¦é©—ä¸­é¡¯è‘—æŠ‘åˆ¶äº†ç´°èƒæ´»æ€§ã€‚\n2. åœ¨å‹•ç‰©å¯¦é©—ä¸­ï¼Œç´ç±³é¡†ç²’é¡¯è‘—æ¸›å°‘äº†è…«ç˜¤çš„é«”ç©å’Œé‡é‡ã€‚\n3. é€™äº›ç´ç±³é¡†ç²’æ¿€æ´»äº†èˆ‡è…«ç˜¤æ­»äº¡ç›¸é—œçš„æŒ‡æ¨™ï¼Œå¢å¼·äº†æŠ—è…«ç˜¤æ•ˆæœã€‚\n\né€™äº›ç ”ç©¶çµæœå¯èƒ½ç‚ºè‚ºç™Œæ²»ç™‚å¸¶ä¾†æ–°çš„å¸Œæœ›ï¼Œä½†ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºèªé€™äº›æ•ˆæœï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on a compound called sulforaphane, derived from broccoli and radishes, focusing on its effects on non-small cell lung cancer. Use simple, flat design elements on a light-colored background. Include symbols representing sulforaphane, simplified illustrations of experimental subjects (like cells or animals), arrows or flow lines to indicate experimental steps, and a section highlighting the main results, such as tumor growth inhibition and enhanced drug efficacy.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "éå°ç´°èƒè‚ºç™Œ Non-Small Cell Lung Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41659256/"
  },
  {
    "id": "41511787",
    "title_en": "Sulforaphane attenuates DSS-induced ulcerative colitis <i>via</i> the Nrf2/STAT3 signaling pathway and gut microbiota modulation.",
    "pub_date": "2026 Jan",
    "journal": "Food & function",
    "abstract_en": "Sulforaphane (SFN) is an isothiocyanate derived from cruciferous vegetables. Our previous studies have shown that nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and signal transducer and activator of transcription 3 (STAT3) may play roles in the protective effects of SFN against dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in mice. This study aims to elucidate the underlying mechanisms. GEO database analysis revealed that <i>Nrf2</i> expression was reduced, while <i>STAT3</i> expression was elevated in the colonic mucosa of UC patients compared to healthy controls (<i>P</i> < 0.01). In the DSS-induced Caco-2 cell model, <i>Nrf2</i> siRNA transfection abolished the effects of SFN on enhancing Nrf2 and tight junction protein expression, suppressing inflammatory factors and reducing the phosphorylated-STAT3/STAT3 ratio. In DSS-induced UC mice, SFN alleviated colitic symptoms in wide-type mice, including weight loss, colon edema and shortening, and inflammatory cell infiltration. SFN also reduced the levels of inflammatory cytokines and enhanced tight junction protein expression in wide-type mice with colitis. However, these protective effects were largely abolished in Nrf2 knockout mice. Moreover, in Nrf2 knockout colitis mice, SFN reduced the gut microbial diversity and decreased the relative abundance of <i>Firmicutes</i> at the phylum level, as well as <i>Muribaculaceae</i> and <i>Lachnospiraceae</i>_NK4A136 at the genus level. In conclusion, the protective effects of SFN against UC may involve the regulation of the Nrf2/STAT3 signaling pathway and modulation of the gut microbiota, highlighting Nrf2 as a key mediator of SFN's action.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼é é˜²å’Œæ”¹å–„æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰æœ‰æ½›åœ¨çš„å¹«åŠ©ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œæœƒå°è‡´è…¸é“ç™¼ç‚å’Œå…¶ä»–ä¸é©ç—‡ç‹€ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é€éèª¿ç¯€ç‰¹å®šçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ä¾†ç™¼æ®ä¿è­·ä½œç”¨ï¼Œé€™æ„å‘³è‘—é€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œæˆ–è¨±èƒ½å°é€™é¡ç–¾ç—…çš„é é˜²å’Œç®¡ç†æœ‰æ‰€åŠ©ç›Šã€‚é€™å°æ–¼å¸Œæœ›æ”¹å–„è…¸é“å¥åº·çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œç‚ºä»€éº¼è˜¿è””ç¡«ç´ èƒ½å¤ å°é€™ç¨®è…¸é“ç–¾ç—…ç”¢ç”Ÿä¿è­·æ•ˆæœï¼Œä¸¦ä¸”æƒ³è¦äº†è§£å…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€éåˆ†ææ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ï¼Œç ”ç©¶è€…ç™¼ç¾èˆ‡å¥åº·å°ç…§çµ„ç›¸æ¯”ï¼ŒæŸäº›é—œéµè›‹ç™½çš„è¡¨é”æ°´å¹³æœ‰é¡¯è‘—è®ŠåŒ–ï¼Œé€™äº›è®ŠåŒ–å¯èƒ½èˆ‡ç–¾ç—…çš„ç™¼å±•æœ‰é—œã€‚é€™äº›ç™¼ç¾ç‚ºé€²ä¸€æ­¥çš„ç ”ç©¶æä¾›äº†åŸºç¤ã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹å’Œç´°èƒæ¨¡å‹ä¾†é€²è¡Œç ”ç©¶ã€‚é¦–å…ˆï¼Œä»–å€‘åœ¨å°é¼ èº«ä¸Šä½¿ç”¨äº†ç¡«é…¸å³æ—‹ç³–é…ï¼ˆDSSï¼‰ä¾†èª˜å°æ½°ç˜æ€§çµè…¸ç‚ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ å°é€™äº›å°é¼ çš„å½±éŸ¿ã€‚åŒæ™‚ï¼Œç ”ç©¶è€…ä¹Ÿåˆ©ç”¨Caco-2ç´°èƒæ¨¡å‹ä¾†æ¨¡æ“¬è…¸é“ç’°å¢ƒï¼Œä¸¦é€²è¡ŒåŸºå› è½‰æŸ“ä»¥æ¢è¨ä¸åŒè›‹ç™½è³ªçš„è¡¨é”è®ŠåŒ–ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ å¾ç´°èƒå±¤é¢å’Œæ•´é«”ç”Ÿç‰©é«”å±¤é¢ä¾†åˆ†æè˜¿è””ç¡«ç´ çš„ä½œç”¨ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„ç—‡ç‹€ï¼ŒåŒ…æ‹¬æ¸›å°‘é«”é‡æå¤±å’Œè…¸é“è…«è„¹ï¼Œä¸¦é™ä½ç™¼ç‚ç´°èƒçš„æµ¸æ½¤ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æå‡è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ï¼Œä¸¦é™ä½ç™¼ç‚ç´°èƒå› å­çš„æ°´å¹³ã€‚ç„¶è€Œï¼Œé€™äº›ä¿è­·æ•ˆæœåœ¨ç¼ºä¹Nrf2çš„åŸºå› å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æœƒå½±éŸ¿è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œé€™äº›çµæœç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„è¦–è§’ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼é é˜²å’Œæ”¹å–„æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰æœ‰æ½›åœ¨çš„å¹«åŠ©ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œæœƒå°è‡´è…¸é“ç™¼ç‚å’Œå…¶ä»–ä¸é©ç—‡ç‹€ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é€éèª¿ç¯€ç‰¹å®šçš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ä¾†ç™¼æ®ä¿è­·ä½œç”¨ï¼Œé€™æ„å‘³è‘—é€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–ï¼Œæˆ–è¨±èƒ½å°é€™é¡ç–¾ç—…çš„é é˜²å’Œç®¡ç†æœ‰æ‰€åŠ©ç›Šã€‚é€™å°æ–¼å¸Œæœ›æ”¹å–„è…¸é“å¥åº·çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œç‚ºä»€éº¼è˜¿è””ç¡«ç´ èƒ½å¤ å°é€™ç¨®è…¸é“ç–¾ç—…ç”¢ç”Ÿä¿è­·æ•ˆæœï¼Œä¸¦ä¸”æƒ³è¦äº†è§£å…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€éåˆ†ææ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„è…¸é“çµ„ç¹”ï¼Œç ”ç©¶è€…ç™¼ç¾èˆ‡å¥åº·å°ç…§çµ„ç›¸æ¯”ï¼ŒæŸäº›é—œéµè›‹ç™½çš„è¡¨é”æ°´å¹³æœ‰é¡¯è‘—è®ŠåŒ–ï¼Œé€™äº›è®ŠåŒ–å¯èƒ½èˆ‡ç–¾ç—…çš„ç™¼å±•æœ‰é—œã€‚é€™äº›ç™¼ç¾ç‚ºé€²ä¸€æ­¥çš„ç ”ç©¶æä¾›äº†åŸºç¤ã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹å’Œç´°èƒæ¨¡å‹ä¾†é€²è¡Œç ”ç©¶ã€‚é¦–å…ˆï¼Œä»–å€‘åœ¨å°é¼ èº«ä¸Šä½¿ç”¨äº†ç¡«é…¸å³æ—‹ç³–é…ï¼ˆDSSï¼‰ä¾†èª˜å°æ½°ç˜æ€§çµè…¸ç‚ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ å°é€™äº›å°é¼ çš„å½±éŸ¿ã€‚åŒæ™‚ï¼Œç ”ç©¶è€…ä¹Ÿåˆ©ç”¨Caco-2ç´°èƒæ¨¡å‹ä¾†æ¨¡æ“¬è…¸é“ç’°å¢ƒï¼Œä¸¦é€²è¡ŒåŸºå› è½‰æŸ“ä»¥æ¢è¨ä¸åŒè›‹ç™½è³ªçš„è¡¨é”è®ŠåŒ–ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ å¾ç´°èƒå±¤é¢å’Œæ•´é«”ç”Ÿç‰©é«”å±¤é¢ä¾†åˆ†æè˜¿è””ç¡«ç´ çš„ä½œç”¨ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚å°é¼ çš„ç—‡ç‹€ï¼ŒåŒ…æ‹¬æ¸›å°‘é«”é‡æå¤±å’Œè…¸é“è…«è„¹ï¼Œä¸¦é™ä½ç™¼ç‚ç´°èƒçš„æµ¸æ½¤ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æå‡è…¸é“ç·Šå¯†é€£æ¥è›‹ç™½çš„è¡¨é”ï¼Œä¸¦é™ä½ç™¼ç‚ç´°èƒå› å­çš„æ°´å¹³ã€‚ç„¶è€Œï¼Œé€™äº›ä¿è­·æ•ˆæœåœ¨ç¼ºä¹Nrf2çš„åŸºå› å°é¼ ä¸­å¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æœƒå½±éŸ¿è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œé€™äº›çµæœç‚ºæœªä¾†çš„ç ”ç©¶æä¾›äº†æ–°çš„è¦–è§’ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood & functionã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿåƒé’èŠ±æ¤°èœå¯èƒ½å°è…¸é“å¥åº·æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹æˆåˆ†å¯èƒ½èƒ½å¤ é é˜²å’Œæ”¹å–„æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®è®“è…¸é“ç™¼ç‚çš„æ…¢æ€§ç–¾ç—…ã€‚ç ”ç©¶äººå“¡æƒ³çŸ¥é“è˜¿è””ç¡«ç´ ç‚ºä»€éº¼èƒ½èµ·ä½œç”¨ï¼Œæ–¼æ˜¯ä»–å€‘é€²è¡Œäº†ä¸€ç³»åˆ—å¯¦é©—ã€‚  \n  \nä»–å€‘ä½¿ç”¨å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬æ½°ç˜æ€§çµè…¸ç‚ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ å°å°é¼ çš„å½±éŸ¿ã€‚åŒæ™‚ï¼Œé‚„åˆ©ç”¨ç´°èƒæ¨¡å‹ä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…¸é“å…§éƒ¨çš„è®ŠåŒ–ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¸›å°‘å°é¼ çš„é«”é‡æå¤±å’Œè…¸é“è…«è„¹ï¼Œé‚„èƒ½é™ä½ç™¼ç‚ç´°èƒçš„æ•¸é‡ï¼Œé€™äº›éƒ½æ˜¯æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€ã€‚  \n  \næ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½ä¿ƒé€²è…¸é“ä¸­æŸäº›é‡è¦è›‹ç™½çš„è¡¨é”ï¼Œé€™å°ç¶­æŒè…¸é“å¥åº·ç›¸ç•¶é‡è¦ã€‚ä¸éï¼Œç•¶ç¼ºä¹ä¸€ç¨®å«åšNrf2çš„åŸºå› æ™‚ï¼Œé€™äº›æ•ˆæœæœƒå¤§å¹…æ¸›å¼±ï¼Œé¡¯ç¤ºNrf2åœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”äº†é—œéµè§’è‰²ã€‚  \n  \né€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚çš„ç—‡ç‹€  \n2. é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–å€¼å¾—é—œæ³¨  \n3. Nrf2åœ¨è…¸é“å¥åº·ä¸­å¯èƒ½éå¸¸é‡è¦  \nè®“æˆ‘å€‘ä¸€èµ·é—œå¿ƒè…¸é“å¥åº·ï¼Œå¾é£²é£Ÿé–‹å§‹ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main findings of a study on sulforaphane and ulcerative colitis. Use a flat design style with a white or light-colored background and soft colors. Include simple icons representing broccoli or sulforaphane, simplified images of experimental subjects like mice and cells, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Findings' highlighting protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41511787/"
  },
  {
    "id": "41540706",
    "title_en": "[Sulforaphane reduces reactive astrocyte-mediated neuron apoptosis <i>in vitro</i> by inhibiting the MAPK/NF-ÎºB signaling pathway in AÎ²42 oligomer-activated astrocytes].",
    "pub_date": "2026 Jan",
    "journal": "Nan fang yi ke da xue xue bao = Journal of Southern Medical University",
    "abstract_en": "To explore the effects of sulforaphane (SFN) on AÎ²42-activated U87 astrocyte-mediated apoptosis of SH-SY5Y neurons <i>in vitro</i>. U87 cells treated with different concentrations of AÎ²42, SFN or both were examined for changes in cell activity, IL-6 and TNF-Î± mRNA expression, release of IL-6 and TNF-Î± proteins, and expressions of p-p38, p-p65 and GFAP using CCK-8 assay, RT-qPCR, ELISA and Western blotting. SH-SY5Y neurons were co-cultured with U87 astrocytes treated with AÎ²42 alone or in combination with SFN or SB203580 for 24 h, and the changes in Bax protein expression levels and viability of SH-SY5Y cells were examined. The effects of AÎ²42, SFN, and their combination were also observed in astrocytes isolated from mouse brain tissues, and the indirect effects of astrocyte treatmentt on viability of the co-cultured primary neurons were assessed. The viability of U87 astrocytes increased significantly following treatment with 1.25 Î¼mol/L AÎ²42 but decreased after AÎ²42 treatment above 5 Î¼mol/L. SFN treatments for 24 h below 5 Î¼mol/L did not significantly affect U87 cell viability. AÎ²42 treatment significantly increased protein expressions of p-p38, p-p65 and GFAP, mRNA expression levels of IL-6 and TNF-Î±, and IL-6 and TNF-Î± levels in culture supernatant of U87 cells. SH-SY5Y cells co-cultured with AÎ²42-treated U87 cells showed significantly increased protein expressions of Bax, and exhibited lowered viability following co-culture with 5 Î¼mol/L AÎ²42-treated U87 cells. The isolated mouse astrocytes showed lowered viability following AÎ²42 treatment above 10 Î¼mol/L, but SFN treatment below 5 Î¼mol/L for 24 did not obviously affect the cell viability. The primary neurons co-cultured with AÎ²42-treated mouse astrocytes showed significantly lower cell viability than those co-cultured with the astrocytes treated with AÎ²+SFN or AÎ²+SB203580. SFN attenuates astrocyte-mediated neuron apoptosis by inhibiting the MAPK/NF-ÎºB signaling pathway in AÎ²42 oligomer-activated astrocytes.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„èƒŒæ™¯ä¸‹ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼æ¸›å°‘ç”±AÎ²42å¼•èµ·çš„ç¥ç¶“ç´°èƒæ­»äº¡æœ‰ä¸€å®šçš„å½±éŸ¿ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­æ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œä¾‹å¦‚é’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·ç¥ç¶“ç³»çµ±ï¼Œæ¸›å°‘èˆ‡è€å¹´ç—´å‘†ç—‡ç­‰ç–¾ç—…ç›¸é—œçš„é¢¨éšªã€‚é€™æ¨£çš„ç™¼ç¾å°æ–¼æœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²ç­–ç•¥å…·æœ‰æ½›åœ¨çš„åƒ¹å€¼ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼AÎ²42æ¿€æ´»çš„U87æ˜Ÿå½¢è† è³ªç´°èƒæ‰€å¼•ç™¼çš„SH-SY5Yç¥ç¶“å…ƒå‡‹äº¡çš„å½±éŸ¿ã€‚AÎ²42æ˜¯ä¸€ç¨®èˆ‡é˜¿èŒ²ç½•é»˜ç—‡ç›¸é—œçš„è›‹ç™½è³ªï¼Œé€™é …ç ”ç©¶é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éè˜¿è””ç¡«ç´ ä¾†æ¸›å°‘é€™ç¨®è›‹ç™½è³ªå°ç¥ç¶“ç´°èƒçš„å‚·å®³ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ”¹å–„ç”±AÎ²42å¼•èµ·çš„ç¥ç¶“ç´°èƒå­˜æ´»ç‡ï¼Œä¸¦æ¢è¨å…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†ä¸åŒæ¿ƒåº¦çš„AÎ²42å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿé€™äº›è™•ç†å°U87æ˜Ÿå½¢è† è³ªç´°èƒå’ŒSH-SY5Yç¥ç¶“å…ƒçš„å½±éŸ¿ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶äººå“¡é¦–å…ˆå°‡U87ç´°èƒèˆ‡ä¸åŒæ¿ƒåº¦çš„AÎ²42å’Œè˜¿è””ç¡«ç´ å…±åŒåŸ¹é¤Šï¼Œç„¶å¾Œä½¿ç”¨å¤šç¨®æŠ€è¡“ä¾†æ¸¬é‡ç´°èƒæ´»æ€§ã€ç‚ç—‡å› å­çš„è¡¨é”ä»¥åŠç›¸é—œçš„ä¿¡è™Ÿé€šè·¯è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œé‚„å°‡SH-SY5Yç¥ç¶“å…ƒèˆ‡è™•ç†éçš„U87ç´°èƒå…±åŒåŸ¹é¤Šï¼Œä»¥è©•ä¼°ç¥ç¶“å…ƒçš„å­˜æ´»æƒ…æ³ã€‚é€™äº›å¯¦é©—ä¸åƒ…åœ¨ç´°èƒå±¤é¢é€²è¡Œï¼Œé‚„åŒ…æ‹¬å¾å°é¼ è…¦çµ„ç¹”ä¸­åˆ†é›¢çš„æ˜Ÿå½¢è† è³ªç´°èƒã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶U87æ˜Ÿå½¢è† è³ªç´°èƒæ¥å—1.25 Î¼mol/Lçš„AÎ²42è™•ç†æ™‚ï¼Œå…¶ç´°èƒæ´»æ€§é¡¯è‘—å¢åŠ ï¼Œä½†ç•¶AÎ²42æ¿ƒåº¦è¶…é5 Î¼mol/Læ™‚ï¼Œç´°èƒæ´»æ€§å‰‡ä¸‹é™ã€‚è˜¿è””ç¡«ç´ åœ¨ä½æ–¼5 Î¼mol/Lçš„æ¿ƒåº¦ä¸‹å°U87ç´°èƒçš„æ´»æ€§å½±éŸ¿ä¸å¤§ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œèˆ‡AÎ²42è™•ç†çš„U87ç´°èƒå…±åŒåŸ¹é¤Šçš„SH-SY5Yç¥ç¶“å…ƒï¼Œå…¶Baxè›‹ç™½è¡¨é”é¡¯è‘—å¢åŠ ï¼Œä¸”å­˜æ´»ç‡é™ä½ã€‚å¾å°é¼ è…¦çµ„ç¹”åˆ†é›¢çš„æ˜Ÿå½¢è† è³ªç´°èƒåœ¨AÎ²42æ¿ƒåº¦è¶…é10 Î¼mol/Læ™‚æ´»æ€§ä¸‹é™ï¼Œä½†åœ¨ä½æ–¼5 Î¼mol/Lçš„è˜¿è””ç¡«ç´ è™•ç†ä¸‹ï¼Œç´°èƒæ´»æ€§ä¸¦æœªæ˜é¡¯å—åˆ°å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ‘åˆ¶MAPK/NF-ÎºBä¿¡è™Ÿé€šè·¯ä¾†æ¸›å°‘æ˜Ÿå½¢è† è³ªç´°èƒä»‹å°çš„ç¥ç¶“å…ƒå‡‹äº¡ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç¥ç¶“é€€è¡Œæ€§ç–¾ç—…çš„èƒŒæ™¯ä¸‹ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ–¼æ¸›å°‘ç”±AÎ²42å¼•èµ·çš„ç¥ç¶“ç´°èƒæ­»äº¡æœ‰ä¸€å®šçš„å½±éŸ¿ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­æ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œä¾‹å¦‚é’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·ç¥ç¶“ç³»çµ±ï¼Œæ¸›å°‘èˆ‡è€å¹´ç—´å‘†ç—‡ç­‰ç–¾ç—…ç›¸é—œçš„é¢¨éšªã€‚é€™æ¨£çš„ç™¼ç¾å°æ–¼æœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²ç­–ç•¥å…·æœ‰æ½›åœ¨çš„åƒ¹å€¼ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼AÎ²42æ¿€æ´»çš„U87æ˜Ÿå½¢è† è³ªç´°èƒæ‰€å¼•ç™¼çš„SH-SY5Yç¥ç¶“å…ƒå‡‹äº¡çš„å½±éŸ¿ã€‚AÎ²42æ˜¯ä¸€ç¨®èˆ‡é˜¿èŒ²ç½•é»˜ç—‡ç›¸é—œçš„è›‹ç™½è³ªï¼Œé€™é …ç ”ç©¶é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éè˜¿è””ç¡«ç´ ä¾†æ¸›å°‘é€™ç¨®è›‹ç™½è³ªå°ç¥ç¶“ç´°èƒçš„å‚·å®³ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æ”¹å–„ç”±AÎ²42å¼•èµ·çš„ç¥ç¶“ç´°èƒå­˜æ´»ç‡ï¼Œä¸¦æ¢è¨å…¶å¯èƒ½çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†ä¸åŒæ¿ƒåº¦çš„AÎ²42å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿé€™äº›è™•ç†å°U87æ˜Ÿå½¢è† è³ªç´°èƒå’ŒSH-SY5Yç¥ç¶“å…ƒçš„å½±éŸ¿ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶äººå“¡é¦–å…ˆå°‡U87ç´°èƒèˆ‡ä¸åŒæ¿ƒåº¦çš„AÎ²42å’Œè˜¿è””ç¡«ç´ å…±åŒåŸ¹é¤Šï¼Œç„¶å¾Œä½¿ç”¨å¤šç¨®æŠ€è¡“ä¾†æ¸¬é‡ç´°èƒæ´»æ€§ã€ç‚ç—‡å› å­çš„è¡¨é”ä»¥åŠç›¸é—œçš„ä¿¡è™Ÿé€šè·¯è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œé‚„å°‡SH-SY5Yç¥ç¶“å…ƒèˆ‡è™•ç†éçš„U87ç´°èƒå…±åŒåŸ¹é¤Šï¼Œä»¥è©•ä¼°ç¥ç¶“å…ƒçš„å­˜æ´»æƒ…æ³ã€‚é€™äº›å¯¦é©—ä¸åƒ…åœ¨ç´°èƒå±¤é¢é€²è¡Œï¼Œé‚„åŒ…æ‹¬å¾å°é¼ è…¦çµ„ç¹”ä¸­åˆ†é›¢çš„æ˜Ÿå½¢è† è³ªç´°èƒã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶U87æ˜Ÿå½¢è† è³ªç´°èƒæ¥å—1.25 Î¼mol/Lçš„AÎ²42è™•ç†æ™‚ï¼Œå…¶ç´°èƒæ´»æ€§é¡¯è‘—å¢åŠ ï¼Œä½†ç•¶AÎ²42æ¿ƒåº¦è¶…é5 Î¼mol/Læ™‚ï¼Œç´°èƒæ´»æ€§å‰‡ä¸‹é™ã€‚è˜¿è””ç¡«ç´ åœ¨ä½æ–¼5 Î¼mol/Lçš„æ¿ƒåº¦ä¸‹å°U87ç´°èƒçš„æ´»æ€§å½±éŸ¿ä¸å¤§ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œèˆ‡AÎ²42è™•ç†çš„U87ç´°èƒå…±åŒåŸ¹é¤Šçš„SH-SY5Yç¥ç¶“å…ƒï¼Œå…¶Baxè›‹ç™½è¡¨é”é¡¯è‘—å¢åŠ ï¼Œä¸”å­˜æ´»ç‡é™ä½ã€‚å¾å°é¼ è…¦çµ„ç¹”åˆ†é›¢çš„æ˜Ÿå½¢è† è³ªç´°èƒåœ¨AÎ²42æ¿ƒåº¦è¶…é10 Î¼mol/Læ™‚æ´»æ€§ä¸‹é™ï¼Œä½†åœ¨ä½æ–¼5 Î¼mol/Lçš„è˜¿è””ç¡«ç´ è™•ç†ä¸‹ï¼Œç´°èƒæ´»æ€§ä¸¦æœªæ˜é¡¯å—åˆ°å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ‘åˆ¶MAPK/NF-ÎºBä¿¡è™Ÿé€šè·¯ä¾†æ¸›å°‘æ˜Ÿå½¢è† è³ªç´°èƒä»‹å°çš„ç¥ç¶“å…ƒå‡‹äº¡ã€‚",
    "fb_post": "æ ¹æ“šã€ŠNan fang yi ke da xue xue bao = Journal of Southern Medical Universityã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿå…¶å¯¦å°å¤§è…¦å¥åº·æœ‰å¾ˆå¤§çš„å½±éŸ¿ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹æˆåˆ†å¯èƒ½å°æˆ‘å€‘çš„ç¥ç¶“ç³»çµ±æœ‰ä¿è­·ä½œç”¨ï¼Œå°¤å…¶æ˜¯åœ¨æŠµæŠ—èˆ‡è€å¹´ç—´å‘†ç—‡ç›¸é—œçš„ç–¾ç—…æ–¹é¢ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ¸›å°‘ä¸€ç¨®å«åšAÎ²42çš„è›‹ç™½è³ªå°ç¥ç¶“ç´°èƒçš„å‚·å®³ã€‚ç ”ç©¶äººå“¡é¦–å…ˆå°‡ä¸åŒæ¿ƒåº¦çš„AÎ²42å’Œè˜¿è””ç¡«ç´ ä¸€èµ·åŸ¹é¤Šåœ¨ç´°èƒä¸­ï¼Œä¸¦è§€å¯Ÿé€™äº›è™•ç†å°ç¥ç¶“ç´°èƒçš„å½±éŸ¿ã€‚çµæœé¡¯ç¤ºï¼Œç•¶AÎ²42æ¿ƒåº¦éé«˜æ™‚ï¼Œç¥ç¶“ç´°èƒçš„æ´»æ€§æœƒä¸‹é™ï¼Œè€Œè˜¿è””ç¡«ç´ åœ¨ä½æ¿ƒåº¦ä¸‹å°ç´°èƒçš„å½±éŸ¿ä¸å¤§ã€‚æœ€æœ‰è¶£çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿æ§æŸäº›ä¿¡è™Ÿé€šè·¯ä¾†æ¸›å°‘ç¥ç¶“ç´°èƒçš„æ­»äº¡ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°ï¼Œé€éé£²é£Ÿæ”¹å–„å¥åº·çš„å¯èƒ½æ€§ï¼\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·ç¥ç¶“ç³»çµ±ã€‚\n2. é«˜æ¿ƒåº¦çš„AÎ²42æœƒé™ä½ç¥ç¶“ç´°èƒæ´»æ€§ã€‚\n3. è˜¿è””ç¡«ç´ åœ¨ä½æ¿ƒåº¦ä¸‹å½±éŸ¿ä¸å¤§ï¼Œå¯èƒ½é€éèª¿æ§ä¿¡è™Ÿé€šè·¯æ¸›å°‘ç¥ç¶“ç´°èƒæ­»äº¡ã€‚",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of a study on the effects of sulforaphane on AÎ²42-induced neuronal apoptosis. Include simple illustrations of broccoli or sulforaphane, simplified representations of experimental subjects like cells or animals, arrows or flow lines indicating the experimental steps, and a section highlighting the main results such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "é˜¿èŒ²ç½•é»˜ç—‡ Alzheimer's Disease",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41540706/"
  },
  {
    "id": "41594902",
    "title_en": "Sulforaphane as a Multi-Scale Mechano-Modulator in Cancer: An Integrative Perspective.",
    "pub_date": "2026 Jan",
    "journal": "Biology",
    "abstract_en": "Cancer progression is driven not only by biochemical signals but also by abnormal physical forces within a stiffened tumor microenvironment. This review re-examines the anticancer compound sulforaphane (SFN) through the integrative lens of tumor biomechanics. We propose SFN functions as a \"mechano-modulator,\" whose pleiotropic effects converge to disrupt pro-invasive mechanotransduction. SFN targets key force-sensitive pathways (e.g., YAP/TEAD, Rho/ROCK), destabilizes invasion machinery (cytoskeleton, invadopodia), and promotes tissue-level changes such as extracellular matrix remodeling. While preclinical evidence for this mechano-modulatory role is compelling, this perspective also highlights the critical need for clinical validation and discusses the key translational challenges. By systematically linking SFN's molecular actions to the biophysics of tumor progression, this synthesis provides a novel framework for understanding its efficacy and outlines a rational path for its future development as a mechano-inspired therapeutic.",
    "para1": "é€™ç¯‡ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡çš„æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œç™Œç—‡çš„é€²å±•ä¸åƒ…å—åˆ°ç”ŸåŒ–ä¿¡è™Ÿçš„å½±éŸ¿ï¼Œé‚„å—åˆ°è…«ç˜¤å¾®ç’°å¢ƒä¸­ç•°å¸¸ç‰©ç†åŠ›é‡çš„é©…å‹•ã€‚é€™æ„å‘³è‘—ï¼Œé™¤äº†å‚³çµ±çš„è—¥ç‰©æ²»ç™‚ï¼Œèª¿æ•´è…«ç˜¤å‘¨åœçš„ç‰©ç†ç’°å¢ƒä¹Ÿå¯èƒ½å°ç™Œç—‡æ²»ç™‚æœ‰å¹«åŠ©ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æ”¹å–„ç™Œç—‡æ‚£è€…çš„æ²»ç™‚æ•ˆæœï¼Œä¸¦é™ä½ç™Œç—‡çš„ä¾µè¥²æ€§ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼æˆ‘å€‘ç†è§£ç™Œç—‡çš„ç”Ÿç‰©å­¸ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿç‰©åŠ›å­¸ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½ä½œç‚ºä¸€ç¨®ã€Œæ©Ÿæ¢°èª¿ç¯€åŠ‘ã€ï¼Œé€éæ”¹è®Šè…«ç˜¤å¾®ç’°å¢ƒä¸­çš„ç‰©ç†åŠ›é‡ä¾†å½±éŸ¿ç™Œç´°èƒçš„è¡Œç‚ºã€‚é€™ç¯‡ç¶œè¿°æ–‡ç« é‡æ–°æª¢è¦–äº†è˜¿è””ç¡«ç´ çš„æŠ—ç™Œç‰¹æ€§ï¼Œä¸¦å°‡å…¶èˆ‡è…«ç˜¤çš„ç”Ÿç‰©åŠ›å­¸çµåˆèµ·ä¾†ï¼Œæå‡ºäº†è˜¿è””ç¡«ç´ å¯èƒ½å¦‚ä½•å¹²æ“¾ç™Œç´°èƒçš„ä¾µè¥²æ€§æ©Ÿåˆ¶ï¼Œé€™å°æ–¼ç†è§£ç™Œç—‡çš„é€²å±•è‡³é—œé‡è¦ã€‚",
    "para3": "åœ¨å¯¦é©—æ–¹æ³•ä¸Šï¼Œé€™ç¯‡ç ”ç©¶ä¸»è¦æ˜¯åŸºæ–¼æ–‡ç»å›é¡§ï¼Œç³»çµ±æ€§åœ°åˆ†æäº†è˜¿è””ç¡«ç´ çš„åˆ†å­ä½œç”¨åŠå…¶èˆ‡è…«ç˜¤é€²å±•çš„ç”Ÿç‰©ç‰©ç†å­¸ä¹‹é–“çš„é—œè¯ã€‚ç ”ç©¶è€…æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸€äº›é—œéµçš„åŠ›æ•æ„Ÿé€šè·¯ï¼Œä¾‹å¦‚YAP/TEADå’ŒRho/ROCKï¼Œä¸¦åˆ†æäº†é€™äº›é€šè·¯å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ä¾µè¥²æ©Ÿåˆ¶ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¹Ÿæåˆ°è˜¿è””ç¡«ç´ å°ç´°èƒéª¨æ¶å’Œä¾µè¥²çªèµ·çš„ç©©å®šæ€§æœ‰å½±éŸ¿ï¼Œä¸¦ä¿ƒé€²äº†çµ„ç¹”å±¤é¢çš„è®ŠåŒ–ï¼Œå¦‚ç´°èƒå¤–åŸºè³ªçš„é‡å¡‘ã€‚",
    "para4": "é€™é …ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å…·æœ‰å¤šé‡ä½œç”¨ï¼Œèƒ½å¤ å¹²æ“¾ç™Œç´°èƒçš„ä¾µè¥²æ€§è¡Œç‚ºï¼Œä¸¦ä¿ƒé€²è…«ç˜¤å¾®ç’°å¢ƒçš„æ”¹è®Šã€‚é›–ç„¶ç›®å‰å·²æœ‰çš„å‰è‡¨åºŠè­‰æ“šæ”¯æŒè˜¿è””ç¡«ç´ çš„æ©Ÿæ¢°èª¿ç¯€ä½œç”¨ï¼Œä½†ç ”ç©¶è€…ä¹Ÿå¼·èª¿äº†è‡¨åºŠé©—è­‰çš„é‡è¦æ€§ï¼Œä¸¦è¨è«–äº†åœ¨å°‡é€™äº›ç™¼ç¾è½‰åŒ–ç‚ºè‡¨åºŠæ‡‰ç”¨æ™‚å¯èƒ½é¢è‡¨çš„æŒ‘æˆ°ã€‚é€™ç¯‡æ–‡ç« æä¾›äº†ä¸€å€‹æ–°çš„æ¡†æ¶ï¼Œå¹«åŠ©æˆ‘å€‘ç†è§£è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦ç‚ºæœªä¾†ä½œç‚ºæ©Ÿæ¢°éˆæ„Ÿæ²»ç™‚çš„ç™¼å±•æŒ‡æ˜äº†æ–¹å‘ã€‚",
    "explanation_zh": "é€™ç¯‡ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡çš„æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œç™Œç—‡çš„é€²å±•ä¸åƒ…å—åˆ°ç”ŸåŒ–ä¿¡è™Ÿçš„å½±éŸ¿ï¼Œé‚„å—åˆ°è…«ç˜¤å¾®ç’°å¢ƒä¸­ç•°å¸¸ç‰©ç†åŠ›é‡çš„é©…å‹•ã€‚é€™æ„å‘³è‘—ï¼Œé™¤äº†å‚³çµ±çš„è—¥ç‰©æ²»ç™‚ï¼Œèª¿æ•´è…«ç˜¤å‘¨åœçš„ç‰©ç†ç’°å¢ƒä¹Ÿå¯èƒ½å°ç™Œç—‡æ²»ç™‚æœ‰å¹«åŠ©ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æ”¹å–„ç™Œç—‡æ‚£è€…çš„æ²»ç™‚æ•ˆæœï¼Œä¸¦é™ä½ç™Œç—‡çš„ä¾µè¥²æ€§ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼æˆ‘å€‘ç†è§£ç™Œç—‡çš„ç”Ÿç‰©å­¸ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿç‰©åŠ›å­¸ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½ä½œç‚ºä¸€ç¨®ã€Œæ©Ÿæ¢°èª¿ç¯€åŠ‘ã€ï¼Œé€éæ”¹è®Šè…«ç˜¤å¾®ç’°å¢ƒä¸­çš„ç‰©ç†åŠ›é‡ä¾†å½±éŸ¿ç™Œç´°èƒçš„è¡Œç‚ºã€‚é€™ç¯‡ç¶œè¿°æ–‡ç« é‡æ–°æª¢è¦–äº†è˜¿è””ç¡«ç´ çš„æŠ—ç™Œç‰¹æ€§ï¼Œä¸¦å°‡å…¶èˆ‡è…«ç˜¤çš„ç”Ÿç‰©åŠ›å­¸çµåˆèµ·ä¾†ï¼Œæå‡ºäº†è˜¿è””ç¡«ç´ å¯èƒ½å¦‚ä½•å¹²æ“¾ç™Œç´°èƒçš„ä¾µè¥²æ€§æ©Ÿåˆ¶ï¼Œé€™å°æ–¼ç†è§£ç™Œç—‡çš„é€²å±•è‡³é—œé‡è¦ã€‚\n\nåœ¨å¯¦é©—æ–¹æ³•ä¸Šï¼Œé€™ç¯‡ç ”ç©¶ä¸»è¦æ˜¯åŸºæ–¼æ–‡ç»å›é¡§ï¼Œç³»çµ±æ€§åœ°åˆ†æäº†è˜¿è””ç¡«ç´ çš„åˆ†å­ä½œç”¨åŠå…¶èˆ‡è…«ç˜¤é€²å±•çš„ç”Ÿç‰©ç‰©ç†å­¸ä¹‹é–“çš„é—œè¯ã€‚ç ”ç©¶è€…æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸€äº›é—œéµçš„åŠ›æ•æ„Ÿé€šè·¯ï¼Œä¾‹å¦‚YAP/TEADå’ŒRho/ROCKï¼Œä¸¦åˆ†æäº†é€™äº›é€šè·¯å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ä¾µè¥²æ©Ÿåˆ¶ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¹Ÿæåˆ°è˜¿è””ç¡«ç´ å°ç´°èƒéª¨æ¶å’Œä¾µè¥²çªèµ·çš„ç©©å®šæ€§æœ‰å½±éŸ¿ï¼Œä¸¦ä¿ƒé€²äº†çµ„ç¹”å±¤é¢çš„è®ŠåŒ–ï¼Œå¦‚ç´°èƒå¤–åŸºè³ªçš„é‡å¡‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å…·æœ‰å¤šé‡ä½œç”¨ï¼Œèƒ½å¤ å¹²æ“¾ç™Œç´°èƒçš„ä¾µè¥²æ€§è¡Œç‚ºï¼Œä¸¦ä¿ƒé€²è…«ç˜¤å¾®ç’°å¢ƒçš„æ”¹è®Šã€‚é›–ç„¶ç›®å‰å·²æœ‰çš„å‰è‡¨åºŠè­‰æ“šæ”¯æŒè˜¿è””ç¡«ç´ çš„æ©Ÿæ¢°èª¿ç¯€ä½œç”¨ï¼Œä½†ç ”ç©¶è€…ä¹Ÿå¼·èª¿äº†è‡¨åºŠé©—è­‰çš„é‡è¦æ€§ï¼Œä¸¦è¨è«–äº†åœ¨å°‡é€™äº›ç™¼ç¾è½‰åŒ–ç‚ºè‡¨åºŠæ‡‰ç”¨æ™‚å¯èƒ½é¢è‡¨çš„æŒ‘æˆ°ã€‚é€™ç¯‡æ–‡ç« æä¾›äº†ä¸€å€‹æ–°çš„æ¡†æ¶ï¼Œå¹«åŠ©æˆ‘å€‘ç†è§£è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œä¸¦ç‚ºæœªä¾†ä½œç‚ºæ©Ÿæ¢°éˆæ„Ÿæ²»ç™‚çš„ç™¼å±•æŒ‡æ˜äº†æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBiologyã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“è˜¿è””è£¡è—è‘—çš„å¥åº·ç§˜å¯†å—ï¼Ÿæœ€è¿‘æœ‰ä¸€ç¯‡ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…åƒ…æ˜¯ç¾å‘³çš„è”¬èœæˆåˆ†ï¼Œé‚„å¯èƒ½åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‰®æ¼”é‡è¦è§’è‰²ï¼ç ”ç©¶è€…å€‘æ¢ç´¢äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…«ç˜¤çš„å¾®ç’°å¢ƒï¼Œä¸¦ç™¼ç¾å®ƒæˆ–è¨±èƒ½æ”¹è®Šè…«ç˜¤å‘¨åœçš„ç‰©ç†åŠ›é‡ï¼Œé€²è€Œå½±éŸ¿ç™Œç´°èƒçš„è¡Œç‚ºã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é€éæ–‡ç»å›é¡§ï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦æ¢è¨äº†å®ƒå°ç´°èƒå’Œçµ„ç¹”çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å¹²æ“¾ç™Œç´°èƒçš„ä¾µè¥²æ€§ï¼Œä¸¦ä¿ƒé€²è…«ç˜¤å¾®ç’°å¢ƒçš„è®ŠåŒ–ã€‚é›–ç„¶ç›®å‰çš„çµæœå¾ˆæœ‰å¸Œæœ›ï¼Œä½†ä»–å€‘ä¹Ÿå¼·èª¿äº†é€²ä¸€æ­¥è‡¨åºŠé©—è­‰çš„é‡è¦æ€§ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½é€éæ”¹è®Šè…«ç˜¤å¾®ç’°å¢ƒä¾†å½±éŸ¿ç™Œç´°èƒè¡Œç‚ºã€‚\n2. ç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼é™ä½ç™Œç´°èƒçš„ä¾µè¥²æ€§ã€‚\n3. é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶å°‡æ˜¯æœªä¾†ç™¼å±•çš„é—œéµï¼",
    "image_prompt": "Create a flat design infographic with a light background that explains the experimental methods and main findings of a study on sulforaphane. Include simplified illustrations of broccoli and sulforaphane, as well as simplified representations of experimental subjects like human cells. Use arrows or flow lines to show the experimental steps. Add a section labeled 'Main Findings' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41594902/"
  },
  {
    "id": "41535692",
    "title_en": "Inhibiting autophagy enhances anti-cancer properties of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Scientific reports",
    "abstract_en": "Bladder cancer (BC) has an extremely low survival rate due to its tendency to metastasize. The antimalarial drug chloroquine (CQ) can inhibit BC progression and invasiveness by targeting basal autophagy. However, the mechanism by which CQ affects BC is not defined. Here, we revealed that although CQ showed an anticancer effect by reducing the migration and proliferation of the analyzed bladder cancer cells, it increased the expression of ICAM-1, a protein whose expression is associated with higher tumorigenic potential. Sulforaphane (SFN), a well-known ICAM-1 inhibitor, significantly contributed to the enhancement of anticancer effect of CQ, through regulation of both AKT/GSK-3Î² and mTOR/ULK pathways, which led to effective inhibition of autophagy, reduced proliferation level or inhibition of migration of the analyzed bladder cells. Moreover, regulation of pathways related to autophagy contributed to the reduction of mitochondrial membrane potential and regulation of ROS level. Nevertheless, the level of influence of CQ and SFN on the anticancer effects strongly depended on the molecular basis of the analyzed bladder cell lines. Our data indicate that although CQ exerts antitumor effects on bladder cancer cells, it should be noted that activation of some pro-tumor pathways may be associated with subsequent disease relapse or treatment resistance.",
    "para1": "è†€èƒ±ç™Œæ˜¯ä¸€ç¨®å­˜æ´»ç‡æ¥µä½çš„ç™Œç—‡ï¼Œå› ç‚ºå®ƒå®¹æ˜“è½‰ç§»ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è†€èƒ±ç™Œçš„æ²»ç™‚ä¸Šã€‚ç ”ç©¶æŒ‡å‡ºï¼Œé›–ç„¶æŸäº›è—¥ç‰©å¦‚æ°¯å–¹ï¼ˆCQï¼‰èƒ½æŠ‘åˆ¶è†€èƒ±ç™Œçš„é€²å±•ï¼Œä½†åŒæ™‚ä¹Ÿå¯èƒ½æ¿€æ´»ä¸€äº›èˆ‡è…«ç˜¤å½¢æˆç›¸é—œçš„é€”å¾‘ï¼Œé€™å¯èƒ½æœƒå½±éŸ¿æ²»ç™‚çš„æ•ˆæœã€‚å› æ­¤ï¼Œäº†è§£é€™äº›è—¥ç‰©çš„ä½œç”¨æ©Ÿåˆ¶å°æ–¼æœªä¾†çš„ç™Œç—‡æ²»ç™‚ç­–ç•¥éå¸¸é‡è¦ï¼Œèƒ½å¹«åŠ©é†«ç™‚äººå“¡æ›´å¥½åœ°é é˜²ç–¾ç—…å¾©ç™¼æˆ–æŠµæŠ—æ²»ç™‚ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨æ°¯å–¹å°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•é€šéèª¿æ§è‡ªå™¬ä½œç”¨ä¾†å½±éŸ¿ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œæ°¯å–¹åœ¨æ²»ç™‚è†€èƒ±ç™Œæ™‚çš„å…·é«”æ©Ÿåˆ¶ï¼Œä»¥åŠå®ƒèˆ‡è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰ä¹‹é–“çš„ç›¸äº’ä½œç”¨ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼ç†è§£è†€èƒ±ç™Œçš„æ²»ç™‚éç¨‹ï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒç³»ï¼Œè§€å¯Ÿæ°¯å–¹å’Œè˜¿è””ç¡«ç´ çš„è¯åˆä½œç”¨ã€‚ä»–å€‘ä½¿ç”¨äº†ç´°èƒé·ç§»å’Œå¢æ®–çš„æ¸¬è©¦ï¼Œä¸¦è©•ä¼°äº†ç›¸é—œçš„ä¿¡è™Ÿå‚³å°é€”å¾‘ï¼Œå¦‚AKT/GSK-3Î²å’ŒmTOR/ULKã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…äº†è§£é€™äº›è—¥ç‰©å¦‚ä½•å½±éŸ¿è‡ªå™¬éç¨‹ï¼Œä»¥åŠå®ƒå€‘å°ç´°èƒç”Ÿé•·å’Œé·ç§»çš„å½±éŸ¿ï¼Œå¾è€Œæä¾›äº†å°è†€èƒ±ç™Œæ²»ç™‚çš„æ·±å…¥è¦‹è§£ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ°¯å–¹å°è†€èƒ±ç™Œç´°èƒå…·æœ‰æŠ—ç™Œæ•ˆæœï¼Œèƒ½æ¸›å°‘ç´°èƒçš„é·ç§»å’Œå¢æ®–ã€‚ç„¶è€Œï¼Œç ”ç©¶ä¹Ÿç™¼ç¾æ°¯å–¹æœƒå¢åŠ ICAM-1çš„è¡¨é”ï¼Œé€™æ˜¯ä¸€ç¨®èˆ‡è…«ç˜¤å½¢æˆæ½›åŠ›ç›¸é—œçš„è›‹ç™½è³ªã€‚è˜¿è””ç¡«ç´ ä½œç‚ºICAM-1çš„æŠ‘åˆ¶åŠ‘ï¼Œé¡¯è‘—å¢å¼·äº†æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœï¼Œä¸¦ä¸”èª¿æ§äº†è‡ªå™¬ç›¸é—œçš„ä¿¡è™Ÿå‚³å°é€”å¾‘ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œæ°¯å–¹å’Œè˜¿è””ç¡«ç´ çš„å½±éŸ¿ç¨‹åº¦å–æ±ºæ–¼æ‰€åˆ†æçš„è†€èƒ±ç™Œç´°èƒç³»çš„åˆ†å­åŸºç¤ï¼Œé€™æ„å‘³è‘—åœ¨æ²»ç™‚éç¨‹ä¸­å¯èƒ½æœƒå‡ºç¾å¾©ç™¼æˆ–æ²»ç™‚æŠµæŠ—çš„é¢¨éšªã€‚",
    "explanation_zh": "è†€èƒ±ç™Œæ˜¯ä¸€ç¨®å­˜æ´»ç‡æ¥µä½çš„ç™Œç—‡ï¼Œå› ç‚ºå®ƒå®¹æ˜“è½‰ç§»ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è†€èƒ±ç™Œçš„æ²»ç™‚ä¸Šã€‚ç ”ç©¶æŒ‡å‡ºï¼Œé›–ç„¶æŸäº›è—¥ç‰©å¦‚æ°¯å–¹ï¼ˆCQï¼‰èƒ½æŠ‘åˆ¶è†€èƒ±ç™Œçš„é€²å±•ï¼Œä½†åŒæ™‚ä¹Ÿå¯èƒ½æ¿€æ´»ä¸€äº›èˆ‡è…«ç˜¤å½¢æˆç›¸é—œçš„é€”å¾‘ï¼Œé€™å¯èƒ½æœƒå½±éŸ¿æ²»ç™‚çš„æ•ˆæœã€‚å› æ­¤ï¼Œäº†è§£é€™äº›è—¥ç‰©çš„ä½œç”¨æ©Ÿåˆ¶å°æ–¼æœªä¾†çš„ç™Œç—‡æ²»ç™‚ç­–ç•¥éå¸¸é‡è¦ï¼Œèƒ½å¹«åŠ©é†«ç™‚äººå“¡æ›´å¥½åœ°é é˜²ç–¾ç—…å¾©ç™¼æˆ–æŠµæŠ—æ²»ç™‚ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨æ°¯å–¹å°è†€èƒ±ç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•é€šéèª¿æ§è‡ªå™¬ä½œç”¨ä¾†å½±éŸ¿ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œæ°¯å–¹åœ¨æ²»ç™‚è†€èƒ±ç™Œæ™‚çš„å…·é«”æ©Ÿåˆ¶ï¼Œä»¥åŠå®ƒèˆ‡è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰ä¹‹é–“çš„ç›¸äº’ä½œç”¨ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°‡æœ‰åŠ©æ–¼ç†è§£è†€èƒ±ç™Œçš„æ²»ç™‚éç¨‹ï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒç³»ï¼Œè§€å¯Ÿæ°¯å–¹å’Œè˜¿è””ç¡«ç´ çš„è¯åˆä½œç”¨ã€‚ä»–å€‘ä½¿ç”¨äº†ç´°èƒé·ç§»å’Œå¢æ®–çš„æ¸¬è©¦ï¼Œä¸¦è©•ä¼°äº†ç›¸é—œçš„ä¿¡è™Ÿå‚³å°é€”å¾‘ï¼Œå¦‚AKT/GSK-3Î²å’ŒmTOR/ULKã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…äº†è§£é€™äº›è—¥ç‰©å¦‚ä½•å½±éŸ¿è‡ªå™¬éç¨‹ï¼Œä»¥åŠå®ƒå€‘å°ç´°èƒç”Ÿé•·å’Œé·ç§»çš„å½±éŸ¿ï¼Œå¾è€Œæä¾›äº†å°è†€èƒ±ç™Œæ²»ç™‚çš„æ·±å…¥è¦‹è§£ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ°¯å–¹å°è†€èƒ±ç™Œç´°èƒå…·æœ‰æŠ—ç™Œæ•ˆæœï¼Œèƒ½æ¸›å°‘ç´°èƒçš„é·ç§»å’Œå¢æ®–ã€‚ç„¶è€Œï¼Œç ”ç©¶ä¹Ÿç™¼ç¾æ°¯å–¹æœƒå¢åŠ ICAM-1çš„è¡¨é”ï¼Œé€™æ˜¯ä¸€ç¨®èˆ‡è…«ç˜¤å½¢æˆæ½›åŠ›ç›¸é—œçš„è›‹ç™½è³ªã€‚è˜¿è””ç¡«ç´ ä½œç‚ºICAM-1çš„æŠ‘åˆ¶åŠ‘ï¼Œé¡¯è‘—å¢å¼·äº†æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœï¼Œä¸¦ä¸”èª¿æ§äº†è‡ªå™¬ç›¸é—œçš„ä¿¡è™Ÿå‚³å°é€”å¾‘ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œæ°¯å–¹å’Œè˜¿è””ç¡«ç´ çš„å½±éŸ¿ç¨‹åº¦å–æ±ºæ–¼æ‰€åˆ†æçš„è†€èƒ±ç™Œç´°èƒç³»çš„åˆ†å­åŸºç¤ï¼Œé€™æ„å‘³è‘—åœ¨æ²»ç™‚éç¨‹ä¸­å¯èƒ½æœƒå‡ºç¾å¾©ç™¼æˆ–æ²»ç™‚æŠµæŠ—çš„é¢¨éšªã€‚",
    "fb_post": "æ ¹æ“šã€ŠScientific reportsã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒŸ è†€èƒ±ç™Œçš„æ²»ç™‚æ–°å¸Œæœ›ï¼ä½ çŸ¥é“å—ï¼Ÿé€™ç¨®ç™Œç—‡çš„å­˜æ´»ç‡å¾ˆä½ï¼Œå› ç‚ºå®ƒå¾ˆå®¹æ˜“è½‰ç§»ã€‚æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®å«æ°¯å–¹çš„è—¥ç‰©ï¼Œç™¼ç¾å®ƒå°è†€èƒ±ç™Œç´°èƒæœ‰ä¸€å®šçš„æŠ‘åˆ¶ä½œç”¨ï¼Œä½†ä¹Ÿå¯èƒ½æ¿€æ´»ä¸€äº›è®“è…«ç˜¤å½¢æˆçš„é€”å¾‘ï¼Œé€™è®“äººæœ‰é»æ“”å¿ƒã€‚ç ”ç©¶è€…å€‘æƒ³è¦äº†è§£æ°¯å–¹å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ï¼Œä¸¦ä¸”é‚„æœ‰ä¸€å€‹å«è˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œå®ƒå¯èƒ½æœƒå¢å¼·æ°¯å–¹çš„æ•ˆæœã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆ†æäº†ä¸åŒçš„è†€èƒ±ç™Œç´°èƒï¼Œè§€å¯Ÿæ°¯å–¹å’Œè˜¿è””ç¡«ç´ çš„è¯åˆä½œç”¨ã€‚ä»–å€‘ç™¼ç¾ï¼Œæ°¯å–¹èƒ½æ¸›å°‘ç™Œç´°èƒçš„é·ç§»å’Œå¢æ®–ï¼Œä½†ä¹Ÿæœƒå¢åŠ ä¸€ç¨®èˆ‡è…«ç˜¤å½¢æˆç›¸é—œçš„è›‹ç™½è³ªã€‚å€¼å¾—ä¸€æçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºé€™ç¨®è›‹ç™½è³ªçš„æŠ‘åˆ¶åŠ‘ï¼Œèƒ½é¡¯è‘—å¢å¼·æ°¯å–¹çš„æŠ—ç™Œæ•ˆæœï¼\n\nğŸ” ç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. æ°¯å–¹å°è†€èƒ±ç™Œç´°èƒæœ‰æŠ—ç™Œæ•ˆæœï¼Œä½†ä¹Ÿå¯èƒ½æœ‰å‰¯ä½œç”¨ã€‚\n2. è˜¿è””ç¡«ç´ èƒ½å¢å¼·æ°¯å–¹çš„æ•ˆæœï¼Œå¹«åŠ©æŠ‘åˆ¶è…«ç˜¤å½¢æˆã€‚\n3. æ²»ç™‚æ•ˆæœå¯èƒ½å› ä¸åŒç´°èƒé¡å‹è€Œç•°ï¼Œæœªä¾†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ï¼",
    "image_prompt": "Create an infographic that visually explains the experimental methods and main findings of a study on bladder cancer treatment. Include simplified illustrations of broccoli or sulforaphane, simplified representations of experimental subjects like cells or humans, arrows or flow lines indicating the steps of the experiment, and a section clearly stating the main results such as protective effects and changes observed. Use a flat design style with a light background and soft colors.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è†€èƒ±ç™Œ Bladder Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41535692/"
  },
  {
    "id": "41543290",
    "title_en": "Elucidation of Sulforaphane-Mediated Effects on the Cellular Human Metabolome Using Metabolic Profiling.",
    "pub_date": "2026 Jan",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Sulforaphane (SFN) is an isothiocyanate derived from glucoraphanin, which occurs in broccoli. Several human health-promoting effects are attributed to the consumption of cruciferous vegetables or food supplements containing SFN. Its described cancer-preventive, chemoprotective, and antioxidant properties made SFN an increasingly important research topic. The antioxidant properties have previously been connected to stimulation of the Nuclear factor erythroid-2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) signaling pathway. However, the global effects of SFN on the primary metabolic pathways have yet to be fully unraveled. Therefore metabolic profiling was used to elucidate the effects of SFN on the cellular metabolome. For this purpose, human hepatoblastoma cells (HepG2) were incubated with SFN and the changes of primary metabolite levels were determined by targeted hydrophilic interaction liquid chromatography tandem mass spectrometry (HILIC-MS/MS) analysis. Metabolic profiling revealed that SFN affects the tricarboxylic acid cycle, the urea cycle and their related amino acids. Furthermore, effects on glycolysis, pentose phosphate pathway and glutathione (GSH) levels were observed. This profound impact on nearly all primary metabolic pathways indicates a high bioactive potential of this natural compound. Especially elevated GSH levels underline the commonly described antioxidant potential of SFN.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†å—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ï¼Œå› ç‚ºå®ƒå¯èƒ½å°å¥åº·æœ‰è¨±å¤šå¥½è™•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé£Ÿç”¨å«æœ‰è˜¿è””ç¡«ç´ çš„åå­—èŠ±ç§‘è”¬èœæˆ–è£œå……å“ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯ç™Œç—‡ã€‚é€™äº›å¥åº·ä¿ƒé€²çš„æ•ˆæœï¼Œè®“æˆ‘å€‘å°å¦‚ä½•é€éé£²é£Ÿä¾†å¢é€²å¥åº·å’Œé é˜²ç–¾ç—…æœ‰äº†æ–°çš„æ€è€ƒã€‚äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¯èƒ½æœƒå¹«åŠ©æˆ‘å€‘æ‰¾åˆ°æ›´æœ‰æ•ˆçš„å¥åº·ç®¡ç†æ–¹æ³•ï¼Œä¸¦ä¿ƒé€²æœªä¾†çš„ç ”ç©¶èˆ‡æ‡‰ç”¨ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚é›–ç„¶éå»çš„ç ”ç©¶å·²ç¶“æŒ‡å‡ºè˜¿è””ç¡«ç´ å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™Œçš„æ½›åŠ›ï¼Œä½†å…¶å°ä¸»è¦ä»£è¬é€”å¾‘çš„å…·é«”å½±éŸ¿ä»ä¸å®Œå…¨æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€éä»£è¬åˆ†æä¾†æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ åœ¨ç´°èƒå…§çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿ç´°èƒçš„ä»£è¬éç¨‹ï¼Œé€™å°æ–¼ç†è§£å…¶å¥åº·æ•ˆç›Šè‡³é—œé‡è¦ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼ˆHepG2ï¼‰ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡é€™äº›ç´°èƒèˆ‡è˜¿è””ç¡«ç´ é€²è¡ŒåŸ¹é¤Šã€‚æ¥è‘—ï¼Œç ”ç©¶åœ˜éšŠåˆ©ç”¨é‡å°æ€§è¦ªæ°´æ€§äº’å‹•æ¶²ç›¸è‰²è­œä¸²è¯è³ªè­œï¼ˆHILIC-MS/MSï¼‰åˆ†æï¼Œä¾†æ¸¬å®šç´°èƒå…§ä¸»è¦ä»£è¬ç‰©çš„è®ŠåŒ–ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ¸…æ¥šåœ°è§€å¯Ÿåˆ°è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ï¼Œä¸¦æ­ç¤ºå…¶åœ¨ä¸åŒä»£è¬é€”å¾‘ä¸­çš„ä½œç”¨ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹ä¸»è¦ä»£è¬é€”å¾‘ç”¢ç”Ÿäº†é¡¯è‘—å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¸‰ç¾§é…¸å¾ªç’°ã€å°¿ç´ å¾ªç’°åŠå…¶ç›¸é—œçš„æ°¨åŸºé…¸ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è§€å¯Ÿåˆ°å°ç³–è§£ä½œç”¨ã€ç£·é…¸æˆŠç³–é€”å¾‘åŠè°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰æ°´å¹³çš„å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¾ˆé«˜çš„ç”Ÿç‰©æ´»æ€§æ½›åŠ›ï¼Œå°¤å…¶æ˜¯æå‡çš„è°·èƒ±ç”˜è‚½æ°´å¹³ï¼Œé€²ä¸€æ­¥å¼·èª¿äº†å…¶æŠ—æ°§åŒ–çš„æ½›åŠ›ï¼Œé€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„å¥åº·ç ”ç©¶æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾é’èŠ±æ¤°èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†å—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ï¼Œå› ç‚ºå®ƒå¯èƒ½å°å¥åº·æœ‰è¨±å¤šå¥½è™•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé£Ÿç”¨å«æœ‰è˜¿è””ç¡«ç´ çš„åå­—èŠ±ç§‘è”¬èœæˆ–è£œå……å“ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯ç™Œç—‡ã€‚é€™äº›å¥åº·ä¿ƒé€²çš„æ•ˆæœï¼Œè®“æˆ‘å€‘å°å¦‚ä½•é€éé£²é£Ÿä¾†å¢é€²å¥åº·å’Œé é˜²ç–¾ç—…æœ‰äº†æ–°çš„æ€è€ƒã€‚äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¯èƒ½æœƒå¹«åŠ©æˆ‘å€‘æ‰¾åˆ°æ›´æœ‰æ•ˆçš„å¥åº·ç®¡ç†æ–¹æ³•ï¼Œä¸¦ä¿ƒé€²æœªä¾†çš„ç ”ç©¶èˆ‡æ‡‰ç”¨ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚é›–ç„¶éå»çš„ç ”ç©¶å·²ç¶“æŒ‡å‡ºè˜¿è””ç¡«ç´ å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™Œçš„æ½›åŠ›ï¼Œä½†å…¶å°ä¸»è¦ä»£è¬é€”å¾‘çš„å…·é«”å½±éŸ¿ä»ä¸å®Œå…¨æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€éä»£è¬åˆ†æä¾†æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ åœ¨ç´°èƒå…§çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿ç´°èƒçš„ä»£è¬éç¨‹ï¼Œé€™å°æ–¼ç†è§£å…¶å¥åº·æ•ˆç›Šè‡³é—œé‡è¦ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼ˆHepG2ï¼‰ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡é€™äº›ç´°èƒèˆ‡è˜¿è””ç¡«ç´ é€²è¡ŒåŸ¹é¤Šã€‚æ¥è‘—ï¼Œç ”ç©¶åœ˜éšŠåˆ©ç”¨é‡å°æ€§è¦ªæ°´æ€§äº’å‹•æ¶²ç›¸è‰²è­œä¸²è¯è³ªè­œï¼ˆHILIC-MS/MSï¼‰åˆ†æï¼Œä¾†æ¸¬å®šç´°èƒå…§ä¸»è¦ä»£è¬ç‰©çš„è®ŠåŒ–ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ æ¸…æ¥šåœ°è§€å¯Ÿåˆ°è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ï¼Œä¸¦æ­ç¤ºå…¶åœ¨ä¸åŒä»£è¬é€”å¾‘ä¸­çš„ä½œç”¨ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹ä¸»è¦ä»£è¬é€”å¾‘ç”¢ç”Ÿäº†é¡¯è‘—å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¸‰ç¾§é…¸å¾ªç’°ã€å°¿ç´ å¾ªç’°åŠå…¶ç›¸é—œçš„æ°¨åŸºé…¸ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è§€å¯Ÿåˆ°å°ç³–è§£ä½œç”¨ã€ç£·é…¸æˆŠç³–é€”å¾‘åŠè°·èƒ±ç”˜è‚½ï¼ˆGSHï¼‰æ°´å¹³çš„å½±éŸ¿ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¾ˆé«˜çš„ç”Ÿç‰©æ´»æ€§æ½›åŠ›ï¼Œå°¤å…¶æ˜¯æå‡çš„è°·èƒ±ç”˜è‚½æ°´å¹³ï¼Œé€²ä¸€æ­¥å¼·èª¿äº†å…¶æŠ—æ°§åŒ–çš„æ½›åŠ›ï¼Œé€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„å¥åº·ç ”ç©¶æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ ï¼Œæœ€è¿‘æˆç‚ºå¥åº·ç ”ç©¶çš„ç†±é»ï¼ç ”ç©¶é¡¯ç¤ºï¼Œé€™ç¨®åŒ–åˆç‰©å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¾ˆå¤šå¥½è™•ï¼Œç‰¹åˆ¥æ˜¯åœ¨é é˜²æŸäº›ç–¾ç—…æ–¹é¢ï¼Œåƒæ˜¯ç™Œç—‡ã€‚æƒ³çŸ¥é“å®ƒæ˜¯æ€éº¼åšåˆ°çš„å—ï¼Ÿ\n\né€™é …ç ”ç©¶ç‰¹åˆ¥é—œæ³¨è˜¿è””ç¡«ç´ å°ç´°èƒä»£è¬çš„å½±éŸ¿ã€‚ç ”ç©¶äººå“¡ä½¿ç”¨äº†äººé¡è‚æ¯ç´°èƒç™Œç´°èƒï¼Œå°‡å®ƒå€‘èˆ‡è˜¿è””ç¡«ç´ ä¸€èµ·åŸ¹é¤Šï¼Œä¸¦åˆ©ç”¨å…ˆé€²çš„æŠ€è¡“åˆ†æç´°èƒå…§çš„è®ŠåŒ–ã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å°å¤šå€‹é‡è¦çš„ä»£è¬é€”å¾‘ç”¢ç”Ÿäº†é¡¯è‘—å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¸‰ç¾§é…¸å¾ªç’°å’Œå°¿ç´ å¾ªç’°ï¼Œç”šè‡³æå‡äº†æŠ—æ°§åŒ–ç‰©è³ªçš„æ°´å¹³ï¼\n\né€™äº›ç™¼ç¾ä¸åƒ…è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ æœ‰äº†æ›´æ·±å…¥çš„äº†è§£ï¼Œé‚„ç‚ºæœªä¾†çš„å¥åº·ç ”ç©¶æä¾›äº†é‡è¦çš„åŸºç¤ã€‚ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²ç–¾ç—…ã€‚\n2. å®ƒå°ç´°èƒçš„ä»£è¬éç¨‹æœ‰é¡¯è‘—å½±éŸ¿ã€‚\n3. æå‡çš„æŠ—æ°§åŒ–ç‰©è³ªæ°´å¹³å¯èƒ½æœ‰åŠ©æ–¼å¥åº·ç®¡ç†ã€‚\n\nè®“æˆ‘å€‘ä¸€èµ·é—œæ³¨é£²é£Ÿå°å¥åº·çš„å½±éŸ¿å§ï¼",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of a study on sulforaphane (from broccoli). The image should have a light background with soft colors. Include symbols for broccoli or sulforaphane, simplified representations of human cells, and arrows or flow lines indicating the experimental steps. Add a section labeled 'Main Results' highlighting key findings such as protective effects and metabolic changes.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‚ç™Œ Hepatocellular Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41543290/"
  },
  {
    "id": "41438577",
    "title_en": "Sulforaphane-cysteine elicits apoptosis through JNK-mediated caspase activation in oral squamous cell carcinoma cells.",
    "pub_date": "2026",
    "journal": "Journal of Cancer",
    "abstract_en": "Sulforaphane-cysteine (SFN-Cys) is a naturally-occurring form of plant-derived isothiocyanate metabolites that displays several tumor-suppressive properties. However, the oncostatic potential of SFN-Cys on oral squamous cell carcinoma (OSCC) is mostly elusive. In this study, we tried to test whether SFN-Cys affects OSCC to progress and further explored the underlying array of molecular cues that SFN-Cys mediates. Our results demonstrate that SFN-Cys was an effective inducer of cytotoxicity to OSCC cells, accompanied with blockage of cell cycling and promotion of apoptotic events. Moreover, treatment of OSCC cells with SFN-Cys attuned an apoptosis-associated protein regulatory program, underlined by downregulation of apoptosis suppressors (cIAP-1 and XIAP) and activation of caspase cascades. Furthermore, caspase activations in SFN-Cys-treated OSCC cells were affected by the pre-incubation with a specific c-Jun N-terminal kinase (JNK) inhibitor, suggesting a functional link of JNK pathway to SFN-Cys's actions in OSCC cells. Collectively, our data revealed that SFN-Cys hampered cell cycle progression and elicited apoptotic responses in OSCC via a JNK-mediated activation of caspase pathways. These findings provide possible avenues for the application of a natural compound in the management of oral malignancies.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°å£è…”é±—ç‹€ç´°èƒç™Œæœ‰æŠ‘åˆ¶ä½œç”¨ï¼Œé€™è®“æˆ‘å€‘å°å¦‚ä½•åˆ©ç”¨å¤©ç„¶æ¤ç‰©åŒ–åˆç‰©ä¾†å°æŠ—ç™Œç—‡æœ‰äº†æ–°çš„æ€è€ƒã€‚é€™äº›ç™¼ç¾å¯èƒ½æœƒä¿ƒä½¿æœªä¾†åœ¨ç™Œç—‡æ²»ç™‚ä¸­ï¼Œæ›´å¤šåœ°è€ƒæ…®ä½¿ç”¨å¤©ç„¶ä¾†æºçš„åŒ–åˆç‰©ï¼Œé€²ä¸€æ­¥æ¢ç´¢å…¶æ½›åœ¨çš„ç™‚æ•ˆå’Œæ‡‰ç”¨ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æŠ‘åˆ¶é€™ç¨®ç™Œç—‡çš„é€²å±•ï¼Œä¸¦é€²ä¸€æ­¥åˆ†æå…¶ä½œç”¨çš„åˆ†å­æ©Ÿåˆ¶ã€‚é€™å€‹å•é¡Œçš„è§£ç­”ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œä¹Ÿå¯èƒ½ç‚ºå£è…”ç™Œçš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å£è…”é±—ç‹€ç´°èƒç™Œçš„ç´°èƒé€²è¡Œæ¸¬è©¦ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è©•ä¼°ç´°èƒçš„ç”Ÿé•·æƒ…æ³ã€ç´°èƒé€±æœŸçš„è®ŠåŒ–ä»¥åŠç´°èƒå‡‹äº¡çš„æƒ…æ³ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿå­˜å’Œæ­»äº¡éç¨‹ï¼Œä¸¦æ¢ç´¢å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦ä¸”èƒ½å¤ é˜»æ­¢ç´°èƒé€±æœŸçš„é€²è¡Œï¼Œä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨èˆ‡ä¸€ç¨®åç‚ºc-Jun N-terminal kinaseï¼ˆJNKï¼‰çš„ä¿¡è™Ÿé€šè·¯æœ‰é—œï¼Œé€™è¡¨æ˜JNKé€šè·¯åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºæœªä¾†åˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†ç®¡ç†å£è…”ç™Œæä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å£è…”ç™Œçš„ç®¡ç†ä¸Šã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°å£è…”é±—ç‹€ç´°èƒç™Œæœ‰æŠ‘åˆ¶ä½œç”¨ï¼Œé€™è®“æˆ‘å€‘å°å¦‚ä½•åˆ©ç”¨å¤©ç„¶æ¤ç‰©åŒ–åˆç‰©ä¾†å°æŠ—ç™Œç—‡æœ‰äº†æ–°çš„æ€è€ƒã€‚é€™äº›ç™¼ç¾å¯èƒ½æœƒä¿ƒä½¿æœªä¾†åœ¨ç™Œç—‡æ²»ç™‚ä¸­ï¼Œæ›´å¤šåœ°è€ƒæ…®ä½¿ç”¨å¤©ç„¶ä¾†æºçš„åŒ–åˆç‰©ï¼Œé€²ä¸€æ­¥æ¢ç´¢å…¶æ½›åœ¨çš„ç™‚æ•ˆå’Œæ‡‰ç”¨ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å£è…”é±—ç‹€ç´°èƒç™Œï¼ˆOSCCï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ æŠ‘åˆ¶é€™ç¨®ç™Œç—‡çš„é€²å±•ï¼Œä¸¦é€²ä¸€æ­¥åˆ†æå…¶ä½œç”¨çš„åˆ†å­æ©Ÿåˆ¶ã€‚é€™å€‹å•é¡Œçš„è§£ç­”ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œä¹Ÿå¯èƒ½ç‚ºå£è…”ç™Œçš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å£è…”é±—ç‹€ç´°èƒç™Œçš„ç´°èƒé€²è¡Œæ¸¬è©¦ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°é€™äº›ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶æ–¹æ³•åŒ…æ‹¬è©•ä¼°ç´°èƒçš„ç”Ÿé•·æƒ…æ³ã€ç´°èƒé€±æœŸçš„è®ŠåŒ–ä»¥åŠç´°èƒå‡‹äº¡çš„æƒ…æ³ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿå­˜å’Œæ­»äº¡éç¨‹ï¼Œä¸¦æ¢ç´¢å…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°å£è…”é±—ç‹€ç´°èƒç™Œç´°èƒçš„ç´°èƒæ¯’æ€§ï¼Œä¸¦ä¸”èƒ½å¤ é˜»æ­¢ç´°èƒé€±æœŸçš„é€²è¡Œï¼Œä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨èˆ‡ä¸€ç¨®åç‚ºc-Jun N-terminal kinaseï¼ˆJNKï¼‰çš„ä¿¡è™Ÿé€šè·¯æœ‰é—œï¼Œé€™è¡¨æ˜JNKé€šè·¯åœ¨è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºæœªä¾†åˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†ç®¡ç†å£è…”ç™Œæä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of Cancerã€‹æ–¼ 2026 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿä¸€ç¨®ä¾†è‡ªè˜¿è””çš„å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½å°å£è…”ç™Œæœ‰å¹«åŠ©ï¼ğŸŒ±é€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ ï¼Œæƒ³çœ‹çœ‹å®ƒèƒ½å¦æŠ‘åˆ¶å£è…”é±—ç‹€ç´°èƒç™Œçš„é€²å±•ã€‚ç ”ç©¶åœ˜éšŠä½¿ç”¨äº†é€™ç¨®ç™Œç—‡ç´°èƒï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ å°å®ƒå€‘çš„å½±éŸ¿ï¼Œä¸¦åˆ†æå®ƒçš„ä½œç”¨æ©Ÿåˆ¶ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æœ‰æ•ˆèª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œé‚„èƒ½é˜»æ­¢å®ƒå€‘çš„ç”Ÿé•·ï¼Œé€™æ˜¯é€éä¸€æ¢å«åšJNKçš„ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†ä½¿ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†å°æŠ—ç™Œç—‡å……æ»¿å¸Œæœ›ï¼âœ¨\n\né‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°å£è…”ç™Œæœ‰æŠ‘åˆ¶ä½œç”¨ã€‚\n2. å®ƒèƒ½ä¿ƒé€²ç™Œç´°èƒå‡‹äº¡ï¼Œä¸¦é˜»æ­¢ç´°èƒç”Ÿé•·ã€‚\n3. JNKé€šè·¯åœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚",
    "image_prompt": "Create a flat design infographic with a light background. Include symbols representing broccoli or daikon sulforaphane. Simplified illustrations of experimental subjects like humans, animals, or cells should be present. Use arrows or flow lines to depict the experimental steps. Include a section labeled 'Key Findings' highlighting protective effects or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å£è…”é±—ç‹€ç´°èƒç™Œ Oral Squamous Cell Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41438577/"
  },
  {
    "id": "41352012",
    "title_en": "Protection against deoxynivalenol (DON)-induced intestinal injury by sulforaphane via modulation of lysosomal function.",
    "pub_date": "2026 Jan",
    "journal": "Journal of hazardous materials",
    "abstract_en": "Deoxynivalenol (DON) is a prevalent mycotoxin commonly detected in both human and animal diets, representing a significant health risk. Sulforaphane (SFN), a bioactive compound from cruciferous vegetables known for its antioxidant. This study aimed to confirm SFN's protective effect against DON-induced intestinal injury and clarify its underlying molecular mechanism. In vivo, C57BL/6 male mice (nâ€¯=â€¯8/group) were treated with DON (2â€¯mg/kg BW) and SFN (10â€¯mg/kg BW) to assess the overall protective effects of SFN; in vitro, intestinal porcine epithelial cells (IPEC-J2) and pig intestinal organoids were treated with DON (1â€¯Î¼g/mL) and SFN (2â€¯Î¼M) to investigate the protective mechanism of SFN. Hematoxylin-eosin staining, western blot and flow cytometry were used to confirm the protective effects of SFN. RNA-seq, CETSA, ITDRF and non-targeted metabolomics was employed to investigate the mechanism of SFN supplementation. This study demonstrated that SFN significantly alleviated DON-induced intestinal toxicity: in vivo, SFN restored jejunal villus height/crypt depth and restored the balance of redox homeostasis (decreased MDA, LDH, SOD and CAT); in vitro, SFN lowered DON-induced cell apoptosis and ROS accumulation. Mechanistically, lysosomal function was critical for SFN's protection-SFN directly targeted ATP6AP1 to enhance lysosomal acidification Moreover, ATP supplementation further potentiated this acidification and SFN's cytoprotective effect. This study identified ATP6AP1-mediated lysosomal acidification as a novel mechanism for SFN to mitigate DON-induced intestinal injury. Therefore, investigating the crosstalk between the SFN-ATP6AP1 axis and gut microbiota warrants further investigation to elucidate a broader protective mechanism.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°é£Ÿç‰©ä¸­å¸¸è¦‹çš„éœ‰èŒæ¯’ç´ æ™‚ã€‚éœ‰èŒæ¯’ç´ å¦‚å»æ°§é‘­é†‡ï¼ˆDONï¼‰åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å¥åº·æ§‹æˆäº†é¡¯è‘—çš„é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½å°æŠ—é€™äº›æ¯’ç´ é€ æˆçš„è…¸é“æå‚·ï¼Œé€™å°æ–¼æ”¹å–„é£²é£Ÿå®‰å…¨å’Œä¿ƒé€²è…¸é“å¥åº·å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éé€²ä¸€æ­¥äº†è§£è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²ç­–ç•¥ï¼Œæ¸›å°‘éœ‰èŒæ¯’ç´ å°å¥åº·çš„å½±éŸ¿ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å»æ°§é‘­é†‡ï¼ˆDONï¼‰å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä¸¦æ¾„æ¸…å…¶æ½›åœ¨çš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•DONå°è…¸é“çš„æ¯’æ€§å½±éŸ¿ï¼Œä¸¦äº†è§£å…¶åœ¨ç´°èƒå±¤é¢ä¸Šå¦‚ä½•ç™¼æ®ä½œç”¨ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©æ´»æ€§ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„å¥åº·å¹²é æªæ–½æä¾›ç§‘å­¸ä¾æ“šã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†C57BL/6å°é¼ ä½œç‚ºå‹•ç‰©æ¨¡å‹ï¼Œå°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆDONå’Œè˜¿è””ç¡«ç´ é€²è¡Œè™•ç†ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•´é«”ä¿è­·æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“é¡å™¨å®˜ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­æ¡ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡æ³•å’Œæµå¼ç´°èƒè¡“ï¼Œä»¥ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœï¼Œä¸¦é€éRNAæ¸¬åºç­‰æ–¹æ³•æ·±å…¥åˆ†æå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•DONå¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†DONå¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€šéç›´æ¥ä½œç”¨æ–¼ATP6AP1ä¾†å¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ï¼Œé€™æ˜¯å…¶ä¿è­·ä½œç”¨çš„ä¸€å€‹æ–°æ©Ÿåˆ¶ã€‚å› æ­¤ï¼Œé€²ä¸€æ­¥ç ”ç©¶è˜¿è””ç¡«ç´ èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤ä¹‹é–“çš„ç›¸äº’ä½œç”¨ï¼Œå°‡æœ‰åŠ©æ–¼æ­ç¤ºæ›´å»£æ³›çš„ä¿è­·æ©Ÿåˆ¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°é£Ÿç‰©ä¸­å¸¸è¦‹çš„éœ‰èŒæ¯’ç´ æ™‚ã€‚éœ‰èŒæ¯’ç´ å¦‚å»æ°§é‘­é†‡ï¼ˆDONï¼‰åœ¨æˆ‘å€‘çš„é£²é£Ÿä¸­æ™®éå­˜åœ¨ï¼Œå°äººé«”å¥åº·æ§‹æˆäº†é¡¯è‘—çš„é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½å°æŠ—é€™äº›æ¯’ç´ é€ æˆçš„è…¸é“æå‚·ï¼Œé€™å°æ–¼æ”¹å–„é£²é£Ÿå®‰å…¨å’Œä¿ƒé€²è…¸é“å¥åº·å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚é€éé€²ä¸€æ­¥äº†è§£è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²ç­–ç•¥ï¼Œæ¸›å°‘éœ‰èŒæ¯’ç´ å°å¥åº·çš„å½±éŸ¿ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å»æ°§é‘­é†‡ï¼ˆDONï¼‰å¼•èµ·çš„è…¸é“æå‚·çš„ä¿è­·ä½œç”¨ï¼Œä¸¦æ¾„æ¸…å…¶æ½›åœ¨çš„åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›ç¢ºèªè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›è¼•DONå°è…¸é“çš„æ¯’æ€§å½±éŸ¿ï¼Œä¸¦äº†è§£å…¶åœ¨ç´°èƒå±¤é¢ä¸Šå¦‚ä½•ç™¼æ®ä½œç”¨ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©æ´»æ€§ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„å¥åº·å¹²é æªæ–½æä¾›ç§‘å­¸ä¾æ“šã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…ä½¿ç”¨äº†C57BL/6å°é¼ ä½œç‚ºå‹•ç‰©æ¨¡å‹ï¼Œå°‡å…¶åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥çµ¦äºˆDONå’Œè˜¿è””ç¡«ç´ é€²è¡Œè™•ç†ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•´é«”ä¿è­·æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–ä½¿ç”¨è±¬è…¸é“ä¸Šçš®ç´°èƒå’Œè…¸é“é¡å™¨å®˜ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„ä¿è­·æ©Ÿåˆ¶ã€‚ç ”ç©¶ä¸­æ¡ç”¨äº†å¤šç¨®æŠ€è¡“ï¼ŒåŒ…æ‹¬çµ„ç¹”æŸ“è‰²ã€è›‹ç™½è³ªå°è·¡æ³•å’Œæµå¼ç´°èƒè¡“ï¼Œä»¥ç¢ºèªè˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœï¼Œä¸¦é€éRNAæ¸¬åºç­‰æ–¹æ³•æ·±å…¥åˆ†æå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›è¼•DONå¼•èµ·çš„è…¸é“æ¯’æ€§ã€‚åœ¨å°é¼ å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ æ¢å¾©äº†è…¸é“çµ¨æ¯›çš„é«˜åº¦å’Œè…ºé«”çš„æ·±åº¦ï¼Œä¸¦æ”¹å–„äº†æ°§åŒ–é‚„åŸå¹³è¡¡ã€‚åœ¨é«”å¤–å¯¦é©—ä¸­ï¼Œè˜¿è””ç¡«ç´ é™ä½äº†DONå¼•èµ·çš„ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç©ç´¯ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€šéç›´æ¥ä½œç”¨æ–¼ATP6AP1ä¾†å¢å¼·æº¶é…¶é«”çš„é…¸åŒ–ï¼Œé€™æ˜¯å…¶ä¿è­·ä½œç”¨çš„ä¸€å€‹æ–°æ©Ÿåˆ¶ã€‚å› æ­¤ï¼Œé€²ä¸€æ­¥ç ”ç©¶è˜¿è””ç¡«ç´ èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤ä¹‹é–“çš„ç›¸äº’ä½œç”¨ï¼Œå°‡æœ‰åŠ©æ–¼æ­ç¤ºæ›´å»£æ³›çš„ä¿è­·æ©Ÿåˆ¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of hazardous materialsã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ å¤§å®¶çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­å¯èƒ½è—è‘—ä¸€äº›çœ‹ä¸è¦‹çš„å±éšªï¼ä¾‹å¦‚ï¼Œéœ‰èŒæ¯’ç´ ï¼ˆåƒæ˜¯å»æ°§é‘­é†‡ï¼‰å°±å¯èƒ½å°æˆ‘å€‘çš„è…¸é“å¥åº·é€ æˆå¨è„…ã€‚ä¸éï¼Œæœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œä¾†è‡ªé’èŠ±èœç­‰åå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½æœ‰åŠ©æ–¼å°æŠ—é€™äº›æ¯’ç´ çš„å½±éŸ¿ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•ä¿è­·æˆ‘å€‘çš„è…¸é“ï¼Œå°¤å…¶æ˜¯é¢å°å»æ°§é‘­é†‡å¼•èµ·çš„æå‚·ã€‚ç ”ç©¶äººå“¡ä½¿ç”¨å°é¼ å’Œè±¬è…¸é“ç´°èƒé€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ¸›å°‘è…¸é“çš„æ¯’æ€§å½±éŸ¿ï¼Œä¸¦æ”¹å–„äº†è…¸é“çš„çµæ§‹èˆ‡åŠŸèƒ½ï¼\n\nğŸ” ä¸»è¦ç™¼ç¾åŒ…æ‹¬ï¼š\n- è˜¿è””ç¡«ç´ å¹«åŠ©æ¢å¾©è…¸é“çµ¨æ¯›çš„é«˜åº¦ï¼Œè®“è…¸é“æ›´å¥åº·ï¼\n- å®ƒæ¸›å°‘äº†ç´°èƒå‡‹äº¡å’Œæ´»æ€§æ°§çš„ç”¢ç”Ÿï¼Œè®“è…¸é“ç´°èƒæ›´æœ‰æ´»åŠ›ï¼\n- è˜¿è””ç¡«ç´ é€éä¸€ç¨®æ–°æ©Ÿåˆ¶å¢å¼·æº¶é…¶é«”çš„åŠŸèƒ½ï¼Œé¡¯ç¤ºå‡ºå…¶æ½›åœ¨çš„ä¿è­·ä½œç”¨ï¼\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘æ›´äº†è§£è˜¿è””ç¡«ç´ çš„å¥½è™•ï¼Œæœªä¾†æˆ–è¨±èƒ½å¹«åŠ©æˆ‘å€‘æ‰¾åˆ°æ›´å¥½çš„é£²é£Ÿå®‰å…¨ç­–ç•¥ï¼",
    "image_prompt": "Create a simple and informative illustration explaining the experiment and main findings of the study on sulforaphane. Use a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like mice and cells), arrows or flow lines to indicate the experimental steps, and a section clearly labeled 'Main Findings' showcasing protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¸é“æå‚· Intestinal Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41352012/"
  },
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2026 Jan",
    "journal": "Food chemistry",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·å…ç–«ç³»çµ±å’ŒæŠ—èŒèƒ½åŠ›ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥æé«˜é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé€²è€Œå¯èƒ½å°å¥åº·ç”¢ç”Ÿæ­£é¢çš„å½±éŸ¿ï¼Œé€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿä¾†é é˜²ç–¾ç—…çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ€è·¯ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£å¦‚ä½•é€éé€™äº›è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦è©•ä¼°é€™äº›è™•ç†å°èŠ½ç²‰çš„å“è³ªæœ‰ä½•å½±éŸ¿ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºå°è±¡ï¼Œä¸¦é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†ã€‚é€™äº›èŠ½åœ¨ç¶“éå››å¤©çš„è™•ç†å¾Œï¼Œç ”ç©¶è€…æ¸¬é‡äº†å…¶è‘¡è„ç³–è‹·ã€ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬å…¶æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ç­‰å“è³ªæŒ‡æ¨™ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„å«é‡ï¼Œå¢åŠ äº†ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ï¼Œä¸¦ä¿ƒé€²äº†é…µç´ æ´»æ€§ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½çš„ä¿ç•™æ–¹é¢è¡¨ç¾è‰¯å¥½ï¼Œä¸¦é¡¯ç¤ºå‡ºå°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒçš„æŠ—èŒæ´»æ€§ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œçµåˆè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„æ‡‰ç”¨ï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„æ–¹æ³•ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·å…ç–«ç³»çµ±å’ŒæŠ—èŒèƒ½åŠ›ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥æé«˜é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé€²è€Œå¯èƒ½å°å¥åº·ç”¢ç”Ÿæ­£é¢çš„å½±éŸ¿ï¼Œé€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿä¾†é é˜²ç–¾ç—…çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ€è·¯ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£å¦‚ä½•é€éé€™äº›è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œä¸¦è©•ä¼°é€™äº›è™•ç†å°èŠ½ç²‰çš„å“è³ªæœ‰ä½•å½±éŸ¿ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºå°è±¡ï¼Œä¸¦é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†ã€‚é€™äº›èŠ½åœ¨ç¶“éå››å¤©çš„è™•ç†å¾Œï¼Œç ”ç©¶è€…æ¸¬é‡äº†å…¶è‘¡è„ç³–è‹·ã€ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬å…¶æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ç­‰å“è³ªæŒ‡æ¨™ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„å«é‡ï¼Œå¢åŠ äº†ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ï¼Œä¸¦ä¿ƒé€²äº†é…µç´ æ´»æ€§ã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½çš„ä¿ç•™æ–¹é¢è¡¨ç¾è‰¯å¥½ï¼Œä¸¦é¡¯ç¤ºå‡ºå°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒçš„æŠ—èŒæ´»æ€§ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œçµåˆè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„æ‡‰ç”¨ï¼Œå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„æ–¹æ³•ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFood chemistryã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ æƒ³çŸ¥é“é’èŠ±æ¤°èœæ€éº¼è®Šå¾—æ›´ç‡Ÿé¤Šå—ï¼Ÿé€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å°å¥åº·éå¸¸æœ‰å¹«åŠ©ï¼Œå¯èƒ½èƒ½å¢å¼·å…ç–«ç³»çµ±å’ŒæŠ—èŒèƒ½åŠ›ï¼ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼å¦‚ä½•é€éç‰¹å®šçš„è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ã€‚  \n  \nä»–å€‘ä½¿ç”¨äº†ä¸€ç¨®å«åšç”²ç¡«æ°¨é…¸-è”—ç³–çš„å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿåˆ°é€™æ¨£çš„è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„å«é‡ï¼Œé€™æ˜¯ä¸€ç¨®å°å¥åº·æœ‰ç›Šçš„åŒ–åˆç‰©ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ¸¬è©¦äº†çœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ï¼Œçµæœé¡¯ç¤ºé€™æ¨£çš„è™•ç†èƒ½æœ‰æ•ˆä¿ç•™è˜¿è””ç¡«ç´ ï¼Œä¸¦ä¸”å°æŸäº›ç´°èŒæœ‰æŠ—èŒæ•ˆæœï¼  \n  \nâœ¨ é€™äº›ç™¼ç¾å‘Šè¨´æˆ‘å€‘ï¼š  \n1. è”—ç³–è™•ç†å¯ä»¥æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ã€‚  \n2. çœŸç©ºå†·å‡ä¹¾ç‡¥èƒ½ä¿ç•™é’èŠ±æ¤°èœçš„å¥åº·æˆåˆ†ã€‚  \n3. é’èŠ±æ¤°èœèŠ½å¯èƒ½å°æŠ—èŒæœ‰å¹«åŠ©ï¼  \n  \nè®“æˆ‘å€‘ä¸€èµ·æŠŠé’èŠ±æ¤°èœç´å…¥é£²é£Ÿï¼Œç‚ºå¥åº·åŠ åˆ†ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main findings of the broccoli study. Include simplified icons of broccoli and sulforaphane, a representation of the experimental subjects (like humans or cells), and arrows or flow lines showing the experimental steps. Include a section labeled 'Main Findings' that summarizes the protective effects and changes observed, using soft colors and a light background.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "journal": "Talanta",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼é é˜²èˆ‡ç™¼ç‚ç›¸é—œçš„ç–¾ç—…æœ‰æ½›åœ¨çš„å¹«åŠ©ã€‚é€™äº›ç™¼ç¾å¯èƒ½ä¿ƒä½¿æˆ‘å€‘æ›´é‡è¦–é£²é£Ÿä¸­å¤©ç„¶æˆåˆ†çš„æ”å–ï¼Œç‰¹åˆ¥æ˜¯é’èŠ±æ¤°èœå’Œé»‘è˜¿è””ç­‰è”¬èœï¼Œå› ç‚ºå®ƒå€‘å«æœ‰çš„æ´»æ€§æˆåˆ†å¯èƒ½å°å¥åº·æœ‰ç›Šã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å°æ–¼å‘¼å¸ç³»çµ±çš„å¥åº·è‡³é—œé‡è¦ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±é€²è¡Œæ¸¬è©¦ã€‚è˜¿è””ç¡«ç´ æ˜¯å¾é»‘è˜¿è””æ±ä¸­æå–çš„ï¼Œä¸¦é€éé«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶è€…é‚„ä½¿ç”¨MTTæ³•ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦æ¸¬é‡ç´°èƒä¸­ç™¼ç‚ç›¸é—œå› å­å’ŒæŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œä»¥äº†è§£é€™äº›ç‰©è³ªçš„ç”ŸåŒ–å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½å¤ é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œå¦‚è°·èƒ±ç”˜è‚½éæ°§åŒ–ç‰©é…¶ï¼ˆGSH-Pxï¼‰å’Œéæ°§åŒ–æ°«é…¶ï¼ˆCATï¼‰ã€‚é€™äº›çµæœçªé¡¯äº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸­çš„æ½›åœ¨ç™‚æ•ˆï¼Œé›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå®ƒå€‘çš„å¯¦éš›æ•ˆæœã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼é é˜²èˆ‡ç™¼ç‚ç›¸é—œçš„ç–¾ç—…æœ‰æ½›åœ¨çš„å¹«åŠ©ã€‚é€™äº›ç™¼ç¾å¯èƒ½ä¿ƒä½¿æˆ‘å€‘æ›´é‡è¦–é£²é£Ÿä¸­å¤©ç„¶æˆåˆ†çš„æ”å–ï¼Œç‰¹åˆ¥æ˜¯é’èŠ±æ¤°èœå’Œé»‘è˜¿è””ç­‰è”¬èœï¼Œå› ç‚ºå®ƒå€‘å«æœ‰çš„æ´»æ€§æˆåˆ†å¯èƒ½å°å¥åº·æœ‰ç›Šã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å°æ–¼å‘¼å¸ç³»çµ±çš„å¥åº·è‡³é—œé‡è¦ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±é€²è¡Œæ¸¬è©¦ã€‚è˜¿è””ç¡«ç´ æ˜¯å¾é»‘è˜¿è””æ±ä¸­æå–çš„ï¼Œä¸¦é€éé«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶è€…é‚„ä½¿ç”¨MTTæ³•ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦æ¸¬é‡ç´°èƒä¸­ç™¼ç‚ç›¸é—œå› å­å’ŒæŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œä»¥äº†è§£é€™äº›ç‰©è³ªçš„ç”ŸåŒ–å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½å¤ é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œå¦‚è°·èƒ±ç”˜è‚½éæ°§åŒ–ç‰©é…¶ï¼ˆGSH-Pxï¼‰å’Œéæ°§åŒ–æ°«é…¶ï¼ˆCATï¼‰ã€‚é€™äº›çµæœçªé¡¯äº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸­çš„æ½›åœ¨ç™‚æ•ˆï¼Œé›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå®ƒå€‘çš„å¯¦éš›æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠTalantaã€‹æ–¼ 2026 å¹´ 1 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›è”¬èœä¸åƒ…å¥½åƒï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„å¥åº·å¤§æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œé»‘è˜¿è””æ±å’Œè˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®å¾é»‘è˜¿è””ä¸­æå–çš„å¤©ç„¶ç‰©è³ªï¼‰å°æˆ‘å€‘çš„å‘¼å¸ç³»çµ±æœ‰ä¿è­·ä½œç”¨ï¼\n\né€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨é€™äº›å¤©ç„¶æˆåˆ†å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒçš„å½±éŸ¿ï¼Œä¸¦çœ‹çœ‹å®ƒå€‘åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†ä¸åŒæ¿ƒåº¦çš„é»‘è˜¿è””æ±å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå®ƒå€‘å°ç´°èƒçš„å½±éŸ¿ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½æœ‰æ•ˆé™ä½ç™¼ç‚å› å­IL-6çš„æ°´å¹³ï¼Œé‚„èƒ½æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œé€™äº›éƒ½æ˜¯å°æŠ—ç™¼ç‚çš„é‡è¦æŒ‡æ¨™ï¼\n\nğŸ”é‡é»æ•´ç†ï¼š\n1. é»‘è˜¿è””æ±å’Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·å‘¼å¸é“ç´°èƒã€‚\n2. é€™äº›æˆåˆ†èƒ½é™ä½ç™¼ç‚å› å­ï¼Œæå‡æŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n3. å¤šåƒè”¬èœï¼Œç‰¹åˆ¥æ˜¯é’èŠ±æ¤°èœå’Œé»‘è˜¿è””ï¼Œå°å¥åº·æœ‰ç›Šï¼",
    "image_prompt": "Create a flat design infographic on a light background that explains the experimental process and main results of a study on the protective effects of radish sulforaphane and black radish juice on bronchial epithelial cells. Include simplified illustrations of broccoli and radish, a human cell as the experimental subject, arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as reduced inflammation markers and increased antioxidant activity.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸é“ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "41487499",
    "title_en": "The dietary phytochemicals carnosic acid and sulforaphane regulate inflammatory markers in ulcerative colitis patient-derived colonoids.",
    "pub_date": "2025",
    "journal": "Frontiers in pharmacology",
    "abstract_en": "The inflammatory bowel disease (IBD) ulcerative colitis (UC) is characterized by continuous inflammation of the colon with erosion and ulcers. Diagnosis typically occurs in patients between their late teens and mid-30s with no cure. Available therapeutics are efficient at controlling symptoms however, they have many serious adverse effects. Thus, additional therapies with limited adverse effects are needed to complement these drugs. In this study, we evaluated the anti-inflammatory potential of carnosic acid (CA), the most abundant diterpene in rosemary (<i>Salvia rosmarinus</i>) and sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables. We used colonic epithelial organoids (colonoids) derived from non-IBD and UC patients as a physiologically relevant testing platform for both phytochemicals. These patient-derived colonoids are a representative model that recapitulates the parent epithelial tissue including its cellular composition and 3D structure. Moreover, we cultured the colonoids at 2% O<sub>2</sub> to better approximate the low oxygen level (physioxia) observed in the colon crypts. To assess the effects of CA and SFN in the nuclear factor erythroid 2-related factor 2 (NRF2) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ÎºB) pathways, we studied modulation of inflammatory cytokines through a 40-plex chemokine assay and ELISA, as well as gene and protein expression of target genes with qPCR and western blot, respectively. Through these techniques, we observed that CA and SFN decreased inflammatory markers and promoted NRF2 activity in patient-derived colonoids. Additionally, SFN and CA modulated the expression and secretion of the NF-ÎºB promoted antibacterial peptide neutrophil gelatinase-associated lipocalin which is highly expressed in the inflamed colonic epithelium and has been suggested as a biomarker for active UC. Together, the results validated the use of colonoids as a pharmacological testing platform for phytochemicals, and that CA and SFN promote NRF2 activation and decrease inflammation in a human physiologically relevant UC model.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç‚ç—‡æ€§è…¸ç—…ï¼ˆIBDï¼‰ä¸­çš„æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ã€‚ç›®å‰ï¼Œé›–ç„¶æœ‰ä¸€äº›è—¥ç‰©å¯ä»¥æ§åˆ¶é€™ç¨®ç–¾ç—…çš„ç—‡ç‹€ï¼Œä½†å®ƒå€‘å¾€å¾€ä¼´éš¨è‘—åš´é‡çš„å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œå°¤å…¶æ˜¯é‚£äº›å‰¯ä½œç”¨è¼ƒå°‘çš„ç™‚æ³•ï¼Œè®Šå¾—éå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æ¢ç´¢äº†å…©ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—ç‚æ½›åŠ›ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è¿·è¿­é¦™ä¸­çš„ä¸»è¦äºŒèœåŒ–åˆç‰©â€”â€”è¿·è¿­é¦™é…¸ï¼ˆcarnosic acid, CAï¼‰å’Œåœ¨åå­—èŠ±ç§‘è”¬èœä¸­ç™¼ç¾çš„è˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰å°æ½°ç˜æ€§çµè…¸ç‚çš„æŠ—ç‚æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™äº›åŒ–åˆç‰©æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›å°‘ç‚ç—‡ï¼Œä¸¦ä¸”å¸Œæœ›èƒ½æ‰¾åˆ°å°æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…æœ‰ç›Šçš„è¼”åŠ©ç™‚æ³•ï¼Œå°¤å…¶æ˜¯åœ¨ç›®å‰çš„è—¥ç‰©æ²»ç™‚æ•ˆæœæœ‰é™çš„æƒ…æ³ä¸‹ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªéç‚ç—‡æ€§è…¸ç—…å’Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„çµè…¸ä¸Šçš®é¡å™¨å®˜ï¼ˆcolonoidsï¼‰ä½œç‚ºæ¸¬è©¦å¹³å°ã€‚é€™äº›é¡å™¨å®˜èƒ½å¤ æ¨¡æ“¬çœŸå¯¦çš„è…¸é“çµ„ç¹”ï¼ŒåŒ…æ‹¬å…¶ç´°èƒçµ„æˆå’Œä¸‰ç¶­çµæ§‹ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…åœ¨ä½æ°§ç’°å¢ƒä¸‹åŸ¹é¤Šé€™äº›é¡å™¨å®˜ï¼Œä»¥æ›´å¥½åœ°æ¨¡æ“¬çµè…¸å…§çš„ç”Ÿç†æ¢ä»¶ã€‚æ¥è‘—ï¼Œä»–å€‘é€šéå¤šç¨®æŠ€è¡“ä¾†è©•ä¼°CAå’ŒSFNå°ç‚ç—‡å› å­çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬åŒ–å­¸å› å­æª¢æ¸¬å’ŒåŸºå› è¡¨é”åˆ†æç­‰ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ èƒ½å¤ é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²NRF2çš„æ´»æ€§ï¼Œé€™æ˜¯ä¸€å€‹èˆ‡æŠ—æ°§åŒ–å’ŒæŠ—ç‚åæ‡‰ç›¸é—œçš„é—œéµé€šè·¯ã€‚æ­¤å¤–ï¼Œé€™äº›åŒ–åˆç‰©é‚„èª¿ç¯€äº†NF-ÎºBé€šè·¯ä¸­ä¿ƒé€²æŠ—èŒè‚½çš„è¡¨é”å’Œåˆ†æ³Œï¼Œé€™ç¨®æŠ—èŒè‚½åœ¨ç‚ç—‡çš„çµè…¸ä¸Šçš®ä¸­è¡¨é”é‡è¼ƒé«˜ï¼Œä¸¦è¢«èªç‚ºæ˜¯æ½°ç˜æ€§çµè…¸ç‚çš„ç”Ÿç‰©æ¨™è¨˜ä¹‹ä¸€ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œçµè…¸é¡å™¨å®˜å¯ä»¥ä½œç‚ºæ¤ç‰©åŒ–å­¸ç‰©è³ªçš„è—¥ç†æ¸¬è©¦å¹³å°ï¼Œä¸¦ä¸”CAå’ŒSFNåœ¨æ¸›å°‘ç‚ç—‡æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°ç‚ç—‡æ€§è…¸ç—…ï¼ˆIBDï¼‰ä¸­çš„æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ã€‚ç›®å‰ï¼Œé›–ç„¶æœ‰ä¸€äº›è—¥ç‰©å¯ä»¥æ§åˆ¶é€™ç¨®ç–¾ç—…çš„ç—‡ç‹€ï¼Œä½†å®ƒå€‘å¾€å¾€ä¼´éš¨è‘—åš´é‡çš„å‰¯ä½œç”¨ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œå°¤å…¶æ˜¯é‚£äº›å‰¯ä½œç”¨è¼ƒå°‘çš„ç™‚æ³•ï¼Œè®Šå¾—éå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æ¢ç´¢äº†å…©ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—ç‚æ½›åŠ›ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è¿·è¿­é¦™ä¸­çš„ä¸»è¦äºŒèœåŒ–åˆç‰©â€”â€”è¿·è¿­é¦™é…¸ï¼ˆcarnosic acid, CAï¼‰å’Œåœ¨åå­—èŠ±ç§‘è”¬èœä¸­ç™¼ç¾çš„è˜¿è””ç¡«ç´ ï¼ˆsulforaphane, SFNï¼‰å°æ½°ç˜æ€§çµè…¸ç‚çš„æŠ—ç‚æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™äº›åŒ–åˆç‰©æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›å°‘ç‚ç—‡ï¼Œä¸¦ä¸”å¸Œæœ›èƒ½æ‰¾åˆ°å°æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…æœ‰ç›Šçš„è¼”åŠ©ç™‚æ³•ï¼Œå°¤å…¶æ˜¯åœ¨ç›®å‰çš„è—¥ç‰©æ²»ç™‚æ•ˆæœæœ‰é™çš„æƒ…æ³ä¸‹ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªéç‚ç—‡æ€§è…¸ç—…å’Œæ½°ç˜æ€§çµè…¸ç‚æ‚£è€…çš„çµè…¸ä¸Šçš®é¡å™¨å®˜ï¼ˆcolonoidsï¼‰ä½œç‚ºæ¸¬è©¦å¹³å°ã€‚é€™äº›é¡å™¨å®˜èƒ½å¤ æ¨¡æ“¬çœŸå¯¦çš„è…¸é“çµ„ç¹”ï¼ŒåŒ…æ‹¬å…¶ç´°èƒçµ„æˆå’Œä¸‰ç¶­çµæ§‹ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…åœ¨ä½æ°§ç’°å¢ƒä¸‹åŸ¹é¤Šé€™äº›é¡å™¨å®˜ï¼Œä»¥æ›´å¥½åœ°æ¨¡æ“¬çµè…¸å…§çš„ç”Ÿç†æ¢ä»¶ã€‚æ¥è‘—ï¼Œä»–å€‘é€šéå¤šç¨®æŠ€è¡“ä¾†è©•ä¼°CAå’ŒSFNå°ç‚ç—‡å› å­çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬åŒ–å­¸å› å­æª¢æ¸¬å’ŒåŸºå› è¡¨é”åˆ†æç­‰ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ èƒ½å¤ é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¿ƒé€²NRF2çš„æ´»æ€§ï¼Œé€™æ˜¯ä¸€å€‹èˆ‡æŠ—æ°§åŒ–å’ŒæŠ—ç‚åæ‡‰ç›¸é—œçš„é—œéµé€šè·¯ã€‚æ­¤å¤–ï¼Œé€™äº›åŒ–åˆç‰©é‚„èª¿ç¯€äº†NF-ÎºBé€šè·¯ä¸­ä¿ƒé€²æŠ—èŒè‚½çš„è¡¨é”å’Œåˆ†æ³Œï¼Œé€™ç¨®æŠ—èŒè‚½åœ¨ç‚ç—‡çš„çµè…¸ä¸Šçš®ä¸­è¡¨é”é‡è¼ƒé«˜ï¼Œä¸¦è¢«èªç‚ºæ˜¯æ½°ç˜æ€§çµè…¸ç‚çš„ç”Ÿç‰©æ¨™è¨˜ä¹‹ä¸€ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œçµè…¸é¡å™¨å®˜å¯ä»¥ä½œç‚ºæ¤ç‰©åŒ–å­¸ç‰©è³ªçš„è—¥ç†æ¸¬è©¦å¹³å°ï¼Œä¸¦ä¸”CAå’ŒSFNåœ¨æ¸›å°‘ç‚ç—‡æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠFrontiers in pharmacologyã€‹æ–¼ 2025 å¹´ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè¿·è¿­é¦™å’Œé’èŠ±æ¤°èœè£¡çš„æˆåˆ†ï¼Œå¯èƒ½å°æ½°ç˜æ€§çµè…¸ç‚æœ‰å¹«åŠ©ï¼é€™æ˜¯ä¸€ç¨®ç‚ç—‡æ€§è…¸ç—…ï¼Œé›–ç„¶ç¾åœ¨æœ‰è—¥ç‰©å¯ä»¥æ§åˆ¶ç—‡ç‹€ï¼Œä½†å‰¯ä½œç”¨å¸¸å¸¸è®“äººå›°æ“¾ã€‚æœ€è¿‘çš„ç ”ç©¶å°±èšç„¦æ–¼è¿·è¿­é¦™ä¸­çš„è¿·è¿­é¦™é…¸å’Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ ï¼Œçœ‹çœ‹å®ƒå€‘èƒ½å¦æ¸›å°‘è…¸é“çš„ç‚ç—‡ã€‚\n\nç ”ç©¶è€…å€‘ä½¿ç”¨äº†æ¨¡æ“¬è…¸é“çµ„ç¹”çš„ç´°èƒï¼Œä¾†æ¸¬è©¦é€™äº›æ¤ç‰©æˆåˆ†çš„æ•ˆæœã€‚ä»–å€‘ç™¼ç¾ï¼Œé€™å…©ç¨®ç‰©è³ªèƒ½å¤ é™ä½ç‚ç—‡æ¨™è¨˜ç‰©ï¼Œä¸¦ä¸”ä¿ƒé€²ä¸€ç¨®å«NRF2çš„è›‹ç™½è³ªæ´»æ€§ï¼Œé€™å°æŠ—æ°§åŒ–å’ŒæŠ—ç‚éƒ½å¾ˆé‡è¦ï¼\n\né€™é …ç ”ç©¶çš„ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°äº†æœªä¾†æ½›åœ¨çš„æ–°ç™‚æ³•ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç¾æœ‰è—¥ç‰©æ•ˆæœæœ‰é™çš„æƒ…æ³ä¸‹ã€‚ç¸½çµä¸€ä¸‹ï¼š\n1. è¿·è¿­é¦™é…¸å’Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è…¸é“ç‚ç—‡ã€‚\n2. é€™äº›æ¤ç‰©æˆåˆ†å¯ä»¥ä¿ƒé€²æŠ—æ°§åŒ–åæ‡‰ã€‚\n3. çµè…¸é¡å™¨å®˜æ˜¯æ¸¬è©¦é€™äº›æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„å¥½æ–¹æ³•ï¼",
    "image_prompt": "Create an informative illustration explaining the experimental method and main results of a study on the anti-inflammatory effects of carnosic acid from rosemary and sulforaphane from broccoli. Use a flat design style with a white or light background and soft colors. Include symbols representing broccoli and sulforaphane, simplified illustrations of experimental subjects like cells or humans, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' showing protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41487499/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "journal": "Journal of agricultural and food chemistry",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰ä¸€äº›å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯é‡å°è˜¿è””ç¡«ç´ é€™ç¨®æœ‰ç›Šçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚è˜¿è””ç¡«ç´ ä¸»è¦ä¾†è‡ªé’èŠ±æ¤°èœï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®å¥åº·ç›Šè™•ï¼ŒåŒ…æ‹¬æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚äº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰æ›ç‡ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·å…¶åœ¨é£²é£Ÿä¸­çš„æœ‰æ•ˆæ€§ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–é é˜²æŸäº›ç–¾ç—…ã€‚é€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿæ”¹å–„å¥åº·ç‹€æ³çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„ç ”ç©¶æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„å‰é«”ç‰©è³ªâ€”è‘¡è„ç³–è‹·ï¼ˆglucoraphaninï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚é›–ç„¶è˜¿è””ç¡«ç´ è¢«èªç‚ºå…·æœ‰å¤šç¨®å¥åº·ç›Šè™•ï¼Œä½†å…¶è½‰æ›ç‡è¼ƒä½ï¼Œä¸”è½‰æ›çš„æ©Ÿåˆ¶å°šä¸æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€éå¯¦é©—ä¾†æ­ç¤ºé€™ä¸€éç¨‹ï¼Œä¸¦å°‹æ‰¾æå‡è½‰æ›ç‡çš„æ–¹æ³•ï¼Œé€²è€Œä¿ƒé€²è˜¿è””ç¡«ç´ çš„æ‡‰ç”¨ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·ä¹³é…¸èŒçš„è˜¿è””ç¡«ç´ è½‰æ›ç‡ã€‚ç ”ç©¶åœ˜éšŠå°ä¹³é…¸èŒé€²è¡Œäº†åŸºå› çµ„å­¸åˆ†æï¼Œè§€å¯Ÿå…¶åœ¨ä¸åŒç’°å¢ƒæ¢ä»¶ä¸‹çš„ä»£è¬è®ŠåŒ–ã€‚å…·é«”ä¾†èªªï¼Œä»–å€‘èª¿æ•´äº†è‘¡è„ç³–çš„æ›¿ä»£æ¯”ä¾‹ï¼Œä¸¦åˆ†æäº†é€™å°ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬çš„å½±éŸ¿ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæœ‰åŠ©æ–¼æ·±å…¥äº†è§£ä¹³é…¸èŒå¦‚ä½•åœ¨ä¸åŒæ¢ä»¶ä¸‹é€²è¡Œä»£è¬èª¿æ•´ï¼Œä¸¦æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ä¾‹å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜ï¼Œé€éèª¿æ•´ç’°å¢ƒæ¢ä»¶ï¼Œå¯ä»¥æœ‰æ•ˆåœ°ä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆéç¨‹ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ­ç¤ºäº†è‘¡è„ç³–è‹·åœ¨ä¹³é…¸èŒç´°èƒå…§çš„è½‰é‹åŠå…¶è½‰æ›çš„å…·é«”æ©Ÿåˆ¶ï¼Œé€™äº›çµæœå°æ–¼æœªä¾†é€²ä¸€æ­¥ç ”ç©¶å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰ä¸€äº›å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯é‡å°è˜¿è””ç¡«ç´ é€™ç¨®æœ‰ç›Šçš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚è˜¿è””ç¡«ç´ ä¸»è¦ä¾†è‡ªé’èŠ±æ¤°èœï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®å¥åº·ç›Šè™•ï¼ŒåŒ…æ‹¬æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚äº†è§£å¦‚ä½•æé«˜è˜¿è””ç¡«ç´ çš„è½‰æ›ç‡ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·å…¶åœ¨é£²é£Ÿä¸­çš„æœ‰æ•ˆæ€§ï¼Œé€²è€Œä¿ƒé€²å¥åº·æˆ–é é˜²æŸäº›ç–¾ç—…ã€‚é€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿæ”¹å–„å¥åº·ç‹€æ³çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„ç ”ç©¶æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°‡é’èŠ±æ¤°èœä¸­çš„å‰é«”ç‰©è³ªâ€”è‘¡è„ç³–è‹·ï¼ˆglucoraphaninï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚é›–ç„¶è˜¿è””ç¡«ç´ è¢«èªç‚ºå…·æœ‰å¤šç¨®å¥åº·ç›Šè™•ï¼Œä½†å…¶è½‰æ›ç‡è¼ƒä½ï¼Œä¸”è½‰æ›çš„æ©Ÿåˆ¶å°šä¸æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€éå¯¦é©—ä¾†æ­ç¤ºé€™ä¸€éç¨‹ï¼Œä¸¦å°‹æ‰¾æå‡è½‰æ›ç‡çš„æ–¹æ³•ï¼Œé€²è€Œä¿ƒé€²è˜¿è””ç¡«ç´ çš„æ‡‰ç”¨ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·ä¹³é…¸èŒçš„è˜¿è””ç¡«ç´ è½‰æ›ç‡ã€‚ç ”ç©¶åœ˜éšŠå°ä¹³é…¸èŒé€²è¡Œäº†åŸºå› çµ„å­¸åˆ†æï¼Œè§€å¯Ÿå…¶åœ¨ä¸åŒç’°å¢ƒæ¢ä»¶ä¸‹çš„ä»£è¬è®ŠåŒ–ã€‚å…·é«”ä¾†èªªï¼Œä»–å€‘èª¿æ•´äº†è‘¡è„ç³–çš„æ›¿ä»£æ¯”ä¾‹ï¼Œä¸¦åˆ†æäº†é€™å°ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬çš„å½±éŸ¿ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæœ‰åŠ©æ–¼æ·±å…¥äº†è§£ä¹³é…¸èŒå¦‚ä½•åœ¨ä¸åŒæ¢ä»¶ä¸‹é€²è¡Œä»£è¬èª¿æ•´ï¼Œä¸¦æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ä¾‹å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜ï¼Œé€éèª¿æ•´ç’°å¢ƒæ¢ä»¶ï¼Œå¯ä»¥æœ‰æ•ˆåœ°ä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆéç¨‹ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„æ­ç¤ºäº†è‘¡è„ç³–è‹·åœ¨ä¹³é…¸èŒç´°èƒå…§çš„è½‰é‹åŠå…¶è½‰æ›çš„å…·é«”æ©Ÿåˆ¶ï¼Œé€™äº›çµæœå°æ–¼æœªä¾†é€²ä¸€æ­¥ç ”ç©¶å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "fb_post": "æ ¹æ“šã€ŠJournal of agricultural and food chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“é’èŠ±æ¤°èœè£¡é¢æœ‰ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„å¥½æ±è¥¿å—ï¼Ÿé€™ç¨®å¤©ç„¶åŒ–åˆç‰©ä¸åƒ…èƒ½æŠ—æ°§åŒ–ï¼Œé‚„æœ‰åŠ©æ–¼æŠ—ç™¼ç‚ï¼Œå°å¥åº·éå¸¸æœ‰ç›Šï¼æœ€è¿‘æœ‰ç ”ç©¶å°ˆæ³¨æ–¼å¦‚ä½•è®“æˆ‘å€‘çš„è…¸é“èŒç¾¤æ›´æœ‰æ•ˆåœ°æŠŠé’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®å‰é«”ç‰©è³ªè½‰æ›æˆè˜¿è””ç¡«ç´ ï¼Œé€™æ¨£æˆ‘å€‘å°±èƒ½æ›´å¥½åœ°å¸æ”¶å®ƒçš„å¥½è™•ã€‚  \n  \né€™é …ç ”ç©¶çš„ç§‘å­¸å®¶å€‘ä½¿ç”¨äº†ä¸€ç¨®å«ä¹³é…¸èŒçš„å¥½èŒï¼Œä¾†æ¢è¨å¦‚ä½•æå‡é€™ç¨®è½‰æ›çš„æ•ˆç‡ã€‚ä»–å€‘ç™¼ç¾ï¼Œç•¶æ”¹è®Šä¸€äº›ç’°å¢ƒæ¢ä»¶ï¼Œæ¯”å¦‚èª¿æ•´è‘¡è„ç³–çš„æ¯”ä¾‹ï¼Œä¹³é…¸èŒçš„ä»£è¬è¡¨ç¾æœƒæœ‰æ‰€ä¸åŒã€‚å…·é«”ä¾†èªªï¼Œç•¶è‘¡è„ç³–çš„æ¯”ä¾‹å¢åŠ æ™‚ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬ä¸Šå‡ï¼Œé€™æ¨£æœ‰åŠ©æ–¼æ›´å¤šè˜¿è””ç¡«ç´ çš„ç”Ÿæˆï¼  \n  \né€™é …ç ”ç©¶è®“æˆ‘å€‘å°å¾®ç”Ÿç‰©å’Œå¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„é—œä¿‚æœ‰äº†æ›´æ·±å…¥çš„äº†è§£ï¼Œæœªä¾†å¯èƒ½æœƒå°å¥åº·é£²é£Ÿçš„è¨­è¨ˆæœ‰å¹«åŠ©ã€‚  \n  \nğŸ” ç ”ç©¶é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœï¼Œå…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ã€‚  \n2. ä¹³é…¸èŒçš„ä»£è¬èª¿æ•´èƒ½æå‡è˜¿è””ç¡«ç´ çš„è½‰æ›ç‡ã€‚  \n3. ç’°å¢ƒæ¢ä»¶çš„æ”¹è®Šå°å¾®ç”Ÿç‰©çš„ä»£è¬æœ‰é¡¯è‘—å½±éŸ¿ã€‚",
    "image_prompt": "Create a simple, flat design infographic that explains the experiment and main findings of the study on sulforaphane from broccoli. Include illustrations of broccoli and sulforaphane, simplified representations of the experimental subjects like humans or cells, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' that highlights the changes in metabolism. Use a light background with soft colors for a scientific and informative look.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "journal": "European journal of medicinal chemistry",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ä¸‰é™°æ€§ä¹³ç™Œä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†åŒ–ç™‚çš„æ•ˆæœå¸¸å¸¸æœ‰é™ï¼Œå› æ­¤é–‹ç™¼æ–°çš„è—¥ç‰©ä¾†æé«˜æ²»ç™‚æ•ˆæœæ˜¯ç•¶å‰çš„ç ”ç©¶é‡é»ã€‚é€™é …ç ”ç©¶ä¸­æ‰€æ¢è¨çš„å¤©ç„¶ç”¢ç‰©ï¼Œå¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šï¼Œé¡¯ç¤ºå‡ºæ½›åœ¨çš„æŠ—è…«ç˜¤æ´»æ€§ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯å’Œé¸æ“‡ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼å’Œè©•ä¼°ä¸€ç³»åˆ—æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä»¥æé«˜å…¶å°ä¸‰é™°æ€§ä¹³ç™Œçš„æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé€™äº›æ–°åˆæˆçš„åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ åœ¨å¯¦é©—ä¸­é¡¯ç¤ºå‡ºæ¯”ç¾æœ‰æ²»ç™‚æ›´å¼·çš„æŠ—è…«ç˜¤æ´»æ€§ï¼Œä¸¦ä¸”æ˜¯å¦èƒ½å¤ åœ¨ä¸ç”¢ç”Ÿæ˜é¡¯æ¯’æ€§çš„æƒ…æ³ä¸‹æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦å°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœé€²è¡Œäº†è©•ä¼°ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸‰é™°æ€§ä¹³ç™Œç´°èƒç³»ä¾†æ¸¬è©¦é€™äº›åŒ–åˆç‰©çš„ç´°èƒå¢æ®–æŠ‘åˆ¶èƒ½åŠ›ï¼Œä¸¦é€²ä¸€æ­¥åœ¨å°é¼ æ¨¡å‹ä¸­æª¢é©—å…¶å°è…«ç˜¤ç”Ÿé•·çš„å½±éŸ¿ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨å…¨é¢äº†è§£é€™äº›æ–°åŒ–åˆç‰©çš„æ½›åŠ›åŠå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ´»æ€§æ–¹é¢è¡¨ç¾æœ€ä½³ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—æŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒå¢æ®–ã€å…‹éš†å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„èƒ½åŠ›ï¼Œä¸¦èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªè§€å¯Ÿåˆ°æ˜é¡¯çš„æ¯’æ€§ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾17aèƒ½ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€”å¾‘ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœé¡¯ç¤º17aå¯èƒ½æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚çš„æ½›åœ¨å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œé€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ä¸‰é™°æ€§ä¹³ç™Œä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†åŒ–ç™‚çš„æ•ˆæœå¸¸å¸¸æœ‰é™ï¼Œå› æ­¤é–‹ç™¼æ–°çš„è—¥ç‰©ä¾†æé«˜æ²»ç™‚æ•ˆæœæ˜¯ç•¶å‰çš„ç ”ç©¶é‡é»ã€‚é€™é …ç ”ç©¶ä¸­æ‰€æ¢è¨çš„å¤©ç„¶ç”¢ç‰©ï¼Œå¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šï¼Œé¡¯ç¤ºå‡ºæ½›åœ¨çš„æŠ—è…«ç˜¤æ´»æ€§ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯å’Œé¸æ“‡ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼å’Œè©•ä¼°ä¸€ç³»åˆ—æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä»¥æé«˜å…¶å°ä¸‰é™°æ€§ä¹³ç™Œçš„æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé€™äº›æ–°åˆæˆçš„åŒ–åˆç‰©æ˜¯å¦èƒ½å¤ åœ¨å¯¦é©—ä¸­é¡¯ç¤ºå‡ºæ¯”ç¾æœ‰æ²»ç™‚æ›´å¼·çš„æŠ—è…«ç˜¤æ´»æ€§ï¼Œä¸¦ä¸”æ˜¯å¦èƒ½å¤ åœ¨ä¸ç”¢ç”Ÿæ˜é¡¯æ¯’æ€§çš„æƒ…æ³ä¸‹æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦å°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœé€²è¡Œäº†è©•ä¼°ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸‰é™°æ€§ä¹³ç™Œç´°èƒç³»ä¾†æ¸¬è©¦é€™äº›åŒ–åˆç‰©çš„ç´°èƒå¢æ®–æŠ‘åˆ¶èƒ½åŠ›ï¼Œä¸¦é€²ä¸€æ­¥åœ¨å°é¼ æ¨¡å‹ä¸­æª¢é©—å…¶å°è…«ç˜¤ç”Ÿé•·çš„å½±éŸ¿ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨å…¨é¢äº†è§£é€™äº›æ–°åŒ–åˆç‰©çš„æ½›åŠ›åŠå…¶ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ´»æ€§æ–¹é¢è¡¨ç¾æœ€ä½³ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—æŠ‘åˆ¶ä¸‰é™°æ€§ä¹³ç™Œç´°èƒå¢æ®–ã€å…‹éš†å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„èƒ½åŠ›ï¼Œä¸¦èƒ½èª˜å°ç´°èƒå‡‹äº¡ã€‚åœ¨å°é¼ æ¨¡å‹ä¸­ï¼Œ17aæœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªè§€å¯Ÿåˆ°æ˜é¡¯çš„æ¯’æ€§ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾17aèƒ½ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€”å¾‘ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœé¡¯ç¤º17aå¯èƒ½æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚çš„æ½›åœ¨å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠEuropean journal of medicinal chemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæœ‰äº›å¤©ç„¶æˆåˆ†å¯èƒ½æˆç‚ºå°æŠ—ç™Œç—‡çš„æ–°æ­¦å™¨ï¼\n\næœ€è¿‘çš„ç ”ç©¶èšç„¦æ–¼ä¸€ç¨®å«åšä¸‰é™°æ€§ä¹³ç™Œçš„ç™Œç—‡ï¼Œé€™ç¨®ç™Œç—‡éå¸¸é›£å°ä»˜ï¼Œå‚³çµ±çš„åŒ–ç™‚æ•ˆæœæœ‰é™ã€‚å› æ­¤ï¼Œç§‘å­¸å®¶å€‘æ­£åœ¨å°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œåƒæ˜¯å¤©ç„¶ç”¢ç‰©è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šï¼Œé€™äº›æˆåˆ†å¯èƒ½å¹«åŠ©æˆ‘å€‘å°æŠ—ç™Œç—‡ã€‚\n\né€™é …ç ”ç©¶çš„ç›®æ¨™æ˜¯å‰µé€ ä¸€ç³»åˆ—æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œçœ‹çœ‹å®ƒå€‘æ˜¯å¦èƒ½åœ¨å¯¦é©—ä¸­è¡¨ç¾å‡ºæ¯”ç¾æœ‰ç™‚æ³•æ›´å¼·çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…å€‘åˆæˆäº†15ç¨®é€™æ¨£çš„æ··åˆç‰©ï¼Œä¸¦åœ¨å¯¦é©—å®¤è£¡æ¸¬è©¦å®ƒå€‘å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å½±éŸ¿ï¼Œç”šè‡³é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é€²ä¸€æ­¥çš„æ¸¬è©¦ã€‚\n\nçµæœé¡¯ç¤ºï¼Œå…¶ä¸­ä¸€ç¨®åŒ–åˆç‰©ï¼ˆ17aï¼‰è¡¨ç¾æœ€ç‚ºçªå‡ºï¼Œä¸åƒ…èƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œé‚„èƒ½èª˜å°ç™Œç´°èƒè‡ªæˆ‘æ¯€æ»…ï¼Œä¸”æ²’æœ‰æ˜é¡¯çš„æ¯’æ€§ã€‚é€™äº›ç™¼ç¾è®“äººæœŸå¾…ï¼Œ17aå¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚ä¸‰é™°æ€§ä¹³ç™Œçš„æ–°é¸æ“‡ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. ä¸‰é™°æ€§ä¹³ç™Œæ˜¯ä¸€ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡ï¼Œå‚³çµ±æ²»ç™‚æ•ˆæœæœ‰é™ã€‚\n2. æ–°åˆæˆçš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©é¡¯ç¤ºå‡ºè‰¯å¥½çš„æŠ—è…«ç˜¤æ´»æ€§ã€‚\n3. åŒ–åˆç‰©17aæœ‰æ½›åŠ›æˆç‚ºæœªä¾†çš„æ²»ç™‚é¸æ“‡ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ã€‚",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on a new compound (17a) combining magnolol and sulforaphane to fight triple-negative breast cancer. Use simple flat illustrations with a light background and soft colors. Include symbols for broccoli and sulforaphane, simplified illustrations of experimental subjects like cells and mice, arrows or flow lines to indicate experimental steps, and a section labeled 'Main Results' highlighting the protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41399453",
    "title_en": "Dual effect of sulforaphane on multi-walled carbon nanotube-induced lung inflammation in mice.",
    "pub_date": "2025 Dec",
    "journal": "Toxicology research",
    "abstract_en": "A previous study demonstrated that Nrf2, a transcription factor, unexpectedly promoted multi-walled carbon nanotube (MWCNT)-induced lung inflammation in mice. This finding contrasts with the well-established role of Nrf2 in suppressing inflammatory responses induced by environmental chemicals, highlighting a critical knowledge gap. The present study investigated the effect of sulforaphane, a known activator of Nrf2, on MWCNT-induced lung inflammation in mice, in order to better understand the underlying mechanisms of this response. Each of 48 C57BL/6Â J male mouse was anesthetized and exposed once via pharyngeal aspiration to MWCNTs (Mitsui-7) at doses of 0, 10, or 20Â Î¼g in 40Â Î¼l of dispersion medium per mouse and treated thereafter with subcutaneous 25Â mg/kg/day sulforaphane or vehicle for 14Â days. Bronchoalveolar lavage fluid (BALF) was collected for differential cell counts. Lung tissues were processed for histopathological analysis and quantification of cytokine or chemokine mRNA expression and Nrf2 protein in nuclear extracts. MWCNTs exposure increased lung weight, BALF lymphocytes, and lung IL-6 expression. Sulforaphane attenuated MWCNTs-induced lung weight gain, lymphocytic infiltration, and upregulation of IL-6 expression, but paradoxically enhanced low-dose MWCNT-induced neutrophil infiltration in BALF, MIP-2 expression, and histopathological inflammation scores. These effects were accompanied by increased levels of active Nrf2 protein in nuclear extracts from lung tissue. Overall, the results indicate that sulforaphane suppresses lymphocyte infiltration while promoting neutrophil recruitment in response to low-dose MWCNTs, suggesting a dual effect of sulforaphane on MWCNT-induced lung inflammation mediated through Nrf2 activation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ è¢«èªç‚ºå¯ä»¥æ¿€æ´»Nrf2ï¼Œä¸¦æœ‰åŠ©æ–¼æ¸›å°‘ç”±ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡åæ‡‰ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œé€™ç¨®ç‰©è³ªçš„ä½œç”¨å¯èƒ½æœƒè®Šå¾—è¤‡é›œã€‚ç‰¹åˆ¥æ˜¯åœ¨æ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¾Œï¼Œè˜¿è””ç¡«ç´ ä¼¼ä¹ä¸åƒ…èƒ½æ¸›å°‘æŸäº›å…ç–«ç´°èƒçš„æµ¸æ½¤ï¼Œé‚„å¯èƒ½åœ¨ä½åŠ‘é‡ä¸‹ä¿ƒé€²å…¶ä»–å…ç–«ç´°èƒçš„æ´»åŒ–ã€‚é€™æé†’æˆ‘å€‘ï¼Œå°æ–¼æŸäº›åŒ–åˆç‰©çš„å¥åº·å½±éŸ¿ï¼Œå¿…é ˆä»”ç´°è€ƒé‡å…¶åœ¨ä¸åŒåŠ‘é‡å’Œç’°å¢ƒä¸‹çš„ä½œç”¨ï¼Œæ‰èƒ½æ›´å¥½åœ°ç†è§£å…¶å°å¥åº·çš„æ½›åœ¨å½±éŸ¿ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£Nrf2åœ¨é€™ä¸€éç¨‹ä¸­çš„è§’è‰²ï¼Œå› ç‚ºå…ˆå‰çš„ç ”ç©¶é¡¯ç¤ºNrf2åœ¨å°é¼ ä¸­æ„å¤–ä¿ƒé€²äº†ç”±MWCNTå¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ï¼Œé€™èˆ‡å…¶é€šå¸¸è¢«èªç‚ºçš„æŠ‘åˆ¶ç‚ç—‡çš„è§’è‰²ç›¸çŸ›ç›¾ã€‚å› æ­¤ï¼Œé€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ï¼Œä¸¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™ç¨®ç‚ç—‡åæ‡‰ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†48éš»C57BL/6 Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ åœ¨éº»é†‰å¾Œé€éå’½å–‰å¸å…¥çš„æ–¹å¼æ¥è§¸äº†ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰ï¼ŒåŠ‘é‡åˆ†åˆ¥ç‚º0ã€10æˆ–20å¾®å…‹ï¼Œä¸¦åœ¨æ¥ä¸‹ä¾†çš„14å¤©å…§ï¼Œçµ¦äºˆå°é¼ æ¯å¤©25æ¯«å…‹æ¯å…¬æ–¤çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§ç‰©è³ªã€‚ç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ï¼ˆBALFï¼‰é€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œäº†çµ„ç¹”ç—…ç†å­¸åˆ†æä»¥åŠç´°èƒå› å­æˆ–è¶¨åŒ–å› å­mRNAè¡¨é”å’ŒNrf2è›‹ç™½çš„å®šé‡åˆ†æã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œæ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡å¾Œï¼Œå°é¼ çš„è‚ºéƒ¨é‡é‡å¢åŠ ã€BALFä¸­çš„æ·‹å·´ç´°èƒæ•¸é‡ä¸Šå‡ï¼Œä»¥åŠè‚ºéƒ¨IL-6çš„è¡¨é”å¢åŠ ã€‚è€Œè˜¿è””ç¡«ç´ çš„è™•ç†å‰‡æ¸›å°‘äº†ç”±MWCNTå¼•èµ·çš„è‚ºéƒ¨é‡é‡å¢åŠ å’Œæ·‹å·´ç´°èƒæµ¸æ½¤ï¼Œä¸¦é™ä½äº†IL-6çš„è¡¨é”ã€‚ç„¶è€Œï¼Œä»¤äººæ„å¤–çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä½åŠ‘é‡MWCNTçš„æƒ…æ³ä¸‹å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å°MWCNTå¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡å¯èƒ½å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€™ä¸€åˆ‡éƒ½èˆ‡Nrf2çš„æ´»åŒ–æœ‰é—œã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ è¢«èªç‚ºå¯ä»¥æ¿€æ´»Nrf2ï¼Œä¸¦æœ‰åŠ©æ–¼æ¸›å°‘ç”±ç’°å¢ƒåŒ–å­¸ç‰©è³ªå¼•èµ·çš„ç‚ç—‡åæ‡‰ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œé€™ç¨®ç‰©è³ªçš„ä½œç”¨å¯èƒ½æœƒè®Šå¾—è¤‡é›œã€‚ç‰¹åˆ¥æ˜¯åœ¨æ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¾Œï¼Œè˜¿è””ç¡«ç´ ä¼¼ä¹ä¸åƒ…èƒ½æ¸›å°‘æŸäº›å…ç–«ç´°èƒçš„æµ¸æ½¤ï¼Œé‚„å¯èƒ½åœ¨ä½åŠ‘é‡ä¸‹ä¿ƒé€²å…¶ä»–å…ç–«ç´°èƒçš„æ´»åŒ–ã€‚é€™æé†’æˆ‘å€‘ï¼Œå°æ–¼æŸäº›åŒ–åˆç‰©çš„å¥åº·å½±éŸ¿ï¼Œå¿…é ˆä»”ç´°è€ƒé‡å…¶åœ¨ä¸åŒåŠ‘é‡å’Œç’°å¢ƒä¸‹çš„ä½œç”¨ï¼Œæ‰èƒ½æ›´å¥½åœ°ç†è§£å…¶å°å¥åº·çš„æ½›åœ¨å½±éŸ¿ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¤šå£ç¢³ç´ç±³ç®¡å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›æ·±å…¥äº†è§£Nrf2åœ¨é€™ä¸€éç¨‹ä¸­çš„è§’è‰²ï¼Œå› ç‚ºå…ˆå‰çš„ç ”ç©¶é¡¯ç¤ºNrf2åœ¨å°é¼ ä¸­æ„å¤–ä¿ƒé€²äº†ç”±MWCNTå¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ï¼Œé€™èˆ‡å…¶é€šå¸¸è¢«èªç‚ºçš„æŠ‘åˆ¶ç‚ç—‡çš„è§’è‰²ç›¸çŸ›ç›¾ã€‚å› æ­¤ï¼Œé€™é …ç ”ç©¶æ—¨åœ¨å¡«è£œé€™ä¸€çŸ¥è­˜ç©ºç™½ï¼Œä¸¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™ç¨®ç‚ç—‡åæ‡‰ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†48éš»C57BL/6 Jé›„æ€§å°é¼ ï¼Œé€™äº›å°é¼ åœ¨éº»é†‰å¾Œé€éå’½å–‰å¸å…¥çš„æ–¹å¼æ¥è§¸äº†ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰ï¼ŒåŠ‘é‡åˆ†åˆ¥ç‚º0ã€10æˆ–20å¾®å…‹ï¼Œä¸¦åœ¨æ¥ä¸‹ä¾†çš„14å¤©å…§ï¼Œçµ¦äºˆå°é¼ æ¯å¤©25æ¯«å…‹æ¯å…¬æ–¤çš„è˜¿è””ç¡«ç´ æˆ–å°ç…§ç‰©è³ªã€‚ç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„æ”¯æ°£ç®¡è‚ºæ³¡çŒæ´—æ¶²ï¼ˆBALFï¼‰é€²è¡Œç´°èƒè¨ˆæ•¸ï¼Œä¸¦å°è‚ºçµ„ç¹”é€²è¡Œäº†çµ„ç¹”ç—…ç†å­¸åˆ†æä»¥åŠç´°èƒå› å­æˆ–è¶¨åŒ–å› å­mRNAè¡¨é”å’ŒNrf2è›‹ç™½çš„å®šé‡åˆ†æã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œæ¥è§¸å¤šå£ç¢³ç´ç±³ç®¡å¾Œï¼Œå°é¼ çš„è‚ºéƒ¨é‡é‡å¢åŠ ã€BALFä¸­çš„æ·‹å·´ç´°èƒæ•¸é‡ä¸Šå‡ï¼Œä»¥åŠè‚ºéƒ¨IL-6çš„è¡¨é”å¢åŠ ã€‚è€Œè˜¿è””ç¡«ç´ çš„è™•ç†å‰‡æ¸›å°‘äº†ç”±MWCNTå¼•èµ·çš„è‚ºéƒ¨é‡é‡å¢åŠ å’Œæ·‹å·´ç´°èƒæµ¸æ½¤ï¼Œä¸¦é™ä½äº†IL-6çš„è¡¨é”ã€‚ç„¶è€Œï¼Œä»¤äººæ„å¤–çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨ä½åŠ‘é‡MWCNTçš„æƒ…æ³ä¸‹å»ä¿ƒé€²äº†ä¸­æ€§ç²’ç´°èƒçš„æµ¸æ½¤ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å°MWCNTå¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡å¯èƒ½å…·æœ‰é›™é‡ä½œç”¨ï¼Œé€™ä¸€åˆ‡éƒ½èˆ‡Nrf2çš„æ´»åŒ–æœ‰é—œã€‚",
    "fb_post": "æ ¹æ“šã€ŠToxicology researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ å¤§å®¶çŸ¥é“è˜¿è””ä¸åªæ˜¯ç¾å‘³çš„é£Ÿæï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„å¥åº·æœ‰å¹«åŠ©å—ï¼Ÿæœ€è¿‘ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®æˆåˆ†åœ¨æŸäº›æƒ…æ³ä¸‹èƒ½å½±éŸ¿æˆ‘å€‘çš„å…ç–«ç³»çµ±ï¼Œé€™å¯ä¸æ˜¯å°äº‹å“¦ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç”±å¤šå£ç¢³ç´ç±³ç®¡ï¼ˆMWCNTï¼‰å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼ŒNrf2é€™å€‹è›‹ç™½è³ªåœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œé›–ç„¶å®ƒé€šå¸¸è¢«èªç‚ºå¯ä»¥å¹«åŠ©æ¸›å°‘ç‚ç—‡ï¼Œä½†åœ¨æŸäº›æƒ…æ³ä¸‹å»å¯èƒ½ä¿ƒé€²ç‚ç—‡ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ç”¨å°é¼ é€²è¡Œæ¸¬è©¦ï¼Œè®“å®ƒå€‘å¸å…¥ä¸åŒåŠ‘é‡çš„å¤šå£ç¢³ç´ç±³ç®¡ï¼Œç„¶å¾Œçµ¦äºˆè˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿè‚ºéƒ¨çš„è®ŠåŒ–ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æ¸›å°‘è‚ºéƒ¨çš„ç‚ç—‡åæ‡‰ï¼Œä½†åœ¨ä½åŠ‘é‡çš„æƒ…æ³ä¸‹å»å¯èƒ½æœƒä¿ƒé€²æŸäº›å…ç–«ç´°èƒçš„æ´»åŒ–ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç”±ç’°å¢ƒæ±¡æŸ“ç‰©å¼•èµ·çš„è‚ºéƒ¨ç‚ç—‡ã€‚\n2. ä½†åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œå®ƒçš„ä½œç”¨å¯èƒ½æœƒè®Šå¾—è¤‡é›œï¼Œç‰¹åˆ¥æ˜¯å°å…ç–«ç³»çµ±çš„å½±éŸ¿ã€‚\n3. ç†è§£é€™äº›åŒ–åˆç‰©çš„ä½œç”¨éœ€è¦åœ¨ä¸åŒåŠ‘é‡å’Œç’°å¢ƒä¸‹ä»”ç´°è€ƒé‡ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main results from the study on sulforaphane and MWCNT-induced lung inflammation. Include symbols representing broccoli or sulforaphane, simplified icons of experimental subjects (like mice or cells), arrows or flow lines to indicate the experiment steps, and a section clearly labeled 'Main Results' showing protective effects or changes observed. Use a light background with soft colors for a scientific and informative style.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºç‚ Lung Inflammation",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41399453/"
  },
  {
    "id": "41409171",
    "title_en": "Investigating the Anticancer Effects of Sulforaphane in an In Vitro Coculture Model of Prostate Cancer Cells with Engineered Heart Tissue.",
    "pub_date": "2025 Dec",
    "journal": "ACS pharmacology & translational science",
    "abstract_en": "Sulforaphane (SFN) is a phytoderived compound abundant in cruciferous plants that possesses a broad spectrum of anticancer properties. We showed that SFN-induced caspase-mediated apoptosis in grade IV bone metastasis-derived androgen-insensitive PC-3 (IC<sub>50</sub> = 4.2 Î¼M), and lymph node metastasis-derived androgen-sensitive LNCaP (IC<sub>50</sub> = 2.8 Î¼M) prostate adenocarcinoma cells. SFN-mediated cardiotoxic side effects were tested in a preclinical in vitro model that enables the study simultaneously of the impact of drugs on cancer cell death and contractile properties of engineered heart tissues generated from human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM EHT). Thereby, SFN exposure induced PC-3 cell death without affecting the contractile force of hiPSC-CM EHT. Interestingly, the irregular beating pattern of hiPSC-CM EHT observed in the presence of PC-3 coculture was normalized compared to vehicle treatment. Overall, this in vitro coculture model of hiPSC-CM EHT and cancer cells could facilitate the study of cardiotoxic cancer drug side-effects.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾åå­—èŠ±ç§‘æ¤ç‰©ä¸­æå–çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®æŠ—ç™Œç‰¹æ€§ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„æ­»äº¡ï¼Œç ”ç©¶äººå“¡å¸Œæœ›èƒ½æ‰¾åˆ°æ›´å®‰å…¨æœ‰æ•ˆçš„ç™Œç—‡æ²»ç™‚æ–¹æ³•ï¼Œä¸¦æ¸›å°‘å°å¿ƒè‡Ÿçš„å‰¯ä½œç”¨ï¼Œé€™å°æ–¼ç™Œç—‡æ‚£è€…çš„æ•´é«”å¥åº·è‡³é—œé‡è¦ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼ä¸åŒé¡å‹çš„å‰åˆ—è…ºè…ºç™Œç´°èƒï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•èª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä»¥åŠå®ƒå°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œé€™å°æ–¼é–‹ç™¼æ–°çš„ç™Œç—‡æ²»ç™‚ç­–ç•¥éå¸¸é‡è¦ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å‰åˆ—è…ºç™Œç´°èƒå’Œäººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒè¡ç”Ÿçš„å¿ƒè‚Œç´°èƒçµ„æˆçš„å…±åŸ¹é¤Šæ¨¡å‹ã€‚é€™å€‹æ¨¡å‹å…è¨±åŒæ™‚ç ”ç©¶è—¥ç‰©å°ç™Œç´°èƒæ­»äº¡çš„å½±éŸ¿ä»¥åŠå°å¿ƒè‡Ÿçµ„ç¹”æ”¶ç¸®ç‰¹æ€§çš„å½±éŸ¿ã€‚ç ”ç©¶è€…æ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿå…¶å°PC-3ç´°èƒçš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°å…¶æ˜¯å¦æœƒå½±éŸ¿å¿ƒè‡Ÿç´°èƒçš„åŠŸèƒ½ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒæ­»äº¡ï¼Œä½†ä¸æœƒå½±éŸ¿å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›ã€‚æ­¤å¤–ï¼Œç•¶PC-3ç´°èƒèˆ‡å¿ƒè‚Œç´°èƒå…±åŸ¹é¤Šæ™‚ï¼Œå¿ƒè‚Œç´°èƒçš„ä¸è¦å‰‡è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æŸäº›ç™Œç—‡è—¥ç‰©çš„å¿ƒè‡Ÿæ¯’æ€§å‰¯ä½œç”¨ã€‚é€™äº›çµæœç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾åå­—èŠ±ç§‘æ¤ç‰©ä¸­æå–çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®æŠ—ç™Œç‰¹æ€§ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„æ­»äº¡ï¼Œç ”ç©¶äººå“¡å¸Œæœ›èƒ½æ‰¾åˆ°æ›´å®‰å…¨æœ‰æ•ˆçš„ç™Œç—‡æ²»ç™‚æ–¹æ³•ï¼Œä¸¦æ¸›å°‘å°å¿ƒè‡Ÿçš„å‰¯ä½œç”¨ï¼Œé€™å°æ–¼ç™Œç—‡æ‚£è€…çš„æ•´é«”å¥åº·è‡³é—œé‡è¦ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å‰åˆ—è…ºç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼ä¸åŒé¡å‹çš„å‰åˆ—è…ºè…ºç™Œç´°èƒï¼ŒåŒ…æ‹¬å°é›„æ¿€ç´ ä¸æ•æ„Ÿçš„PC-3ç´°èƒå’Œå°é›„æ¿€ç´ æ•æ„Ÿçš„LNCaPç´°èƒã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•èª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä»¥åŠå®ƒå°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿ï¼Œé€™å°æ–¼é–‹ç™¼æ–°çš„ç™Œç—‡æ²»ç™‚ç­–ç•¥éå¸¸é‡è¦ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å‰åˆ—è…ºç™Œç´°èƒå’Œäººé¡èª˜å°å¤šèƒ½å¹¹ç´°èƒè¡ç”Ÿçš„å¿ƒè‚Œç´°èƒçµ„æˆçš„å…±åŸ¹é¤Šæ¨¡å‹ã€‚é€™å€‹æ¨¡å‹å…è¨±åŒæ™‚ç ”ç©¶è—¥ç‰©å°ç™Œç´°èƒæ­»äº¡çš„å½±éŸ¿ä»¥åŠå°å¿ƒè‡Ÿçµ„ç¹”æ”¶ç¸®ç‰¹æ€§çš„å½±éŸ¿ã€‚ç ”ç©¶è€…æ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„è˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿå…¶å°PC-3ç´°èƒçš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°å…¶æ˜¯å¦æœƒå½±éŸ¿å¿ƒè‡Ÿç´°èƒçš„åŠŸèƒ½ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°PC-3ç´°èƒæ­»äº¡ï¼Œä½†ä¸æœƒå½±éŸ¿å¿ƒè‚Œç´°èƒçš„æ”¶ç¸®åŠ›ã€‚æ­¤å¤–ï¼Œç•¶PC-3ç´°èƒèˆ‡å¿ƒè‚Œç´°èƒå…±åŸ¹é¤Šæ™‚ï¼Œå¿ƒè‚Œç´°èƒçš„ä¸è¦å‰‡è·³å‹•æ¨¡å¼å¾—åˆ°äº†æ”¹å–„ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æŸäº›ç™Œç—‡è—¥ç‰©çš„å¿ƒè‡Ÿæ¯’æ€§å‰¯ä½œç”¨ã€‚é€™äº›çµæœç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚",
    "fb_post": "æ ¹æ“šã€ŠACS pharmacology & translational scienceã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„æ—¥å¸¸é£²é£Ÿä¸­ï¼Œåƒé’èŠ±æ¤°èœé€™æ¨£çš„åå­—èŠ±ç§‘è”¬èœï¼Œå¯èƒ½å°å¥åº·æœ‰æ„æƒ³ä¸åˆ°çš„å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œé€™ç¨®ç‰©è³ªè¢«èªç‚ºå°ç™Œç—‡æœ‰æŠ—æ“Šçš„æ•ˆæœï¼Œå°¤å…¶æ˜¯å‰åˆ—è…ºç™Œã€‚ç ”ç©¶äººå“¡æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„æ­»äº¡ï¼Œä¸¦ä¸”å°å¿ƒè‡Ÿç´°èƒçš„å½±éŸ¿åˆæ˜¯ä»€éº¼ã€‚é€™æ¨£çš„ç ”ç©¶å¸Œæœ›èƒ½æ‰¾åˆ°æ›´å®‰å…¨çš„ç™Œç—‡æ²»ç™‚æ–¹æ³•ï¼Œè®“æ‚£è€…åœ¨æ²»ç™‚éç¨‹ä¸­ï¼Œå¿ƒè‡Ÿä¹Ÿèƒ½ä¿æŒå¥åº·ï¼\n\nåœ¨å¯¦é©—ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨äº†å‰åˆ—è…ºç™Œç´°èƒå’Œå¿ƒè‡Ÿç´°èƒçš„å…±åŸ¹é¤Šæ¨¡å‹ï¼Œé€™æ¨£å¯ä»¥åŒæ™‚è§€å¯Ÿè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„æ­»äº¡å’Œå¿ƒè‡Ÿç´°èƒçš„åŠŸèƒ½ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆèª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œå»ä¸æœƒå½±éŸ¿å¿ƒè‡Ÿç´°èƒçš„æ”¶ç¸®åŠ›ï¼Œç”šè‡³æ”¹å–„äº†å¿ƒè‡Ÿç´°èƒçš„è·³å‹•æ¨¡å¼ï¼é€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æŸäº›ç™Œç—‡è—¥ç‰©çš„å¿ƒè‡Ÿæ¯’æ€§å‰¯ä½œç”¨ã€‚\n\nğŸ” é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡æ²»ç™‚ï¼Œç‰¹åˆ¥æ˜¯å‰åˆ—è…ºç™Œã€‚\n2. å®ƒèƒ½èª˜å°ç™Œç´°èƒæ­»äº¡ï¼Œä½†ä¸å½±éŸ¿å¿ƒè‡Ÿç´°èƒçš„åŠŸèƒ½ã€‚\n3. å¯èƒ½æ¸›å°‘æŸäº›ç™Œç—‡è—¥ç‰©å°å¿ƒè‡Ÿçš„å‰¯ä½œç”¨ã€‚\n\né€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ï¼Œä½†é‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå®ƒçš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§å“¦ï¼",
    "image_prompt": "Create an informative illustration that explains the experimental method and main results of a study on sulforaphane. Use a simple and clear style, with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified images of human, animal, or cell subjects, arrows or flow lines showing the experimental steps, and a section labeled 'Main Results' highlighting protective effects or observed changes.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‰åˆ—è…ºç™Œ Prostate Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41409171/"
  },
  {
    "id": "41387309",
    "title_en": "Monovalent mannose-glycoconjugates of sulforaphane reprogram human dendritic cells via NFATc1 to induce immune tolerance under inflammatory conditions.",
    "pub_date": "2025 Dec",
    "journal": "British journal of pharmacology",
    "abstract_en": "Immune tolerance prevents inflammation and autoimmunity, with dendritic cells (DCs) playing a key role. Reprogramming DCs towards a tolerogenic state represents a promising therapeutic strategy. Sulforaphane (SFN) has known immunomodulatory effects, but its clinical application is limited by poor stability and bioavailability. To enhance its therapeutic potential, SFN was conjugated with mannose (SFNMan) or fucose (SFNFuc), aiming to induce a tolerogenic phenotype in human monocyte-derived DCs (moDCs) under inflammation and to explore NFATc1's involvement. moDCs were exposed to inflammatory conditions and treated with SFN, SFNMan or SFNFuc. Their phenotype, cytokine profile, T cell-modulating capacity and NFATc1 signalling were evaluated. SFNMan selectively induced a tolerogenic phenotype, characterised by an increased PD-L1/CD86 ratio and IL-10 production; up-regulation of SOCS1 and IDO transcripts; and Treg expansion and reduced proliferation of cytotoxic T cell proliferation. Functional assays and confocal microscopy revealed that SFNMan, but not SFNFuc, promoted NFATc1 nuclear translocation. Pharmacological inhibition of NFATc1 with cyclosporin A (CsA) abolished these effects, confirming NFATc1 as a central mediator of SFNMan-induced immune tolerance. Our findings identify NFATc1 as a key transcriptional switch in moDCs tolerogenic programming and highlight the carbohydrate-dependent specificity of SFN conjugates. SFNMan represents a novel carbohydrate-engineered immunomodulator capable of driving immune tolerance through NFATc1 activation. These results provide a mechanistic framework for the development of precision therapies targeting inflammatory and autoimmune diseases.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºã€‚å…ç–«è€å—æ€§å¯ä»¥é˜²æ­¢èº«é«”å‡ºç¾ç‚ç—‡å’Œè‡ªé«”å…ç–«åæ‡‰ï¼Œè€Œæ¨¹çªç´°èƒåœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ã€‚é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œä½¿å…¶æœå‘è€å—æ€§ç‹€æ…‹ç™¼å±•ï¼Œå¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æ²»ç™‚ç­–ç•¥ã€‚é€™æ„å‘³è‘—å¦‚æœèƒ½æœ‰æ•ˆåœ°ä¿ƒé€²å…ç–«è€å—ï¼Œæˆ–è¨±èƒ½æ¸›å°‘è¨±å¤šèˆ‡ç‚ç—‡å’Œè‡ªé«”å…ç–«ç›¸é—œçš„ç–¾ç—…é¢¨éšªï¼Œé€²è€Œæ”¹å–„äººå€‘çš„å¥åº·ç‹€æ³ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨èª¿ç¯€å…ç–«ç³»çµ±ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒï¼ˆmoDCsï¼‰ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éæ”¹è®Šé€™äº›æ¨¹çªç´°èƒçš„ç‰¹æ€§ï¼Œä¾†ä¿ƒé€²å…ç–«è€å—æ€§ï¼Œä¸¦é€²ä¸€æ­¥äº†è§£NFATc1é€™å€‹å› å­åœ¨éç¨‹ä¸­çš„è§’è‰²ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°æ–¼é–‹ç™¼é‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒæš´éœ²æ–¼ç‚ç—‡ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€èˆ‡ç”˜éœ²ç³–çµåˆçš„è˜¿è””ç¡«ç´ ï¼ˆSFNManï¼‰å’Œèˆ‡å²©è—»ç³–çµåˆçš„è˜¿è””ç¡«ç´ ï¼ˆSFNFucï¼‰é€²è¡Œè™•ç†ã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°é€™äº›æ¨¹çªç´°èƒçš„è¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€èª¿ç¯€Tç´°èƒçš„èƒ½åŠ›ä»¥åŠNFATc1çš„ä¿¡è™Ÿå‚³éã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨æ‰¾å‡ºå“ªä¸€ç¨®è™•ç†æ–¹å¼èƒ½æœ‰æ•ˆä¿ƒé€²è€å—æ€§è¡¨å‹çš„å½¢æˆã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿä¸Šå‡ã€‚æ­¤å¤–ï¼ŒSFNMané‚„ä¿ƒé€²äº†SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä¸¦æ“´å±•äº†èª¿ç¯€æ€§Tç´°èƒï¼ŒåŒæ™‚æ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒSFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œè€Œé€™ä¸€éç¨‹åœ¨ä½¿ç”¨ç’°å­¢ç´ AæŠ‘åˆ¶NFATc1å¾Œè¢«é˜»æ­¢ï¼Œé¡¯ç¤ºNFATc1åœ¨SFNManèª˜å°å…ç–«è€å—ä¸­çš„é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºé‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚æä¾›äº†æ©Ÿåˆ¶åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºã€‚å…ç–«è€å—æ€§å¯ä»¥é˜²æ­¢èº«é«”å‡ºç¾ç‚ç—‡å’Œè‡ªé«”å…ç–«åæ‡‰ï¼Œè€Œæ¨¹çªç´°èƒåœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ã€‚é€éèª¿æ•´æ¨¹çªç´°èƒçš„åŠŸèƒ½ï¼Œä½¿å…¶æœå‘è€å—æ€§ç‹€æ…‹ç™¼å±•ï¼Œå¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æ²»ç™‚ç­–ç•¥ã€‚é€™æ„å‘³è‘—å¦‚æœèƒ½æœ‰æ•ˆåœ°ä¿ƒé€²å…ç–«è€å—ï¼Œæˆ–è¨±èƒ½æ¸›å°‘è¨±å¤šèˆ‡ç‚ç—‡å’Œè‡ªé«”å…ç–«ç›¸é—œçš„ç–¾ç—…é¢¨éšªï¼Œé€²è€Œæ”¹å–„äººå€‘çš„å¥åº·ç‹€æ³ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰åœ¨èª¿ç¯€å…ç–«ç³»çµ±ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒï¼ˆmoDCsï¼‰ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€éæ”¹è®Šé€™äº›æ¨¹çªç´°èƒçš„ç‰¹æ€§ï¼Œä¾†ä¿ƒé€²å…ç–«è€å—æ€§ï¼Œä¸¦é€²ä¸€æ­¥äº†è§£NFATc1é€™å€‹å› å­åœ¨éç¨‹ä¸­çš„è§’è‰²ã€‚é€™äº›å•é¡Œçš„è§£ç­”å°æ–¼é–‹ç™¼é‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡äººé¡å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒæš´éœ²æ–¼ç‚ç—‡ç’°å¢ƒä¸­ï¼Œä¸¦åˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ ã€èˆ‡ç”˜éœ²ç³–çµåˆçš„è˜¿è””ç¡«ç´ ï¼ˆSFNManï¼‰å’Œèˆ‡å²©è—»ç³–çµåˆçš„è˜¿è””ç¡«ç´ ï¼ˆSFNFucï¼‰é€²è¡Œè™•ç†ã€‚æ¥è‘—ï¼Œä»–å€‘è©•ä¼°é€™äº›æ¨¹çªç´°èƒçš„è¡¨å‹ã€ç´°èƒå› å­ç”¢ç”Ÿã€èª¿ç¯€Tç´°èƒçš„èƒ½åŠ›ä»¥åŠNFATc1çš„ä¿¡è™Ÿå‚³éã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨æ‰¾å‡ºå“ªä¸€ç¨®è™•ç†æ–¹å¼èƒ½æœ‰æ•ˆä¿ƒé€²è€å—æ€§è¡¨å‹çš„å½¢æˆã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼ŒSFNManèƒ½å¤ é¸æ“‡æ€§åœ°èª˜å°æ¨¹çªç´°èƒç”¢ç”Ÿè€å—æ€§è¡¨å‹ï¼Œé€™è¡¨ç¾ç‚ºPD-L1/CD86æ¯”ç‡çš„å¢åŠ å’ŒIL-10çš„ç”¢ç”Ÿä¸Šå‡ã€‚æ­¤å¤–ï¼ŒSFNMané‚„ä¿ƒé€²äº†SOCS1å’ŒIDOè½‰éŒ„æœ¬çš„ä¸Šèª¿ï¼Œä¸¦æ“´å±•äº†èª¿ç¯€æ€§Tç´°èƒï¼ŒåŒæ™‚æ¸›å°‘äº†ç´°èƒæ¯’æ€§Tç´°èƒçš„å¢æ®–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒSFNManä¿ƒé€²äº†NFATc1çš„æ ¸è½‰ä½ï¼Œè€Œé€™ä¸€éç¨‹åœ¨ä½¿ç”¨ç’°å­¢ç´ AæŠ‘åˆ¶NFATc1å¾Œè¢«é˜»æ­¢ï¼Œé¡¯ç¤ºNFATc1åœ¨SFNManèª˜å°å…ç–«è€å—ä¸­çš„é‡è¦è§’è‰²ã€‚é€™äº›çµæœç‚ºé‡å°ç‚ç—‡å’Œè‡ªé«”å…ç–«ç–¾ç—…çš„ç²¾æº–æ²»ç™‚æä¾›äº†æ©Ÿåˆ¶åŸºç¤ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBritish journal of pharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å…ç–«ç³»çµ±å…¶å¯¦å¯ä»¥é€éä¸€äº›é£Ÿç‰©ä¾†è®Šå¾—æ›´å¼·å¤§ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç‰©è³ªï¼Œå®ƒä¾†è‡ªæ–¼é’èŠ±èœå’Œå…¶ä»–åå­—èŠ±ç§‘è”¬èœï¼Œä¸¦ä¸”åœ¨èª¿ç¯€æˆ‘å€‘å…ç–«ç³»çµ±ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œé€™ç¨®ç‰©è³ªå¦‚ä½•å½±éŸ¿æˆ‘å€‘çš„æ¨¹çªç´°èƒï¼ˆå®ƒå€‘å°±åƒæ˜¯å…ç–«ç³»çµ±çš„å°è¡›å…µï¼‰ï¼Œè®“å®ƒå€‘è®Šå¾—æ›´èƒ½è€å—èº«é«”å…§çš„ç‚ç—‡ã€‚  \n\nä»–å€‘åœ¨å¯¦é©—ä¸­æŠŠæ¨¹çªç´°èƒæ”¾åœ¨ä¸€å€‹æ¨¡æ“¬ç‚ç—‡çš„ç’°å¢ƒä¸­ï¼Œç„¶å¾Œåˆ†åˆ¥ç”¨è˜¿è””ç¡«ç´ åŠå…¶è®Šé«”é€²è¡Œè™•ç†ï¼Œè§€å¯Ÿå®ƒå€‘çš„è®ŠåŒ–ã€‚çµæœç™¼ç¾ï¼ŒæŸç¨®ç‰¹åˆ¥çš„è™•ç†æ–¹å¼ï¼ˆèˆ‡ç”˜éœ²ç³–çµåˆçš„è˜¿è””ç¡«ç´ ï¼‰èƒ½æœ‰æ•ˆä¿ƒé€²æ¨¹çªç´°èƒçš„è€å—æ€§ï¼Œé€™æ„å‘³è‘—å®ƒå€‘èƒ½æ›´å¥½åœ°ä¿è­·æˆ‘å€‘çš„èº«é«”ï¼Œæ¸›å°‘ç‚ç—‡çš„å½±éŸ¿ï¼  \n\nâœ¨ é€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æˆ‘å€‘çš„å…ç–«ç³»çµ±æ›´å¥½åœ°é‹ä½œã€‚  \n2. æ¨¹çªç´°èƒçš„è€å—æ€§å°æ–¼é é˜²è‡ªé«”å…ç–«ç–¾ç—…éå¸¸é‡è¦ã€‚  \n3. é€éé£²é£Ÿèª¿æ•´ï¼Œæˆ–è¨±èƒ½æ”¹å–„æˆ‘å€‘çš„å¥åº·ç‹€æ…‹ï¼",
    "image_prompt": "Create an informative and simple infographic illustrating the experiment and main results of a study on sulforaphane. The image should have a light background and soft colors. Include representations of broccoli or sulforaphane, simplified icons of human cells, and arrows or flow lines showing the experimental process. There should be a section labeled 'Main Results' highlighting the protective effects and changes observed in the dendritic cells.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé«”å…ç–«ç–¾ç—… Autoimmune Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41387309/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "journal": "International immunopharmacology",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¿ƒè‡Ÿå¥åº·çš„å½±éŸ¿ã€‚Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ˜¯ä¸€ç¨®å¯èƒ½å°è‡´å¿ƒè‡Ÿæå‚·çš„ç–¾ç—…ï¼Œé›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½å°ç”Ÿå‘½é€ æˆå¨è„…ã€‚é€™é …ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¤©ç„¶çš„Nrf2æ¿€æ´»åŠ‘ï¼Œå¯èƒ½åœ¨æ¸›è¼•TTSç›¸é—œçš„å¿ƒè‡Ÿæå‚·æ–¹é¢ç™¼æ®é‡è¦ä½œç”¨ã€‚é€™æ„å‘³è‘—é€éé£²é£Ÿæˆ–è£œå……è˜¿è””ç¡«ç´ ï¼Œæˆ–è¨±èƒ½å°å¿ƒè‡Ÿå¥åº·æœ‰æ‰€å¹«åŠ©ï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„æƒ…æ³ä¸‹ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°Takotsuboç—‡å€™ç¾¤çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œé€™ç¨®ç—‡å€™ç¾¤å¦‚ä½•å°è‡´å¿ƒè‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰ï¼Œä»¥åŠæ˜¯å¦æœ‰é‡å°æ€§çš„æ²»ç™‚æ–¹æ³•å¯ä»¥æ¸›è¼•é€™äº›å½±éŸ¿ã€‚ç”±æ–¼ç›®å‰å°æ–¼TTSçš„æ²»ç™‚é¸æ“‡æœ‰é™ï¼Œå› æ­¤å°‹æ‰¾æ–°çš„æ²»ç™‚ç­–ç•¥æ˜¯éå¸¸é‡è¦çš„ã€‚é€™é …ç ”ç©¶å¸Œæœ›èƒ½æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨é€™æ–¹é¢çš„æ½›åŠ›ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚é€éé€™äº›æ¨¡å‹ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†ç•°ä¸™è…ä¸Šè…ºç´ å¦‚ä½•å¼•èµ·æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œä¸¦è©•ä¼°äº†è˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶ä¸­æ¸¬é‡äº†å¿ƒè‡Ÿçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦åˆ†æäº†æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·å’Œéµæ­»äº¡æ¨™è¨˜ç‰©çš„è®ŠåŒ–ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ å…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶åŠå…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒæ™‚æ¸›å°‘ç·šç²’é«”æå‚·å’ŒæŠ‘åˆ¶éµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä¸¦æ¿€æ´»Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œç•¶æŠ‘åˆ¶Nrf2æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„ç›Šè™•æœƒæ¶ˆå¤±ï¼Œé€™è¡¨æ˜Nrf2åœ¨å…¶æ²»ç™‚æ•ˆæœä¸­æ‰®æ¼”äº†é—œéµè§’è‰²ã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨çš„æ²»ç™‚æ–¹æ³•ï¼Œå¯èƒ½åœ¨æ”¹å–„TTSçš„çµæœä¸Šå…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¿ƒè‡Ÿå¥åº·çš„å½±éŸ¿ã€‚Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ˜¯ä¸€ç¨®å¯èƒ½å°è‡´å¿ƒè‡Ÿæå‚·çš„ç–¾ç—…ï¼Œé›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½å°ç”Ÿå‘½é€ æˆå¨è„…ã€‚é€™é …ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¤©ç„¶çš„Nrf2æ¿€æ´»åŠ‘ï¼Œå¯èƒ½åœ¨æ¸›è¼•TTSç›¸é—œçš„å¿ƒè‡Ÿæå‚·æ–¹é¢ç™¼æ®é‡è¦ä½œç”¨ã€‚é€™æ„å‘³è‘—é€éé£²é£Ÿæˆ–è£œå……è˜¿è””ç¡«ç´ ï¼Œæˆ–è¨±èƒ½å°å¿ƒè‡Ÿå¥åº·æœ‰æ‰€å¹«åŠ©ï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„æƒ…æ³ä¸‹ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°Takotsuboç—‡å€™ç¾¤çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œé€™ç¨®ç—‡å€™ç¾¤å¦‚ä½•å°è‡´å¿ƒè‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼ˆferroptosisï¼‰ï¼Œä»¥åŠæ˜¯å¦æœ‰é‡å°æ€§çš„æ²»ç™‚æ–¹æ³•å¯ä»¥æ¸›è¼•é€™äº›å½±éŸ¿ã€‚ç”±æ–¼ç›®å‰å°æ–¼TTSçš„æ²»ç™‚é¸æ“‡æœ‰é™ï¼Œå› æ­¤å°‹æ‰¾æ–°çš„æ²»ç™‚ç­–ç•¥æ˜¯éå¸¸é‡è¦çš„ã€‚é€™é …ç ”ç©¶å¸Œæœ›èƒ½æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨é€™æ–¹é¢çš„æ½›åŠ›ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ç•°ä¸™è…ä¸Šè…ºç´ èª˜å°çš„è€é¼ æ¨¡å‹å’ŒAC16å¿ƒè‚Œç´°èƒä¾†æ¨¡æ“¬TTSçš„æƒ…æ³ã€‚é€éé€™äº›æ¨¡å‹ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†ç•°ä¸™è…ä¸Šè…ºç´ å¦‚ä½•å¼•èµ·æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡ï¼Œä¸¦è©•ä¼°äº†è˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶ä¸­æ¸¬é‡äº†å¿ƒè‡Ÿçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦åˆ†æäº†æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·å’Œéµæ­»äº¡æ¨™è¨˜ç‰©çš„è®ŠåŒ–ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶è€…èƒ½å¤ å…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶åŠå…¶æ½›åœ¨çš„æ²»ç™‚æ•ˆæœã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒæ™‚æ¸›å°‘ç·šç²’é«”æå‚·å’ŒæŠ‘åˆ¶éµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä¸¦æ¿€æ´»Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œç•¶æŠ‘åˆ¶Nrf2æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„ç›Šè™•æœƒæ¶ˆå¤±ï¼Œé€™è¡¨æ˜Nrf2åœ¨å…¶æ²»ç™‚æ•ˆæœä¸­æ‰®æ¼”äº†é—œéµè§’è‰²ã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨çš„æ²»ç™‚æ–¹æ³•ï¼Œå¯èƒ½åœ¨æ”¹å–„TTSçš„çµæœä¸Šå…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "fb_post": "æ ¹æ“šã€ŠInternational immunopharmacologyã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæœ‰ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½å°æˆ‘å€‘çš„å¿ƒè‡Ÿå¥åº·æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶é‡å°ä¸€ç¨®åç‚ºTakotsuboç—‡å€™ç¾¤çš„å¿ƒè‡Ÿå•é¡Œé€²è¡Œäº†æ¢ç´¢ã€‚é€™ç¨®ç—‡å€™ç¾¤é›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å…¶å¯¦å¯èƒ½å°ç”Ÿå‘½é€ æˆå¨è„…ã€‚\n\nç ”ç©¶è€…ä½¿ç”¨å°é¼ å’Œå¿ƒè‡Ÿç´°èƒæ¨¡å‹ä¾†æ¨¡æ“¬é€™å€‹ç—‡å€™ç¾¤ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„å¿ƒè‡Ÿçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œé‚„èƒ½å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç´°èƒæå‚·å’Œæ­»äº¡ã€‚\n\né€™é …ç ”ç©¶çš„ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°ï¼Œé€éé£²é£Ÿæˆ–è£œå……è˜¿è””ç¡«ç´ ï¼Œæˆ–è¨±èƒ½å°å¿ƒè‡Ÿå¥åº·æœ‰æ‰€å¹«åŠ©ã€‚ä»¥ä¸‹æ˜¯å¹¾å€‹é‡è¦çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ¸›è¼•å¿ƒè‡Ÿæå‚·ã€‚\n2. å®ƒèƒ½æå‡æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä¿è­·ç´°èƒã€‚\n3. Nrf2é€™å€‹å› å­åœ¨è˜¿è””ç¡«ç´ çš„æ•ˆæœä¸­æ‰®æ¼”äº†é—œéµè§’è‰²ã€‚\n\né›–ç„¶é€™äº›çµæœå¾ˆæœ‰å¸Œæœ›ï¼Œä½†æˆ‘å€‘ä»éœ€æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªå®ƒçš„ç™‚æ•ˆå“¦ï¼",
    "image_prompt": "Create a flat design infographic on a light background explaining the experiment and main results of a study on sulforaphane and Takotsubo syndrome. Include simplified icons of broccoli or sulforaphane, experimental subjects like mice or heart cells, arrows or flow lines showing the experimental steps, and a section highlighting the main results such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "Takotsuboç—‡å€™ç¾¤ Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "journal": "Research in pharmaceutical sciences",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™å°è‚ºéƒ¨é€ æˆçš„å‚·å®³ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·ç´°èƒæŠµæŠ—å£“åŠ›çš„èƒ½åŠ›ï¼Œå¾è€Œä¿è­·è‚ºéƒ¨ç´°èƒå…å—å¸ç…™é€ æˆçš„æå®³ã€‚é€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸äºŒæ‰‹ç…™çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·æç¤ºï¼Œè®“ä»–å€‘äº†è§£æŸäº›å¤©ç„¶æˆåˆ†å¯èƒ½å°è‚ºéƒ¨å¥åº·æœ‰ç›Šã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¸ç…™æå–ç‰©å¼•èµ·çš„äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„å£“åŠ›åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯å®ƒå°SIRT1è¡¨é”çš„èª¿ç¯€ä½œç”¨ã€‚SIRT1æ˜¯ä¸€ç¨®èˆ‡ç´°èƒå£½å‘½å’ŒæŠ—æ°§åŒ–èƒ½åŠ›æœ‰é—œçš„è›‹ç™½è³ªï¼Œå› æ­¤äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶å°æ–¼é–‹ç™¼æ½›åœ¨çš„ä¿è­·ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„è€åŒ–æƒ…æ³ï¼Œä¸¦é€éqRT-PCRé‡åŒ–èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ ï¼Œç ”ç©¶è€…å‰‡ä½¿ç”¨äº†å¸ç…™æå–ç‰©ä¾†èª˜å°è‚ºæ°£è…«æ¨¡å‹ï¼Œä¸¦è§€å¯Ÿè‚ºçµ„ç¹”çš„ç—…ç†è®ŠåŒ–ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†æœ‰æ•ˆæ¸›è¼•äº†å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–å’Œç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„äº†å°é¼ è‚ºéƒ¨çš„ç—…ç†è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„ä¸‹èª¿å’ŒNF-ÎºBçš„ä¸Šèª¿ï¼Œä¸¦é€šéå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶å¸ç…™å¼•èµ·çš„éµæ­»äº¡ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›å’Œç´°èƒè€åŒ–æœ‰ä¸€å®šçš„ä¿è­·ä½œç”¨ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸ç…™å°è‚ºéƒ¨é€ æˆçš„å‚·å®³ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·ç´°èƒæŠµæŠ—å£“åŠ›çš„èƒ½åŠ›ï¼Œå¾è€Œä¿è­·è‚ºéƒ¨ç´°èƒå…å—å¸ç…™é€ æˆçš„æå®³ã€‚é€™å°æ–¼å¸ç…™è€…æˆ–é•·æœŸæ¥è§¸äºŒæ‰‹ç…™çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·æç¤ºï¼Œè®“ä»–å€‘äº†è§£æŸäº›å¤©ç„¶æˆåˆ†å¯èƒ½å°è‚ºéƒ¨å¥åº·æœ‰ç›Šã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¸ç…™æå–ç‰©å¼•èµ·çš„äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„å£“åŠ›åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯å®ƒå°SIRT1è¡¨é”çš„èª¿ç¯€ä½œç”¨ã€‚SIRT1æ˜¯ä¸€ç¨®èˆ‡ç´°èƒå£½å‘½å’ŒæŠ—æ°§åŒ–èƒ½åŠ›æœ‰é—œçš„è›‹ç™½è³ªï¼Œå› æ­¤äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶å°æ–¼é–‹ç™¼æ½›åœ¨çš„ä¿è­·ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„è€åŒ–æƒ…æ³ï¼Œä¸¦é€éqRT-PCRé‡åŒ–èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ ï¼Œç ”ç©¶è€…å‰‡ä½¿ç”¨äº†å¸ç…™æå–ç‰©ä¾†èª˜å°è‚ºæ°£è…«æ¨¡å‹ï¼Œä¸¦è§€å¯Ÿè‚ºçµ„ç¹”çš„ç—…ç†è®ŠåŒ–ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†æœ‰æ•ˆæ¸›è¼•äº†å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–å’Œç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„äº†å°é¼ è‚ºéƒ¨çš„ç—…ç†è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å°SIRT1çš„ä¸‹èª¿å’ŒNF-ÎºBçš„ä¸Šèª¿ï¼Œä¸¦é€šéå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶å¸ç…™å¼•èµ·çš„éµæ­»äº¡ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›å’Œç´°èƒè€åŒ–æœ‰ä¸€å®šçš„ä¿è­·ä½œç”¨ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœã€‚",
    "fb_post": "æ ¹æ“šã€ŠResearch in pharmaceutical sciencesã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„è‚ºéƒ¨å…¶å¯¦ä¹Ÿéœ€è¦ä¿è­·ï¼Œå°±åƒæˆ‘å€‘çš„çš®è†šä¸€æ¨£ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½å°å¸ç…™é€ æˆçš„è‚ºéƒ¨æå®³æœ‰å¹«åŠ©ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„å£“åŠ›åæ‡‰ï¼Œç‰¹åˆ¥æ˜¯å®ƒå°ä¸€ç¨®å« SIRT1 çš„è›‹ç™½è³ªçš„å½±éŸ¿ã€‚é€™å€‹è›‹ç™½è³ªè·Ÿæˆ‘å€‘çš„ç´°èƒå£½å‘½å’ŒæŠ—æ°§åŒ–èƒ½åŠ›æœ‰é—œã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨äº†äººé¡çš„æ°£é“ç´°èƒå’Œå°é¼ ï¼Œå°‡å®ƒå€‘æš´éœ²æ–¼å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›å°‘ç´°èƒçš„æå®³å’Œè€åŒ–ï¼Œä¸¦æ”¹å–„å°é¼ çš„è‚ºéƒ¨å¥åº·ã€‚åŒæ™‚ï¼Œå®ƒé‚„èƒ½èª¿æ•´ä¸€äº›é‡è¦è›‹ç™½è³ªçš„è¡¨é”ï¼Œå¹«åŠ©æŠµæŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€‚\n\né€™äº›ç ”ç©¶çµæœå‘Šè¨´æˆ‘å€‘ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è‚ºéƒ¨ç´°èƒã€‚\n2. å®ƒèƒ½æ¸›å°‘å› å¸ç…™å¼•èµ·çš„ç´°èƒè€åŒ–ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„è‚ºéƒ¨ä¿è­·ç­–ç•¥æä¾›äº†æ–°çš„æ€è·¯ã€‚\n\né›–ç„¶çµæœå¾ˆæœ‰å¸Œæœ›ï¼Œä½†æˆ‘å€‘é‚„éœ€è¦æ›´å¤šçš„ç ”ç©¶ä¾†ç¢ºèªé€™äº›æ•ˆæœï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study on the protective effects of sulforaphane against smoking-induced lung damage. Include simple icons representing sulforaphane (like broccoli), human airway epithelial cells, and mice. Show arrows or flow lines to indicate the experimental steps. Include a section labeled 'Main Results' that highlights the protective effects and changes observed in the study.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "journal": "Molecular nutrition & food research",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šè€åŒ–æœƒå½±éŸ¿æˆ‘å€‘çš„å¥åº·ï¼Œä¸¦å¯èƒ½å°è‡´èº«é«”è™›å¼±ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªåœ¨æ¸›ç·©çš®è†šè€åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚é›–ç„¶è˜¿è””ç¡«ç´ å·²è¢«å»£æ³›æ‡‰ç”¨æ–¼å¤šç¨®ç™Œç—‡æ²»ç™‚ï¼Œä½†å®ƒåœ¨æ”¹å–„çš®è†šè€åŒ–çš„å…·é«”ä½œç”¨ä»ç„¶ä¸æ˜ç¢ºã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæˆ‘å€‘æä¾›æ–°çš„è¦‹è§£ï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°ç†è§£å¦‚ä½•é€éé£²é£Ÿæˆ–è£œå……å“ä¾†å°æŠ—çš®è†šè€åŒ–ï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§éƒ¨çš®è†šè€åŒ–éç¨‹ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®ç‰©è³ªå¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹åŠŸèƒ½ï¼Œä»¥åŠå®ƒæ˜¯å¦èƒ½æ”¹å–„èˆ‡å¹´é½¡ç›¸é—œçš„çš®è†šè®ŠåŒ–ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ çš„æ½›åœ¨æ©Ÿåˆ¶ï¼Œä¸¦æ‰¾å‡ºå®ƒå°çš®è†šè€åŒ–çš„å…·é«”å½±éŸ¿ï¼Œé€™å°æ–¼æœªä¾†çš„æŠ—è€åŒ–ç”¢å“é–‹ç™¼å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "ç ”ç©¶ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€éæ•´åˆç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œç ”ç©¶è€…è­˜åˆ¥å‡º51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„ç›®æ¨™ï¼Œä¸¦åˆ†æäº†è˜¿è””ç¡«ç´ å¦‚ä½•åœ¨é€™äº›ç›®æ¨™ä¸Šç™¼æ®ä½œç”¨ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚ç ”ç©¶ç™¼ç¾233ç¨®ä¸åŒè¡¨é”çš„è›‹ç™½è³ªï¼Œä¸¦ä¸”é€™äº›è›‹ç™½è³ªåœ¨è˜¿è””ç¡«ç´ æ¿€æ´»çš„apelinä¿¡è™Ÿé€šè·¯ä¸­è¡¨ç¾å‡ºé«˜åº¦å¯Œé›†ã€‚æ­¤å¤–ï¼Œå…ç–«ç´°èƒçš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¢å¾©çš®è†šçµ„ç¹”ä¸­Tç´°èƒçš„æ¸›å°‘ï¼Œé€™èˆ‡è˜¿è””ç¡«ç´ çš„ä½œç”¨å¯†åˆ‡ç›¸é—œã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šè€åŒ–çš„æƒ…æ³ã€‚",
    "explanation_zh": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šè€åŒ–æœƒå½±éŸ¿æˆ‘å€‘çš„å¥åº·ï¼Œä¸¦å¯èƒ½å°è‡´èº«é«”è™›å¼±ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªåœ¨æ¸›ç·©çš®è†šè€åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚é›–ç„¶è˜¿è””ç¡«ç´ å·²è¢«å»£æ³›æ‡‰ç”¨æ–¼å¤šç¨®ç™Œç—‡æ²»ç™‚ï¼Œä½†å®ƒåœ¨æ”¹å–„çš®è†šè€åŒ–çš„å…·é«”ä½œç”¨ä»ç„¶ä¸æ˜ç¢ºã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæˆ‘å€‘æä¾›æ–°çš„è¦‹è§£ï¼Œå¹«åŠ©æˆ‘å€‘æ›´å¥½åœ°ç†è§£å¦‚ä½•é€éé£²é£Ÿæˆ–è£œå……å“ä¾†å°æŠ—çš®è†šè€åŒ–ï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§éƒ¨çš®è†šè€åŒ–éç¨‹ä¸­çš„ä½œç”¨ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®ç‰©è³ªå¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹åŠŸèƒ½ï¼Œä»¥åŠå®ƒæ˜¯å¦èƒ½æ”¹å–„èˆ‡å¹´é½¡ç›¸é—œçš„çš®è†šè®ŠåŒ–ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å€‘å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ çš„æ½›åœ¨æ©Ÿåˆ¶ï¼Œä¸¦æ‰¾å‡ºå®ƒå°çš®è†šè€åŒ–çš„å…·é«”å½±éŸ¿ï¼Œé€™å°æ–¼æœªä¾†çš„æŠ—è€åŒ–ç”¢å“é–‹ç™¼å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nç ”ç©¶ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¾†æ¨¡æ“¬çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…å°é€™äº›å°é¼ é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚é€éæ•´åˆç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ï¼Œç ”ç©¶è€…è­˜åˆ¥å‡º51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„ç›®æ¨™ï¼Œä¸¦åˆ†æäº†è˜¿è””ç¡«ç´ å¦‚ä½•åœ¨é€™äº›ç›®æ¨™ä¸Šç™¼æ®ä½œç”¨ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚ç ”ç©¶ç™¼ç¾233ç¨®ä¸åŒè¡¨é”çš„è›‹ç™½è³ªï¼Œä¸¦ä¸”é€™äº›è›‹ç™½è³ªåœ¨è˜¿è””ç¡«ç´ æ¿€æ´»çš„apelinä¿¡è™Ÿé€šè·¯ä¸­è¡¨ç¾å‡ºé«˜åº¦å¯Œé›†ã€‚æ­¤å¤–ï¼Œå…ç–«ç´°èƒçš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¢å¾©çš®è†šçµ„ç¹”ä¸­Tç´°èƒçš„æ¸›å°‘ï¼Œé€™èˆ‡è˜¿è””ç¡«ç´ çš„ä½œç”¨å¯†åˆ‡ç›¸é—œã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šè€åŒ–çš„æƒ…æ³ã€‚",
    "fb_post": "æ ¹æ“šã€ŠMolecular nutrition & food researchã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒŸ ä½ çŸ¥é“å—ï¼Ÿéš¨è‘—å¹´é½¡å¢é•·ï¼Œæˆ‘å€‘çš„çš®è†šä¹Ÿæœƒè®Šå¾—è¶Šä¾†è¶Šè„†å¼±ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆé–€æ¢è¨äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç‰©è³ªï¼Œçœ‹çœ‹å®ƒèƒ½å¦å¹«åŠ©æˆ‘å€‘å°æŠ—çš®è†šè€åŒ–ã€‚\n\né€™é …ç ”ç©¶çš„é‡é»åœ¨æ–¼äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šçš„çµæ§‹å’ŒåŠŸèƒ½ã€‚ç ”ç©¶äººå“¡ä½¿ç”¨äº†ä¸€ç¨®18å€‹æœˆå¤§çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ çš„çš®è†šè€åŒ–æƒ…æ³èˆ‡äººé¡ç›¸ä¼¼ã€‚ä»–å€‘çµ¦é€™äº›å°é¼ è£œå……äº†è˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿçš®è†šçš„è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è£œå……ï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½éƒ½æœ‰äº†æ˜é¡¯æ”¹å–„ï¼ç ”ç©¶é‚„ç™¼ç¾äº†233ç¨®ä¸åŒçš„è›‹ç™½è³ªè®ŠåŒ–ï¼Œé€™äº›è®ŠåŒ–èˆ‡è˜¿è””ç¡«ç´ çš„ä½œç”¨å¯†åˆ‡ç›¸é—œã€‚\n\nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„çš®è†šè€åŒ–ã€‚\n2. ç ”ç©¶ç™¼ç¾äº†èˆ‡æŠ—è€åŒ–ç›¸é—œçš„å¤šç¨®è›‹ç™½è³ªã€‚\n3. é€™é …ç ”ç©¶å¯èƒ½ç‚ºæœªä¾†çš„è­·è†šç”¢å“é–‹ç™¼æä¾›æ–°æ€è·¯ï¼\n\nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æ›´å¤šæœ‰è¶£çš„ç ”ç©¶å§ï¼",
    "image_prompt": "Create a simple and informative illustration to explain the experimental method and key findings of a study on sulforaphane. The image should have a light background with soft colors and a flat design style. Include symbols representing broccoli or sulforaphane, simplified representations of experimental subjects like mice or cells, arrows or flow lines to indicate the steps of the experiment, and a designated area highlighting the main results, such as protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "çš®è†šè€åŒ– Skin Aging",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "journal": "Comparative biochemistry and physiology. Part D, Genomics & proteomics",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™æœ‰ä¸€å®šçš„ä¿è­·ä½œç”¨ã€‚é€™æ„å‘³è‘—é€éé£²é£Ÿä¸­æ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œä¾‹å¦‚é’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æŸäº›ç’°å¢ƒæ¯’ç´ å°æˆ‘å€‘èº«é«”çš„å½±éŸ¿ï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚é€™äº›ç™¼ç¾å¯èƒ½å°æœªä¾†çš„å¥åº·é£²é£ŸæŒ‡å°å’Œç–¾ç—…é é˜²ç­–ç•¥æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°æŠ—ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿å’Œè…¸é“å¾®ç”Ÿç‰©å¤±è¡¡æ–¹é¢çš„ä¿è­·æ•ˆæœã€‚ä¸‰è‹¯éŒ«æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œå·²çŸ¥æœƒå°ç”Ÿç‰©é«”é€ æˆå‚·å®³ï¼Œå› æ­¤äº†è§£å¦‚ä½•é€éå¤©ç„¶ç‰©è³ªä¾†æ¸›è¼•å…¶å½±éŸ¿ï¼Œå°æ–¼ä¿è­·å¥åº·è‡³é—œé‡è¦ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼æ­ç¤ºè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‚è‡Ÿå’Œè…¸é“çš„å¥åº·ï¼Œä¸¦æ”¹å–„ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è² é¢å½±éŸ¿ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶äººå“¡å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†ç‚ºä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚å…¶ä¸­ä¸€çµ„ç‚ºå°ç…§çµ„ï¼Œå¦ä¸€çµ„å‰‡æš´éœ²æ–¼10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«ï¼Œç¬¬ä¸‰çµ„å‰‡åœ¨ç›¸åŒçš„ä¸‰è‹¯éŒ«æ¿ƒåº¦ä¸‹æ·»åŠ äº†10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…é€éæ¸¬é‡è‚è‡Ÿçš„ç¸½è†½é¹½å’Œç¸½è†½å›ºé†‡æ°´å¹³ï¼Œä»¥åŠåŸºå› è¡¨é”çš„è®ŠåŒ–ï¼Œä¾†è©•ä¼°ä¸‰è‹¯éŒ«çš„æ¯’æ€§å½±éŸ¿å’Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œä¸¦å½±éŸ¿äº†å…ç–«ç³»çµ±å’Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆã€‚ç„¶è€Œï¼Œç•¶æ·»åŠ è˜¿è””ç¡«ç´ å¾Œï¼Œé€™äº›è² é¢å½±éŸ¿æœ‰æ‰€æ¸›è¼•ï¼Œè‚è‡Ÿçš„è†½é¹½ç©ç´¯æ¸›å°‘ï¼Œå…ç–«ç›¸é—œåŸºå› çš„è¡¨é”ä¹Ÿæ¢å¾©æ­£å¸¸ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œå‡ºç¾äº†æœ‰ç›ŠèŒç¾¤çš„å¢åŠ å’Œæœ‰å®³èŒç¾¤çš„æ¸›å°‘ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æ”¹å–„ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„å¥åº·å•é¡Œæ–¹é¢ç™¼æ®äº†é‡è¦ä½œç”¨ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä»¥ç¢ºèªå…¶å…·é«”æ©Ÿåˆ¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™æœ‰ä¸€å®šçš„ä¿è­·ä½œç”¨ã€‚é€™æ„å‘³è‘—é€éé£²é£Ÿä¸­æ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œä¾‹å¦‚é’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘æŸäº›ç’°å¢ƒæ¯’ç´ å°æˆ‘å€‘èº«é«”çš„å½±éŸ¿ï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚é€™äº›ç™¼ç¾å¯èƒ½å°æœªä¾†çš„å¥åº·é£²é£ŸæŒ‡å°å’Œç–¾ç—…é é˜²ç­–ç•¥æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°æŠ—ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½å¤±èª¿å’Œè…¸é“å¾®ç”Ÿç‰©å¤±è¡¡æ–¹é¢çš„ä¿è­·æ•ˆæœã€‚ä¸‰è‹¯éŒ«æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œå·²çŸ¥æœƒå°ç”Ÿç‰©é«”é€ æˆå‚·å®³ï¼Œå› æ­¤äº†è§£å¦‚ä½•é€éå¤©ç„¶ç‰©è³ªä¾†æ¸›è¼•å…¶å½±éŸ¿ï¼Œå°æ–¼ä¿è­·å¥åº·è‡³é—œé‡è¦ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼æ­ç¤ºè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‚è‡Ÿå’Œè…¸é“çš„å¥åº·ï¼Œä¸¦æ”¹å–„ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è² é¢å½±éŸ¿ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶äººå“¡å°‡é¯‰é­šï¼ˆCyprinus carpioï¼‰åˆ†ç‚ºä¸‰çµ„ï¼Œé€²è¡Œç‚ºæœŸå…«é€±çš„å¯¦é©—ã€‚å…¶ä¸­ä¸€çµ„ç‚ºå°ç…§çµ„ï¼Œå¦ä¸€çµ„å‰‡æš´éœ²æ–¼10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«ï¼Œç¬¬ä¸‰çµ„å‰‡åœ¨ç›¸åŒçš„ä¸‰è‹¯éŒ«æ¿ƒåº¦ä¸‹æ·»åŠ äº†10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…é€éæ¸¬é‡è‚è‡Ÿçš„ç¸½è†½é¹½å’Œç¸½è†½å›ºé†‡æ°´å¹³ï¼Œä»¥åŠåŸºå› è¡¨é”çš„è®ŠåŒ–ï¼Œä¾†è©•ä¼°ä¸‰è‹¯éŒ«çš„æ¯’æ€§å½±éŸ¿å’Œè˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿæ¯’æ€§ï¼Œä¸¦å½±éŸ¿äº†å…ç–«ç³»çµ±å’Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆã€‚ç„¶è€Œï¼Œç•¶æ·»åŠ è˜¿è””ç¡«ç´ å¾Œï¼Œé€™äº›è² é¢å½±éŸ¿æœ‰æ‰€æ¸›è¼•ï¼Œè‚è‡Ÿçš„è†½é¹½ç©ç´¯æ¸›å°‘ï¼Œå…ç–«ç›¸é—œåŸºå› çš„è¡¨é”ä¹Ÿæ¢å¾©æ­£å¸¸ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œå‡ºç¾äº†æœ‰ç›ŠèŒç¾¤çš„å¢åŠ å’Œæœ‰å®³èŒç¾¤çš„æ¸›å°‘ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æ”¹å–„ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„å¥åº·å•é¡Œæ–¹é¢ç™¼æ®äº†é‡è¦ä½œç”¨ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä»¥ç¢ºèªå…¶å…·é«”æ©Ÿåˆ¶ã€‚",
    "fb_post": "æ ¹æ“šã€ŠComparative biochemistry and physiology. Part D, Genomics & proteomicsã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼Œä½ çŸ¥é“å—ï¼Ÿä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç‰©è³ªï¼Œå¯èƒ½å°æˆ‘å€‘çš„è‚è‡Ÿå’Œå…ç–«ç³»çµ±æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ å°æŠ—ä¸€ç¨®å«ä¸‰è‹¯éŒ«çš„ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œé€™ç¨®ç‰©è³ªæœƒå°æˆ‘å€‘çš„å¥åº·é€ æˆå‚·å®³ã€‚ç ”ç©¶äººå“¡ç”¨é¯‰é­šé€²è¡Œäº†ç‚ºæœŸå…«é€±çš„å¯¦é©—ï¼Œåˆ†æˆä¸‰çµ„ï¼šä¸€çµ„ä¸æ¥è§¸ä¸‰è‹¯éŒ«ï¼Œå¦ä¸€çµ„æ¥è§¸äº†ä¸‰è‹¯éŒ«ï¼Œæœ€å¾Œä¸€çµ„å‰‡åœ¨æ¥è§¸ä¸‰è‹¯éŒ«çš„åŒæ™‚ï¼Œé‚„æ”å–äº†è˜¿è””ç¡«ç´ ã€‚çµæœç™¼ç¾ï¼Œæ¥è§¸ä¸‰è‹¯éŒ«çš„é¯‰é­šè‚è‡Ÿå‡ºç¾äº†æ¯’æ€§ï¼Œå…ç–«ç³»çµ±å’Œè…¸é“å¾®ç”Ÿç‰©ä¹Ÿå—åˆ°å½±éŸ¿ã€‚ä½†ç•¶ä»–å€‘æ”å–è˜¿è””ç¡«ç´ å¾Œï¼Œé€™äº›è² é¢å½±éŸ¿æ˜é¡¯æ¸›è¼•äº†ï¼Œè‚è‡Ÿçš„å¥åº·ç‹€æ³ä¹Ÿæœ‰æ‰€æ”¹å–„ï¼\n\né€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è‚è‡Ÿï¼Œæ¸›å°‘ç’°å¢ƒæ¯’ç´ çš„å½±éŸ¿ã€‚\n2. æ”å–å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¦‚é’èŠ±æ¤°èœï¼Œå°å¥åº·æœ‰ç›Šã€‚\n3. äº†è§£å¤©ç„¶ç‰©è³ªçš„ä¿è­·ä½œç”¨ï¼Œå°æ–¼æœªä¾†çš„å¥åº·é£²é£Ÿå’Œç–¾ç—…é é˜²éå¸¸é‡è¦ï¼",
    "image_prompt": "Create a flat design infographic on the effects of sulforaphane in a study. Include simplified illustrations of broccoli or sulforaphane, experimental subjects like fish, and arrows or lines showing the experimental steps. Highlight a section with key results, such as protective effects against toxicity and changes in gut microbiota composition. Use a light background with soft colors for a scientific and informative style.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚è‡Ÿæ¯’æ€§ Hepatotoxicity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "journal": "The Journal of nutritional biochemistry",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶çš„çµæœå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„æ­£å¸¸é‹ä½œå°æ–¼ç¶­æŒæ•´é«”å¥åº·è‡³é—œé‡è¦ï¼Œè€Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±èª¿å‰‡å¯èƒ½å°è‡´å¤šç¨®ç–¾ç—…ï¼ŒåŒ…æ‹¬æ½°ç˜æ€§çµè…¸ç‚ã€‚é€éæ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è…¸é“ç™¼ç‚çš„é¢¨éšªï¼Œé€™å°æ–¼æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…ä¾†èªªå°¤ç‚ºé‡è¦ã€‚å› æ­¤ï¼Œç ”ç©¶è˜¿è””ç¡«ç´ å°è…¸é“å¥åº·çš„å½±éŸ¿ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„ç–¾ç—…é é˜²å’Œæ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para2": "æœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œèˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±èª¿æœ‰é—œã€‚å„˜ç®¡å…ˆå‰çš„ç ”ç©¶å·²ç¶“é¡¯ç¤ºè˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚æœ‰ç›Šï¼Œä½†å…¶å…·é«”çš„ä½œç”¨æ©Ÿåˆ¶ä»ä¸å¤ æ¸…æ¥šã€‚å› æ­¤ï¼Œæœ¬ç ”ç©¶æ—¨åœ¨æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ä¾†æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚çš„ç—…ç†ç‹€æ³ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚ç ”ç©¶åœ˜éšŠçµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ã€‚å¯¦é©—ä¸­é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œè©•ä¼°è˜¿è””ç¡«ç´ å°è…¸é“å¾®ç”Ÿç‰©çµ„æˆçš„èª¿æ•´ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åˆ©ç”¨æœªæ¨™çš„ä»£è¬çµ„å­¸åˆ†æï¼Œæª¢æ¸¬å°é¼ è…¸é“ä¸­çš„ä»£è¬è®ŠåŒ–ï¼Œç‰¹åˆ¥æ˜¯èˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„è®ŠåŒ–ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„DSSèª˜å°çš„çµè…¸ç‚å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘çµè…¸çš„ç™¼ç‚ã€‚è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡DSSèª˜å°å°é¼ çš„è…¸é“å¾®ç”Ÿç‰©çµ„æˆã€‚æ­¤å¤–ï¼Œä»£è¬çµ„å­¸åˆ†æç™¼ç¾ï¼ŒDSSèª˜å°å°é¼ çš„è°·èƒ±ç”˜è‚½ä»£è¬å’Œç›¸é—œä»£è¬ç‰©çš„æ°´å¹³é¡¯è‘—æ”¹è®Šï¼Œè€Œè˜¿è””ç¡«ç´ æ²»ç™‚èƒ½å¤ æ¢å¾©é€™äº›è®ŠåŒ–ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œè°·èƒ±ç”˜è‚½ä»£è¬ä¾†æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘çµè…¸ç™¼ç‚ï¼Œç‚ºæœªä¾†çš„æ½°ç˜æ€§çµè…¸ç‚æ²»ç™‚æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶çš„çµæœå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„æ­£å¸¸é‹ä½œå°æ–¼ç¶­æŒæ•´é«”å¥åº·è‡³é—œé‡è¦ï¼Œè€Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±èª¿å‰‡å¯èƒ½å°è‡´å¤šç¨®ç–¾ç—…ï¼ŒåŒ…æ‹¬æ½°ç˜æ€§çµè…¸ç‚ã€‚é€éæ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è…¸é“ç™¼ç‚çš„é¢¨éšªï¼Œé€™å°æ–¼æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…ä¾†èªªå°¤ç‚ºé‡è¦ã€‚å› æ­¤ï¼Œç ”ç©¶è˜¿è””ç¡«ç´ å°è…¸é“å¥åº·çš„å½±éŸ¿ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„ç–¾ç—…é é˜²å’Œæ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\næœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚æ½°ç˜æ€§çµè…¸ç‚æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ï¼Œèˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±èª¿æœ‰é—œã€‚å„˜ç®¡å…ˆå‰çš„ç ”ç©¶å·²ç¶“é¡¯ç¤ºè˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚æœ‰ç›Šï¼Œä½†å…¶å…·é«”çš„ä½œç”¨æ©Ÿåˆ¶ä»ä¸å¤ æ¸…æ¥šã€‚å› æ­¤ï¼Œæœ¬ç ”ç©¶æ—¨åœ¨æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ä¾†æ”¹å–„æ½°ç˜æ€§çµè…¸ç‚çš„ç—…ç†ç‹€æ³ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚ç ”ç©¶åœ˜éšŠçµ¦äºˆå°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾çš„å½±éŸ¿ã€‚å¯¦é©—ä¸­é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œè©•ä¼°è˜¿è””ç¡«ç´ å°è…¸é“å¾®ç”Ÿç‰©çµ„æˆçš„èª¿æ•´ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åˆ©ç”¨æœªæ¨™çš„ä»£è¬çµ„å­¸åˆ†æï¼Œæª¢æ¸¬å°é¼ è…¸é“ä¸­çš„ä»£è¬è®ŠåŒ–ï¼Œç‰¹åˆ¥æ˜¯èˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„è®ŠåŒ–ï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„DSSèª˜å°çš„çµè…¸ç‚å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘çµè…¸çš„ç™¼ç‚ã€‚è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡DSSèª˜å°å°é¼ çš„è…¸é“å¾®ç”Ÿç‰©çµ„æˆã€‚æ­¤å¤–ï¼Œä»£è¬çµ„å­¸åˆ†æç™¼ç¾ï¼ŒDSSèª˜å°å°é¼ çš„è°·èƒ±ç”˜è‚½ä»£è¬å’Œç›¸é—œä»£è¬ç‰©çš„æ°´å¹³é¡¯è‘—æ”¹è®Šï¼Œè€Œè˜¿è””ç¡«ç´ æ²»ç™‚èƒ½å¤ æ¢å¾©é€™äº›è®ŠåŒ–ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œè°·èƒ±ç”˜è‚½ä»£è¬ä¾†æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘çµè…¸ç™¼ç‚ï¼Œç‚ºæœªä¾†çš„æ½°ç˜æ€§çµè…¸ç‚æ²»ç™‚æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "fb_post": "æ ¹æ“šã€ŠThe Journal of nutritional biochemistryã€‹æ–¼ 2025 å¹´ 12 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½å°è…¸é“å¥åº·æœ‰å¹«åŠ©ï¼æœ€è¿‘ä¸€é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚çš„å½±éŸ¿ï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„æ…¢æ€§ç–¾ç—…ã€‚ç ”ç©¶äººå“¡ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œæ¸›å°‘è…¸é“ç™¼ç‚ï¼Œé€™å°æ½°ç˜æ€§çµè…¸ç‚æ‚£è€…ä¾†èªªéå¸¸é‡è¦ã€‚\n\né€™é …ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨äº†èª˜å°çµè…¸ç‚çš„å°é¼ ï¼Œçµ¦äºˆå®ƒå€‘è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“çš„å½±éŸ¿ã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ¢å¾©è…¸é“çš„å®Œæ•´æ€§ï¼Œé‚„èƒ½èª¿æ•´è…¸é“ä¸­çš„å¾®ç”Ÿç‰©çµ„æˆï¼Œé€™æ˜¯ç¶­æŒè…¸é“å¥åº·çš„é—œéµã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½æ”¹å–„èˆ‡æŠ—æ°§åŒ–åŠ‘è°·èƒ±ç”˜è‚½ç›¸é—œçš„ä»£è¬è®ŠåŒ–ã€‚\n\nç¸½çµä¾†èªªï¼Œé€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ã€‚\n2. å®ƒèƒ½æ¸›å°‘çµè…¸çš„ç™¼ç‚ï¼Œæ¢å¾©è…¸é“å±éšœã€‚\n3. é€éèª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤ï¼Œå¯èƒ½é–‹å•Ÿæ–°çš„æ½°ç˜æ€§çµè…¸ç‚æ²»ç™‚æ–¹å‘ã€‚ è®“æˆ‘å€‘ä¸€èµ·é—œæ³¨è…¸é“å¥åº·å§ï¼",
    "image_prompt": "Create an informative illustration to explain the experiment and main results of a study on the effects of sulforaphane from radishes on colitis. Use a flat design style with a light background and soft colors. Include symbolic representations of broccoli or radish, simplified images of experimental subjects like mice or cells, arrows or flow lines to show the experimental steps, and a section highlighting the main results, such as protective effects or changes in gut barrier integrity.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "journal": "BMC cancer",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€éèª¿ç¯€å¤šæ¢ä¿¡è™Ÿé€šè·¯ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œæˆ–è¨±èƒ½åœ¨æŸç¨®ç¨‹åº¦ä¸Šå¹«åŠ©é é˜²ç™Œç—‡ï¼Œæˆ–è¼”åŠ©æ²»ç™‚æŸäº›ç™Œç—‡ï¼Œå°¤å…¶æ˜¯é‡å°ç‰¹å®šé¡å‹çš„è…«ç˜¤ã€‚é€™äº›ç™¼ç¾ä¹Ÿå¯èƒ½ä¿ƒä½¿æœªä¾†çš„ç ”ç©¶é€²ä¸€æ­¥æ¢ç´¢è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œä¸¦å°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å°é¼ åŸƒçˆ¾åˆ©å¸Œè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸åŒçš„æ©Ÿåˆ¶ä¾†å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œç™¼å±•ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨å°é¼ æ¨¡å‹ä¸­çš„å…·é«”ä½œç”¨ã€‚é€™é …ç ”ç©¶ä¸åƒ…è‘—çœ¼æ–¼è˜¿è””ç¡«ç´ æœ¬èº«çš„æ•ˆæœï¼Œé‚„è€ƒé‡äº†å…¶èˆ‡ç´ç±³è„‚è³ªé«”çµåˆå¾Œçš„æ•ˆæœï¼Œé€™å¯èƒ½æœƒæ”¹è®Šå…¶åœ¨é«”å…§çš„ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†ç‚ºå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ï¼Œä»¥åŠå¸¶æœ‰EACçš„é¼ é¡ï¼Œå¾Œè€…åˆåˆ†ç‚ºæ¥å—ä¸åŒæ²»ç™‚çš„çµ„åˆ¥ã€‚æ‰€æœ‰æ²»ç™‚æŒçºŒ20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ã€ä»¥åŠè‚è‡Ÿå¥åº·ç­‰å¤šæ–¹é¢çš„æŒ‡æ¨™ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ åŠå…¶ç´ç±³å½¢å¼çš„æŠ—è…«ç˜¤æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ•ˆæœé¡¯è‘—å„ªæ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ ã€‚æ­¤å¤–ï¼Œé€™äº›ç´ç±³è„‚è³ªé«”é‚„èƒ½æ”¹å–„å°é¼ çš„ç”Ÿå­˜ç‡ï¼Œä¸¦æ¸›å°‘è‚è‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œç‚ç—‡åæ‡‰ã€‚ç ”ç©¶çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€éèª¿ç¯€é—œéµçš„åˆ†å­é€šè·¯ï¼Œä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼ŒåŒæ™‚ä¿è­·è‚è‡Ÿçš„å¥åº·ï¼Œé€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€éèª¿ç¯€å¤šæ¢ä¿¡è™Ÿé€šè·¯ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œæˆ–è¨±èƒ½åœ¨æŸç¨®ç¨‹åº¦ä¸Šå¹«åŠ©é é˜²ç™Œç—‡ï¼Œæˆ–è¼”åŠ©æ²»ç™‚æŸäº›ç™Œç—‡ï¼Œå°¤å…¶æ˜¯é‡å°ç‰¹å®šé¡å‹çš„è…«ç˜¤ã€‚é€™äº›ç™¼ç¾ä¹Ÿå¯èƒ½ä¿ƒä½¿æœªä¾†çš„ç ”ç©¶é€²ä¸€æ­¥æ¢ç´¢è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œä¸¦å°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å°é¼ åŸƒçˆ¾åˆ©å¸Œè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸åŒçš„æ©Ÿåˆ¶ä¾†å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œç™¼å±•ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨å°é¼ æ¨¡å‹ä¸­çš„å…·é«”ä½œç”¨ã€‚é€™é …ç ”ç©¶ä¸åƒ…è‘—çœ¼æ–¼è˜¿è””ç¡«ç´ æœ¬èº«çš„æ•ˆæœï¼Œé‚„è€ƒé‡äº†å…¶èˆ‡ç´ç±³è„‚è³ªé«”çµåˆå¾Œçš„æ•ˆæœï¼Œé€™å¯èƒ½æœƒæ”¹è®Šå…¶åœ¨é«”å…§çš„ç©©å®šæ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†ç‚ºå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›çµ„åˆ¥åŒ…æ‹¬æœªè™•ç†çš„å°ç…§çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ï¼Œä»¥åŠå¸¶æœ‰EACçš„é¼ é¡ï¼Œå¾Œè€…åˆåˆ†ç‚ºæ¥å—ä¸åŒæ²»ç™‚çš„çµ„åˆ¥ã€‚æ‰€æœ‰æ²»ç™‚æŒçºŒ20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ã€ä»¥åŠè‚è‡Ÿå¥åº·ç­‰å¤šæ–¹é¢çš„æŒ‡æ¨™ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ åŠå…¶ç´ç±³å½¢å¼çš„æŠ—è…«ç˜¤æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ•ˆæœé¡¯è‘—å„ªæ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ ã€‚æ­¤å¤–ï¼Œé€™äº›ç´ç±³è„‚è³ªé«”é‚„èƒ½æ”¹å–„å°é¼ çš„ç”Ÿå­˜ç‡ï¼Œä¸¦æ¸›å°‘è‚è‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œç‚ç—‡åæ‡‰ã€‚ç ”ç©¶çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€éèª¿ç¯€é—œéµçš„åˆ†å­é€šè·¯ï¼Œä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼ŒåŒæ™‚ä¿è­·è‚è‡Ÿçš„å¥åº·ï¼Œé€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC cancerã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰æœ‰å¯èƒ½å°å¥åº·æœ‰å¹«åŠ©å—ï¼Ÿæœ€è¿‘çš„ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œé€™ç¨®æˆåˆ†å¯èƒ½åœ¨æŠ—ç™Œæ–¹é¢æœ‰ä¸éŒ¯çš„æ½›åŠ›ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å°å°é¼ åŸƒçˆ¾åˆ©å¸Œè…¹æ°´ç™Œï¼ˆEACï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œå®ƒæ˜¯å¦‚ä½•å½±éŸ¿è…«ç˜¤ç”Ÿé•·çš„ï¼Œå°¤å…¶æ˜¯ç•¶å®ƒèˆ‡ç´ç±³è„‚è³ªé«”çµåˆå¾Œï¼Œæ•ˆæœæœƒæœ‰ä»€éº¼è®ŠåŒ–ã€‚å¯¦é©—ä¸­ï¼Œ90éš»å°é¼ è¢«åˆ†æˆä¸åŒçµ„åˆ¥ï¼Œæœ‰çš„æ¥å—è˜¿è””ç¡«ç´ ï¼Œæœ‰çš„å‰‡æ˜¯ç´ç±³è„‚è³ªé«”ï¼Œé‚„æœ‰ä¸€äº›æ˜¯å°ç…§çµ„ï¼ŒæŒçºŒè§€å¯Ÿ20å¤©ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘è…«ç˜¤é«”ç©å’Œæ´»ç´°èƒæ•¸é‡æ–¹é¢ï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ•ˆæœæ›´å¥½ï¼è€Œä¸”ï¼Œå®ƒé‚„èƒ½æé«˜å°é¼ çš„ç”Ÿå­˜ç‡ï¼Œä¸¦æ¸›å°‘è‚è‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œç‚ç—‡åæ‡‰ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„ç™Œç—‡æ²»ç™‚å……æ»¿æœŸå¾…ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ã€‚\n2. èˆ‡ç´ç±³è„‚è³ªé«”çµåˆå¾Œï¼Œæ•ˆæœæ›´é¡¯è‘—ï¼\n3. æœ‰åŠ©æ–¼ä¿è­·è‚è‡Ÿå¥åº·ï¼Œæ¸›å°‘ç‚ç—‡åæ‡‰ã€‚",
    "image_prompt": "Create a simple infographic that explains the experimental methods and main results of a study on sulforaphane (SFN) and its effects on Ehrlich ascites carcinoma (EAC) in mice. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified images of experimental subjects (like mice or cells), arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' showing protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "åŸƒçˆ¾åˆ©å¸Œè…¹æ°´ç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "journal": "Phytomedicine : international journal of phytotherapy and phytopharmacology",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œæ˜¯ä¸€ç¨®å°äººé¡å¥åº·å¨è„…æ¥µå¤§çš„ç–¾ç—…ï¼Œç›®å‰æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œä»¥åŠå…¶ä½œç”¨çš„å…·é«”åˆ†å­è·¯å¾‘ï¼Œé€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥è‡³é—œé‡è¦ã€‚",
    "para3": "ç ”ç©¶è€…é€²è¡Œäº†é«”å…§å’Œé«”å¤–çš„å¯¦é©—ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœï¼Œä¸¦é€éåŸºå› æ¸¬åºåˆ†æä¾†è­˜åˆ¥å…¶é¶å‘çš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œä»–å€‘é€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåƒèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸çš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§çµ„ä»¶ï¼Œå¾è€Œæ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒæŠ‘åˆ¶CKMT2-AS1èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚é€™äº›ç™¼ç¾ä¸åƒ…æ­ç¤ºäº†è˜¿è””ç¡«ç´ é€šéSTAT3/CKMT2-AS1èª¿æ§è»¸çš„è…«ç˜¤æŠ‘åˆ¶æ©Ÿåˆ¶ï¼Œé‚„ç¢ºèªäº†CKMT2-AS1ä½œç‚ºèƒƒç™Œå¹²é çš„æ½›åœ¨æ²»ç™‚é¶é»ã€‚",
    "explanation_zh": "èƒƒç™Œæ˜¯ä¸€ç¨®å°äººé¡å¥åº·å¨è„…æ¥µå¤§çš„ç–¾ç—…ï¼Œç›®å‰æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œæˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œä»¥åŠå…¶ä½œç”¨çš„å…·é«”åˆ†å­è·¯å¾‘ï¼Œé€™å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚ç­–ç•¥è‡³é—œé‡è¦ã€‚\n\nç ”ç©¶è€…é€²è¡Œäº†é«”å…§å’Œé«”å¤–çš„å¯¦é©—ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœï¼Œä¸¦é€éåŸºå› æ¸¬åºåˆ†æä¾†è­˜åˆ¥å…¶é¶å‘çš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œä»–å€‘é€²è¡Œäº†æ©Ÿåˆ¶é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåƒèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸çš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§çµ„ä»¶ï¼Œå¾è€Œæ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒæŠ‘åˆ¶CKMT2-AS1èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚é€™äº›ç™¼ç¾ä¸åƒ…æ­ç¤ºäº†è˜¿è””ç¡«ç´ é€šéSTAT3/CKMT2-AS1èª¿æ§è»¸çš„è…«ç˜¤æŠ‘åˆ¶æ©Ÿåˆ¶ï¼Œé‚„ç¢ºèªäº†CKMT2-AS1ä½œç‚ºèƒƒç™Œå¹²é çš„æ½›åœ¨æ²»ç™‚é¶é»ã€‚",
    "fb_post": "æ ¹æ“šã€ŠPhytomedicine : international journal of phytotherapy and phytopharmacologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸ½ï¸ è½èªªä½ å–œæ­¡åƒè˜¿è””ï¼Ÿé‚£ä½ çŸ¥é“è˜¿è””è£¡é¢æœ‰ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„æˆåˆ†å—ï¼Ÿæœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾å®ƒå°èƒƒç™Œæœ‰å¯èƒ½çš„æŠ—è…«ç˜¤æ•ˆæœï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯åœ¨æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„è¡Œç‚ºï¼Œç ”ç©¶è€…å€‘é€²è¡Œäº†è¨±å¤šå¯¦é©—ï¼ŒåŒ…æ‹¬åœ¨å¯¦é©—å®¤è£¡è§€å¯Ÿç´°èƒçš„è®ŠåŒ–ï¼Œé‚„æœ‰åŸºå› åˆ†æä¾†äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦ä¸”é™ä½ä¸€ç¨®åç‚ºCKMT2-AS1çš„åŸºå› çš„è¡¨é”ã€‚é€™å€‹åŸºå› åœ¨èƒƒç™Œæ‚£è€…ä¸­è¡¨ç¾éé«˜ï¼Œèˆ‡ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œè¯ã€‚æŠ‘åˆ¶é€™å€‹åŸºå› èƒ½é¡¯è‘—æ¸›å°‘ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œé€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚èƒƒç™Œçš„ä¸€å€‹æ–°æ–¹å‘ï¼\n\nğŸ” ä¸»è¦ç™¼ç¾ï¼š\n1. è˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æŠ‘åˆ¶èƒƒç™Œç´°èƒçš„ç”Ÿé•·ã€‚\n2. CKMT2-AS1åŸºå› çš„é«˜è¡¨é”èˆ‡ä½ç”Ÿå­˜ç‡æœ‰é—œã€‚\n3. æŠ‘åˆ¶CKMT2-AS1èƒ½æ¸›å°‘ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚\n\nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æ›´å¤šé—œæ–¼å¥åº·é£²é£Ÿçš„ç ”ç©¶æˆæœå§ï¼",
    "image_prompt": "Create an infographic illustrating the research on the anti-tumor effects of sulforaphane found in radishes on gastric cancer. The image should have a light background with soft colors and a flat design style. Include symbols for radishes or sulforaphane, simplified representations of experimental subjects such as cells or animals, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting the protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "journal": "BMC pharmacology & toxicology",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„é£²é£Ÿè£œå……æœ‰å¹«åŠ©ã€‚é›–ç„¶é€™ç¨®ç‰©è³ªçš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä½†å®ƒçš„æ½›åœ¨å¥åº·ç›Šè™•å¼•èµ·äº†è¨±å¤šç ”ç©¶è€…çš„é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºè‡ªé–‰ç—‡æ‚£è€…æä¾›æ–°çš„è¼”åŠ©æ²»ç™‚é¸æ“‡ï¼Œä¸¦ä¸”æœ‰åŠ©æ–¼äº†è§£å¦‚ä½•é€éé£²é£Ÿä¾†æ”¹å–„é€™é¡ç–¾ç—…çš„ç—‡ç‹€ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œç–¾ç—…çš„é é˜²ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰ä¸­çš„ä½œç”¨åŠå…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä¸¦ä¸”åˆ†æå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€™å€‹å•é¡Œçš„ç ”ç©¶ä¸åƒ…æ¶‰åŠåˆ°è˜¿è””ç¡«ç´ çš„ç›´æ¥æ•ˆæœï¼Œé‚„åŒ…æ‹¬å…¶å¦‚ä½•å½±éŸ¿ç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜å’Œä¿¡è™Ÿé€šè·¯ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—é€²è¡Œç¶œåˆåˆ†æã€‚ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ç­‰ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‡ªé–‰ç—‡çš„ç›¸é—œç”Ÿç‰©é€”å¾‘ï¼Œä¸¦è©•ä¼°å…¶å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°5é€±å’Œ8åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡çš„ç¤¾äº¤èƒ½åŠ›æœ‰ä¸€å®šçš„å¹«åŠ©ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨äº‹ä»¶ï¼Œé¡¯ç¤ºå…¶å®‰å…¨æ€§ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†æç¢ºå®šäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„10å€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ä¿¡è™Ÿé€šè·¯ï¼Œé€²ä¸€æ­¥æ”¯æŒäº†è˜¿è””ç¡«ç´ ä½œç‚ºè¼”åŠ©æ²»ç™‚çš„æ½›åŠ›ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„é£²é£Ÿè£œå……æœ‰å¹«åŠ©ã€‚é›–ç„¶é€™ç¨®ç‰©è³ªçš„ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä½†å®ƒçš„æ½›åœ¨å¥åº·ç›Šè™•å¼•èµ·äº†è¨±å¤šç ”ç©¶è€…çš„é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºè‡ªé–‰ç—‡æ‚£è€…æä¾›æ–°çš„è¼”åŠ©æ²»ç™‚é¸æ“‡ï¼Œä¸¦ä¸”æœ‰åŠ©æ–¼äº†è§£å¦‚ä½•é€éé£²é£Ÿä¾†æ”¹å–„é€™é¡ç–¾ç—…çš„ç—‡ç‹€ï¼Œé€²è€Œä¿ƒé€²å¥åº·å’Œç–¾ç—…çš„é é˜²ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰ä¸­çš„ä½œç”¨åŠå…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆæ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä¸¦ä¸”åˆ†æå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚é€™å€‹å•é¡Œçš„ç ”ç©¶ä¸åƒ…æ¶‰åŠåˆ°è˜¿è””ç¡«ç´ çš„ç›´æ¥æ•ˆæœï¼Œé‚„åŒ…æ‹¬å…¶å¦‚ä½•å½±éŸ¿ç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜å’Œä¿¡è™Ÿé€šè·¯ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—é€²è¡Œç¶œåˆåˆ†æã€‚ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†æ¢è¨è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ç­‰ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‡ªé–‰ç—‡çš„ç›¸é—œç”Ÿç‰©é€”å¾‘ï¼Œä¸¦è©•ä¼°å…¶å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°5é€±å’Œ8åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„è‡ªé–‰ç—‡çš„ç¤¾äº¤èƒ½åŠ›æœ‰ä¸€å®šçš„å¹«åŠ©ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªç™¼ç¾é¡¯è‘—çš„å‰¯ä½œç”¨äº‹ä»¶ï¼Œé¡¯ç¤ºå…¶å®‰å…¨æ€§ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†æç¢ºå®šäº†è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„10å€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ä¿¡è™Ÿé€šè·¯ï¼Œé€²ä¸€æ­¥æ”¯æŒäº†è˜¿è””ç¡«ç´ ä½œç‚ºè¼”åŠ©æ²»ç™‚çš„æ½›åŠ›ã€‚",
    "fb_post": "æ ¹æ“šã€ŠBMC pharmacology & toxicologyã€‹æ–¼ 2025 å¹´ 11 æœˆ ç™¼è¡¨çš„è«–æ–‡ï¼ŒğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½å°è‡ªé–‰ç—‡çš„ç¤¾äº¤èƒ½åŠ›æœ‰å¹«åŠ©å“¦ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰ä¸­çš„æ½›åœ¨ä½œç”¨ã€‚ç ”ç©¶äººå“¡æƒ³çŸ¥é“é€™ç¨®ç‰©è³ªæ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰ï¼Œä¸¦åˆ†æå®ƒèƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ã€‚ç‚ºäº†é€²è¡Œé€™é …ç ”ç©¶ï¼Œä»–å€‘æª¢ç´¢äº†å¤šå€‹è³‡æ–™åº«ï¼Œé¸æ“‡äº†å…­é …åˆé©çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±æœ‰333ååƒèˆ‡è€…ã€‚\n\nç ”ç©¶åœ˜éšŠä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ç­‰æŠ€è¡“ã€‚ä»–å€‘ç™¼ç¾ï¼Œç¶“é4åˆ°10é€±çš„è£œå……ï¼Œåƒèˆ‡è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œé€™è¡¨ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½å°æ”¹å–„ç¤¾äº¤èƒ½åŠ›æœ‰å¹«åŠ©ï¼è€Œä¸”ï¼Œç ”ç©¶ä¸­ä¸¦æ²’æœ‰ç™¼ç¾æ˜é¡¯çš„å‰¯ä½œç”¨ï¼Œé€™ä¹Ÿè®“äººæ„Ÿåˆ°å®‰å¿ƒã€‚\n\nğŸ“Œ ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚\n2. ç ”ç©¶ä¸­ç™¼ç¾çš„å®‰å…¨æ€§ï¼Œè®“äººæ„Ÿåˆ°æ”¾å¿ƒã€‚\n3. è˜¿è””ç¡«ç´ çš„æ½›åœ¨ä½œç”¨æ©Ÿåˆ¶å€¼å¾—é€²ä¸€æ­¥æ¢ç´¢ï¼",
    "image_prompt": "Create a simple infographic explaining the experimental methods and main results of a study on sulforaphane and autism. Use flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like people or cells), arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  }
]